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Abstract
Increased expression of tissue factor (TF) has been associated with invasive forms of breast 
cancer. In contrast, the expression of oestrogen receptor alpha (ERa) in breast cancer cells 
is associated with well differentiated breast tumours, with a low invasive potential. The aim 
of this study was to examine the influence of exogenous TF on the expression of ERa in 
breast cancer cells, as well as alterations in cell proliferation and invasiveness, and to 
explore the underlying mechanisms. Incubation of the MCF-7 and T47D breast cancer cell 
lines with exogenous TF resulted in decreases in the expression of ERa mRNA and protein 
by a mechanism requiring the interaction of TF with pi integrin leading to the activation of 
the ERK1/2 pathway, but was independent of PAR1 and PAR2 activation. Furthermore, 
exogenous TF suppressed oestradiol-mediated cell proliferation through a pathway partly 
mediated through PAR2 activation, and also reversed the inhibitory influence of oestradiol 
on cell invasion. Exogenous TF also decreased the transcriptional activity of ERa via the 
classical ERE pathway through a mechanism that involved decreases in the DNA binding 
activity of ERa to ERE sequences, although the phosphorylation state of serine 118 within 
ERa was unaffected. Moreover, while TF alone was capable of downregulating the 
transcriptional activity of AP-1, oestradiol did not affect the transcriptional activity of AP- 
1. Exogenous TF was shown to bind to the surface of MCF-7 cells by direct interaction 
with cell surface pi integrin which could be disrupted with polyclonal antibodies against 
TF or pi integrin. Furthermore, using computer-aided analysis, a putative binding site for 
TF within the EGF-4 domain of pi integrin was identified which had structural 
resemblance to the EGF-1 domain of FXa responsible for binding to TF. These data suggest 
that exogenous TF released from stromal cells interacts with breast cancer cells resulting in 
the downregulation of ERa which in turn leads to the loss of oestradiol-controlled
proliferation and contributes to the progression of breast cancers to an invasive phenotype.
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CHAPTER 1
General Introduction
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1. General Introduction
1.1. Breast cancer
Breast cancer is the most common form of malignancy in women in developed 
countries and accounts for 20% of female cancers in these countries (Cassidy et al 
2004). A small percentage (approximately 5%) of breast cancers are hereditary, and 
attributed to inherited mutations in genes such as BRCA1 and BRCA2 (Futreal et al 
1994). However, sporadic forms of breast cancer, which are due to a combination of 
random genetic alterations and environmental factors, constitute the majority of 
observed cases. The mammary gland consists of a branching network of ducts which 
end in lobules termed terminal duct lobuloalveolar units (Fig 1.1 A). The lobules are 
composed of a layer of luminal epithelial cells surrounded by an outer layer of 
myoepithelial cells which are in contact with the basement membrane. The whole 
structure is surrounded by fibroblasts and supported by the extracellular matrix 
(stroma). Histological studies of breast tumours have revealed that about 90% of breast 
cancers arise from the luminal epithelial cells of the ducts (Santini et al 1996).
The transformation of normal breast epithelial cells into cancerous cells involves the 
loss of mechanisms that control normal cell proliferation and programmed cell death. 
This results in increased proliferation of cells which do not respond to normal 
regulatory signals, resulting in a mass of abnormal cells and the formation of a tumour 
(Macdonald et al 2004). These benign breast tumours may then develop into malignant 
tumours that are able to invade surrounding tissues and metastasise to secondary sites, 
such as the liver, lungs and bone marrow (Price 1990). Recently, a number of mutations 
in tumour suppressor genes and oncogenes that result in hereditary breast cancers have 
been identified. However, less is known about the molecular mechanisms that lead to
22
Figure 1.1. Diagram of the mammary gland and structure of 17 (J-oestradiol 
A.
The mammary gland consists of a branching network of ducts which end in terminal 
duct lobuloalveolar units. The whole structure is surrounded by an extracellular matrix 
(stroma) and adipose tissue. A = ducts, B= terminal duct lobuloalveolar units, C= duct, 
D=duct opening, E= adipose tissue, F= pectoralis major muscle, G= rib cage. Adapted 
from www.breastcancer.org.
B.
H
The four ring structure of 17 p-oestradiol. Adapted from Garrett & Grisham (2005).
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sporadic breast cancer initiation (oncogenesis) and the transformation of benign to 
malignant breast cancers (tumourigenesis) (Macdonald et al 2004). A number of risk 
factors for the development of breast cancer have been identified, including early 
menarche, late menopause, nulliparity, obesity, and exposure to exogenous oestrogens 
(Cassidy et al 2004). Moreover, many of these risk factors involve the increased 
exposure of breast tissue to oestrogens.
1.2. Oestrogen and the oestrogen receptor 
1.2.1. Oestrogens
Oestrogens are steroid hormones which have a four ring structure and are synthesised 
from cholesterol (Fig LIB). The three main forms of oestrogen are oestradiol, oestriol 
and oestrone of which 17 p-oestradiol (E2) is the most abundant and physiologically 
active form (Behl 2001). This group of steroid hormones controls reproductive 
processes such as normal mammary gland growth, differentiation and function, as well 
as the regulation of the menstrual cycle (Anderson et al 1998, Laidlaw et al 1995, 
Chabbert-Buffet et al 1998). Furthermore, oestrogens have functions in the 
cardiovascular system, nervous system and in the maintenance of the skeleton (Deroo & 
Korach 2006, Behl 2001).
The physiological concentration of 17 p-oestradiol in the blood plasma varies during the 
menstrual cycle and typically ranges between 50 and 1200 pM (Marshall 1995). In non- 
pregnant, premenopausal women, the main sites of oestrogen production are the ovaries 
whereas in post-menopausal women oestrogens are produced within the adipose tissue 
of the mammary gland. In both cases, oestradiol is synthesised from testosterone in a 
reaction catalysed by the enzyme aromatase. Oestrogens are secreted into the blood- 
stream and transported to target organs in complex with blood plasma proteins
24
including sex hormone-binding globulin and albumin (Behl 2001), and released at target 
tissues. Since oestrogens are small, hydrophobic, lipid-soluble molecules, they are able 
to diffuse directly across the cell membrane and bind to their intracellular receptors, 
oestrogen receptors (ER), which are located in the cell nucleus.
1.2.2. Oestrogen receptors
Two forms of the oestrogen receptor have been identified and are encoded by separate 
genes. Oestrogen receptor alpha (ERa) was first cloned by Green et al in 1986. The ERa 
gene is located on chromosome 6 and encodes a 595 amino acid protein with a 
molecular mass of 66 kDa. Oestrogen receptor beta (ERP) was identified more recently 
(Mosselman et al 1996) as a 530 amino acid protein, the gene for which is located on 
chromosome 14.
Both ERa and ERP belong to the nuclear receptor family and share a large degree of 
structural homology. Both receptors are composed of six domains (A-F) (Fig 1.2) that 
have distinct functions. The N-terminus contains domains A and B and includes the N- 
terminal activation function-1 (AF-1), which modulates the transcriptional activity of 
ERa in a ligand-independent manner. The adjacent DNA binding domain (DBD) 
contains two zinc finger motifs which directly interact with specific DNA sequences 
known as oestrogen response elements (ERE) (Klein-Hitpass et al 1988). This domain is 
highly conserved between ERa and ERp and they share 96 % homology (Mosselman et 
al 1996) allowing both types of the receptor to bind to the same DNA response 
elements. Domain D forms the hinge region of the protein which allows dimerisation 
and nuclear localisation of the receptor. The ligand binding domain (LBD) of ER is 
composed of 11 alpha helices which form a pocket for its interaction with 17 P- 
oestradiol (Kong et al 2003). This domain also interacts with co-activator proteins and
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Figure 1.2. Arrangement of the structural domains of ERa and ERp
A/B
ERa N-
D E
DBD LBD -C
1 __ 1 U
AF-1 AF-2
Homology 16 % 96 % 30 % 58% 18%
ERp N- DBD LBD -C
AF-1
U 
AF-2
ERa and ER|5 are composed of six conserved structural domains (A-F). The A/B 
domain contains the N-terminal activation function-1 (AF-1). Domain C consists of the 
DNA binding domain (DBD) and is highly conserved between the two forms of ER. 
The hinge region (D) allows dimerisation of the receptor. Domain E is the ligand 
binding domain (LBD) and contains the activation function-2 (AF-2). Percentages of 
homology observed between the six domains of ERa and ERp are shown in red. 
Adapted from Platet et al (2004).
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contains activation function-2 (AF-2). AF-2 is activated following binding of 17 |3- 
oestradiol to the LBD and regulates transcriptional activation of the receptor (Kong et al 
2003). The LBD domain is closely conserved with 58 % homology between the two 
forms of ER (Mosselman et al 1996). Finally, the C-terminus contains domain F which 
interacts with co-activator proteins and regulates the transcriptional activity of ER in 
response to oestradiol (Koide et al 2007). The human ERa gene is composed of 8 exons 
(Ponglikitmongkol et al 1988) and alternative splicing of the precursor RNA produces 
variant forms of ERa that lack one or more exons and therefore lack some functional 
domains of the wild type ERa (Ferro et al 2003). For example, deletion of exon 3 results 
in an ERa variant that cannot bind to DNA, and deletion of exon 4 or 5 results in a form 
of ERa that has reduced ability to bind oestradiol since these exons encode parts of the 
DNA binding domain and ligand binding domains respectively (Leygue et al 2000). The 
expression of ERa splice variants has been detected both in normal and breast cancer 
cells and it has been suggested that ERa splice variants interfere with wild type ERa 
signalling in these cells (Leygue et al 2000).
In addition to the structural variations, the two forms of ER have different expression 
patterns in the body. ER|3 is more generally expressed and more widely distributed 
throughout the body than ERa (Taylor & Al-Azzawi 2000, Balfe et al 2004). Moreover, 
the ratio of ERa to ER|3 expression varies between different tissues, with higher levels 
of ERa expressed in the mammary glands and uterus (Gustafsson 1999). In breast 
tissue, ERa is predominantly expressed in the luminal epithelial cells (Clarke et al 
1997). Within cells, ERa is mainly located in the nucleus while a small proportion is 
found in the cytoplasm and also bound to the inner side of the cell membrane. Since ER 
is both a receptor and a transcription factor mainly located in the nucleus of cells, ER is
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able to regulate gene expression rapidly in response to oestradiol, and induce long-term 
changes in gene expression.
1.2.3. ERa signalling mechanisms
ERa can modulate gene transcription through four different mechanisms. The classical 
pathway of ERa transcriptional activation involves the binding of oestrogen to the 
ligand binding domain of ERa. This results in a conformational change within the 
receptor, the release of inhibitory proteins, and dimerisation of ERa. The activated ERa 
dimers then bind to ERE DNA sequences located in the promoter regions of ERa-target 
genes, resulting in transcription (Fig 1.3). ERa may also regulate gene expression in an 
ERE-independent manner, hi this mechanism, ERa directly binds to other transcription 
factors, such as activator protein-1 (AP-1) (Teyssier et al 2001) and Sp-1 (Porter et al 
1997), which are associated with their own target DNA binding elements (Fig 1.3). hi 
this way, ERa acts as a co-activator protein, increasing the transcriptional activity of the 
AP-1 or Sp-1 transcription factor complexes and altering the rate of gene transcription. 
In addition to the two oestradiol-mediated mechanisms, ERa may also be activated in 
the absence of its ligand through the activation of intracellular signalling pathways in 
response to extracellular stimuli. For example, it has been demonstrated that the 
activation of the mitogen-activated protein kinase (MAPK) pathway, in response to 
growth factors results in the phosphorylation of "Serine residues within the N-terminal 
A/B domain of ERa (Chen et al 2002, Kato et al 1995), which in turn increases the 
transcriptional activity of ERa (Kato et al 1995). Finally, a membrane-bound form of 
ERa has been identified which is capable of rapidly activating intracellular signalling 
pathways, such as the MAPK pathway, in response to the binding of oestradiol (Zhang 
et al 2002). This mechanism has been suggested to involve the interaction of ERa with 
G protein-coupled receptors at the cell membrane (Albanito et al 2007).
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Figure 1.3. Oestrogen-mediated ERa signalling pathways
E2
E2
ERa ERa
ERE TRE
Oestradiol (E2) enters the nucleus and binds to inactive ERa (squares), resulting in a 
conformational change within the receptor, the release of inhibitory proteins, and 
subsequent activation and dimerisation of ERa (circles). In the classical pathway, ERa 
dimers bind to oestrogen response elements (ERE) upstream of ERa target genes, 
leading to the initiation of gene transcription. ERa can also act through the ERE- 
independent pathway by binding to transcription factors such as AP-1 through protein- 
protein interactions. This binding of ERa to AP-1 then enhances AP-1 mediated 
transcription through TPA response elements (TRE), which are located upstream of AP- 
1 target genes.
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1.3. The role of oestrogen-ER cell signalling in breast cancer
In normal breast tissue oestrogens regulate the development of the mammary gland by 
inducing cell proliferation and differentiation (Anderson et al 1998, Laidlaw et al 1995). 
However, oestrogens also promote breast cancer and many of the risk factors for breast 
cancer involve increased exposure to oestrogens. It was first shown in the early 1900's 
that the removal of the ovaries prevents breast cancer and also leads to the regression of 
existing breast tumours (Beatson 1896). Approximately 70 % of breast tumours express 
ERa and the majority of breast tumours are derived from ERa positive luminal 
epithelial cells. Moreover, using ER knock-out mice it has been shown that ERa but not 
ERP is required for mammary gland development and tumourigenesis (Korach 1994, 
Krege et al 1998). Among the oestrogen-target genes identified, a number are involved 
in the regulation of the cell cycle (Prall et al 1998). An outcome of oestrogen-ERa 
signalling is therefore the increased rate of cell proliferation, as the cells are signalled to 
enter and progress through the cell cycle (Prall et al 1998). In the early stages of breast 
cancer, ERa is often overexpressed, leading to increased rates of proliferation hi 
response to oestradiol (Clarke et al 1997). Oestrogen-ERa signalling is therefore 
thought to have a crucial role in breast cancer initiation by increasing the proliferation 
rate of the cells. The high rate of cell proliferation in turn increases the risk of 
spontaneous mutations, and provides an association between the increased rate of cell 
proliferation and the promotion of tumourigenesis in breast cancer cells.
While benign tumours are often enclosed in a capsule, unable to invade surrounding 
tissue, malignant tumours have attained the ability to invade the surrounding tissues and 
metastasise. The ability of cancer cells to migrate and invade surrounding tissues are 
therefore important events in the progression of breast tumours to malignant forms. 
Despite the ability of oestrogens to promote cell proliferation and breast cancer growth,
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the presence of ERa in breast tumour cells is often associated with the more 
differentiated, low grade forms of breast tumours (Desombre 1984). These tumours are 
also less invasive and have a better prognosis for the patient (Godolphin et al 1981). 
However, ERa expression is often lost during breast cancer progression and one third of 
breast tumours lack ERa expression (Lapidus et al 1998). ERa negative breast tumours 
are often less differentiated, more aggressive and invasive, with a poorer prognosis 
(Desombre 1984). Furthermore, it has been demonstrated that the downregulation of 
ERa in breast tumours is associated with the progression of breast cancers to more 
invasive forms of the disease (Thompson et al 1992). In support of these findings, 
Rochefort et al (1998) demonstrated that ERa-positive breast cancer cell lines are less 
invasive compared to ERa-negative cell lines both in vitro and in vivo. In addition, 
overexpression of ERa in normally invasive, ERa-negative breast cancer cell lines 
results in reduced invasiveness of these cells (Platet et al 2000, Garcia et al 1992). 
Therefore, these studies suggest that although ERa-oestradiol cell signalling stimulates 
the growth of breast tumours, ERa has a protective role against breast tumour cell 
invasion by regulating cancer cell invasiveness. Furthermore, the presence of functional 
ERa is clinically important, since it indicates that the breast tumour will respond to 
treatment with anti-hormone therapies such as Tamoxifen that inhibit ERa activity 
(Platet et al 2004).
In conclusion, factors involved in regulating ERa expression and activity are crucial in 
the induction of mechanisms involved in breast cancer progression to invasive forms. 
Since mutations in ERa are rare (Lapidus et al 1998), the loss of ERa expression in 
breast tumours is thought to arise from external influences. One significant factor is 
increased inflammation at the site of breast tumours, which is associated with more 
invasive tumours with a poor prognosis (Blot et al 2003). An inflammatory protein that
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is expressed in breast tumours and is associated with an invasive phenotype is the pro- 
inflammatory protein tissue factor (TF) (Ueno et al 2000, Vrana et al 1996).
1.4. Tissue factor
1.4.1. TF structure and biochemistry
Tissue factor (TF), also known as CD 142, is a 47 kDa transmembrane glycoprotein of 
295 amino acids, which is processed after translation into a mature protein of 263 amino 
acids. TF is a type I integral membrane protein that consists of a large extracellular 
domain of 219 amino acids, a single hydrophobic membrane-spanning domain of 23 
amino acids and a short cytoplasmic domain of 21 amino acids (Fig 1.4) (Morrissey et 
al 1987). Structurally, TF is similar to class II cytokine receptors such as the interferon- 
y receptor (Bazan 1990). Crystallographic studies have shown that the extracellular 
domain of TF is composed of two fibronectin type III domains, joined at an angle of 
120 degrees (Harlos et al 1994). The transmembrane domain of TF is essential for 
anchoring the molecule to the cell membrane and also for the procoagulant activity of 
TF. In contrast to cytokine receptors, TF has a small cytoplasmic domain. However, this 
domain contains three serine residues, two of which (serine 253 and 258) can be 
phosphorylated (Zioncheck et al 1992).
TF is an early immediate gene composed of 6 exons, located on chromosome 1 
(Mackman et al 1989). TF is expressed by cells in response to inflammatory cytokines, 
growth factors and lipopolysaccharide (Flossel et al 1992, Mackman et al 1993). 
Following expression, the extracellular domain of TF is glycosylated by post- 
translational modification at three sites, but this glycosylation is not required for TF 
function (Paborsky et al 1989). In order to be procoagulantly active, TF requires the
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Figure 1.4. Schematic representation of the domains of tissue factor
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TF is an integral membrane glycoprotein that consists of 263 amino acids in its mature 
form. TF has three structural domains; a large extracellular domain of 219 amino acids 
which is glycosylated (CHO) at three sites and composed of two fibronectin type III 
domains, a single hydrophobic transmembrane domain that is composed of 23 amino 
acids and a short cytoplasmic domain of 21 amino acids. Adapted from Spicer et al 
(1987).
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presence of negatively charged phospholipids on the outer side of the cell membrane 
(Paborsky et al 1991). However, cell surface TF can be encrypted in an inactive form 
that only becomes functional following cell activation. The mechanism of TF 
encryption is currently unclear although suggested mechanisms involve asymmetric 
distribution of negatively charged phospholipids within the inner side of the cell 
membrane (Bach 2006), sequestering of TF within lipid rafts (Bach 2006) and 
dimerisation of TF molecules (Roy et al 1991).
In addition to full length TF, an alternatively spliced form of TF (asTF) has been 
identified (Bogdanov et al 2003). asTF lacks exon 5 and therefore has no 
transmembrane or cytoplasmic domain but has a unique C-terminus. Due to the lack of 
a transmembrane domain, asTF is soluble and circulates in the blood stream (Bogdanov 
et al 2003). Furthermore, asTF has been shown to be released from cells in response to 
inflammatory cytokines (Szotowski et al 2005). The absence of a transmembrane 
domain suggests that asTF should have no procoagulant activity, but there are 
conflicting data on the procoagulant activity of asTF (Censarek et al 2007, Bogdanov et 
al 2003). In addition, the physiological function of this form of TF is not known.
1.4.2. The role of TF in haemostasis
TF has a crucial role in haemostasis as the principal initiator of the extrinsic blood 
coagulation cascade and functions as a receptor and cofactor for coagulation factor VII 
(FVII). Many cell types, including epithelial cells of the skin, fibroblasts and astrocytes 
of the brain, constitutively express TF (Drake et al 1989). Additionally, cells of the 
intima and adventitia of the vascular wall and cells of the connective tissue surrounding 
organs constitutively express TF, forming a haemostatic envelope which is activated 
when vascular integrity is disrupted. In contrast, cells that are in contact with the
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bloodstream, principally circulating blood cells and vascular endothelial cells, do not 
constitutively express TF (Drake et al 1989), although these cells are capable of TF 
expression upon activation by inflammatory cytokines (Ruf & Edgington 1994).
The coagulation cascade is comprised of two separate pathways which converge at the 
activation of coagulation factor X (FX) and lead to activation of the common pathway 
(Fig 1.5). The intrinsic pathway is activated by exposure of the blood stream to 
negatively charged surfaces such as collagen and leads to FX activation by FFXa in the 
presence of FVIIIa. The extrinsic pathway of coagulation is activated when blood is 
exposed to TF from the injured tissue. Circulating FVII within the bloodstream binds to 
the extracellular domain of membrane bound TF, resulting in the activation of FVII to 
FVIIa and the formation of a TF:FVIIa complex. The TF:FVIIa complex then activates 
circulating FX to activated factor Xa (FXa), which in turn converts prothrombin to 
thrombin. Moreover, the TF:FVIIa complex also activates FIX and therefore feeds back 
into the intrinsic pathway. Thrombin is a serine protease which digests fibrinogen to 
fibrin. The fibrin monomers then polymerise, resulting in the formation of a fibrin clot 
(Fig 1.5). Ultimately, the coagulation mechanism together with platelet activation and 
aggregation maintains vascular integrity and prevents excessive blood loss through the 
rapid production of a blood clot at the site of injury.
The physiological inhibitor of the TF:FVIIa complex is a protein known as tissue factor 
pathway inhibitor (TFPI) (Broze 1995). TFPI contains three protease inhibitor domains, 
one of which binds to and inhibits FXa. The TFPI:FXa complex then binds to TF:FVIIa 
on the surface of cells, resulting in the formation of a fully inhibited 
TF:FVIIa:FXa:TFPI complex, preventing further initiation of the blood coagulation
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Figure 1.5. Coagulation cascade pathways
Cross-linked fibrin
The extrinsic pathway (blue) is activated following injury to blood vessel walls and 
exposure of TF to FVH in the blood stream. The intrinsic pathway (red) is activated by 
negatively charged surfaces, such as collagen, in the presence of adenosine diphosphate 
(ADP). Both pathways lead to the activation of FXa and the common pathway (green), 
ultimately resulting in the formation of a fibrin clot. (* requires Ca2+ ions and 
phospholipids).
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cascade by TF (Broze 1995). Hence, the release of TFPI from endothelial cells into the 
blood circulation acts as a mechanism of preventing excessive blood coagulation.
1.4.3. Factor VII
Factor VII is a 406 amino acid protein with a molecular mass of 50 kDa (Broze & 
Majerus 1980). FVII is a vitamin K-dependent serine protease and a member of the 
trypsin superfamily, which is activated following binding to its receptor and cofactor, 
TF. FVII circulates in the blood stream at a concentration of 10 nM and a small 
percentage (1 %) of this is in the active form (FVIIa). FVII is an elongated molecule 
that consists of a Gla domain, two epidermal growth factor-like domains (EGF 
domains), and a serine protease domain. The C-terminal Gla domain of FVII contains 
10 y-carboxyglutamic acid residues that allow FVII to bind to the negatively charged 
phospholipids within the cell membrane via calcium ion bridges. The two EGF domains 
interact with the extracellular domain of TF and the serine protease domain is 
responsible for the cleavage of coagulation factor X to its active form (FXa).
1.4.4. Factor X
Factor X (FX) is a vitamin K-dependent serine protease with a molecular weight of 59 
kDa. FX is activated by proteolytic cleavage of the heavy chain by either FVIIa or 
FIXa. Activated FXa consists of two chains that are linked by a disulphide bond. The 
light chain of FXa contains a Gla domain, which has the same function as the Gla 
domain of FVIIa. The light chain also contains two EGF domains and the first EGF 
domain interacts with the extracellular domain of TF (Zhong et al 2002). The heavy 
chain of FXa contains a serine protease domain, which converts prothrombin to 
thrombin.
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1.5. Non-haemostatic and signalling properties of TF:FVIIa 
1.5.1. The function of TF as a cell signalling receptor
In addition to its role in haemostasis, TF has been shown to function as a cell signalling 
receptor. The first evidence for the role of TF as a cell signalling receptor protein came 
from a study by Bazan (1990), which showed that TF shares a large degree of structural 
homology with the class II cytokine receptor family, especially with the interferon-y 
receptor. Subsequently, it was demonstrated that the binding of FVIIa to TF results in 
intracellular calcium ion (Ca2+) oscillations in several cell types (Camerer et al 1996, 
Rottingen et al 1995). FVIIa binding to TF was also shown to induce tyrosine 
phosphorylation in monocytes upon formation of the TFrFVIIa complex (Masuda et al 
1996), indicating the activation of cell signalling pathways within the cells. This finding 
was confirmed by the demonstration that TF:FVIIa signalling results in the activation of 
several intracellular signalling pathways including all three MAPK pathways: 
extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAPK and c-Jun N-terminal 
kinase (JNK) (Poulsen et al 1998, Camerer et al 1999). The TF:FVIIa complex has also 
been shown to activate the phosphatidylinositol 3-kinase (PI3K) pathway (Versteeg et al 
2000). The activation of these pathways by TF:FVIIa signalling has been associated 
with changes in the expression of many genes including the expression of transcription 
factors (Camerer et al 2000a, Camerer et al 1999), proinflammatory cytokines (Wang et 
al 2002), growth factors (Ollivier et al 1998) ahd proteins involved in cytoskeleton 
reorganisation and cell migration (Camerer et al 2000a).
TF has been shown to be essential for embryonic development and TF-deficient mice 
are known to die following 8 days gestation due to abnormalities in blood vessel 
formation (Carmeliet et al 1996). In addition, TF influences a number of physiological 
processes including angiogenesis (Abe et al 1999), cell migration (Jiang et al 2004) and
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wound healing (Chen et al 2005). Furthermore, TF signalling has been implicated in 
pathological conditions such as inflammation (Cunningham et al 1999), tumour 
angiogenesis (Mueller & Ruf 1998), tumour metastasis (Bromberg et al 1995) and 
cardiovascular disease (Taubman et al 1997). TF-mediated cell signalling has been 
suggested to occur via three main mechanisms involving protease-dependent signalling, 
signal transduction by the cytoplasmic domain of TF, and the binding of TF to other 
transmembrane receptors such as integrins (Fig 1.6).
1.5.2. TF signalling through protease activated receptors (PARs)
Protease activated receptors (PARs) are G protein-coupled receptors which have seven 
membrane-spanning regions. PARs are activated by proteolytic cleavage of the N- 
terminal extracellular domain of the receptor, leading to the formation of a new N- 
terminus. The new N-terminus then acts as a tethered ligand and binds to the receptor, 
resulting in the activation of the PAR and the initiation of downstream signalling 
pathways. To date, four PARs have been identified (PAR 1-4). PAR1 is activated by 
proteolytic cleavage by FXa and thrombin (Riewald & Ruf 2001) whereas PAR2 is 
activated by FVIIa, FXa and trypsin (Camerer et al 2000b) and PARS and PAR4 are 
activated by the action of thrombin. The activation of PAR2 by the TFrFVIIa complex 
and FXa has been shown to result in the induction of MAPK signalling pathways 
(Morris et al 2006, Jiang et al 2004) and upregulation of the expression of growth 
factors and proinflammatory cytokines (Morris et al 2006, Hjortoe et al 2004). PARs 
also have an important role in the initiation of inflammatory responses since they are 
activated by serine proteases during tissue injury. PAR activation also leads to the 
upregulation of the expression of proinflammatory cytokines such as interleukin-8 (IL- 
8) (Hjortoe et al 2004). Furthermore, PAR2 signalling results in increased migration and 
invasion of breast cancer cells (Morris et al 2006, Jiang et al 2004). The formation of
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Figure 1.6. TF signalling mechanisms
FX
FXa
PAR2
ACTIVATION OF CELL SIGNALLING
TF activates cell signalling through three main pathways. In the first mechanism, TF 
mediated activation of FVIIa and FXa leads to the activation of PAR2 and FXa also 
activates PAR1. The activation of PARs then leads to the activation of intracellular 
signalling pathways. TF can signal independently of PARs through the cytoplasmic 
domain. The cytoplasmic domain of TF binds to actin-binding protein 280 (ABP-280) 
and leads to reorganisation of the cytoskeleton and cell migration. Finally, TF can 
directly bind to the (31 integrin subunit, resulting in increased cell migration.
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the TF:FVIIa complex can also indirectly lead to PAR1 activation through the 
generation of FXa. The activation of PAR 1 by FXa has been demonstrated to lead to the 
upregulation of the expression of genes involved in angiogenesis and growth (Riewald 
et al 2001) and also lead to increased tumour metastasis (Bromberg et al 2001).
1.5.3. TF signalling through the cytoplasmic domain of TF
The cytoplasmic domain of TF is small compared to other cytokine receptors and has no 
intrinsic enzymatic activity. However, this domain of TF is phosphorylated at serine 
residues 253 and 258 following stimulation of cells with phorbol esters (Zioncheck et al 
1992). Serine 253 is phosphorylated by protein kinase C (PKC) following the activation 
of PAR2 and recruitment of phosphatidylcholine-specific phospholipase C (PC-PLC) 
(Ahamed & Ruf 2004). This phosphorylation causes a conformational change within the 
cytoplasmic domain and allows serine 258 phosphorylation by a putative proline 
directed kinase (Ahamed & Ruf 2004). The cytoplasmic domain of TF has been 
implicated in tumour metastasis (Bromberg et al 1995), inflammation (Ahamed et al 
2007), cell migration (Siegbahn et al 2005), and angiogenesis (Abe et al 1999). 
Furthermore, a study by Ott et al (1998) demonstrated that the cytoplasmic domain of 
TF binds to actin-binding protein 280 (ABP-280), a component of the cytoskeleton, 
independently of FVIIa binding (Fig 1.6). The interaction between TF and ABP-280 
results in the reorganisation of the cytoskeleton, cell adhesion and cell migration (Ott et 
al 1998).
1.5.4. TF signalling through integrins
Integrins are transmembrane adhesion receptors which exist as heterodimers of a and P 
integrin subunits. The 18 a-subunits and 8 (3-subunits combine to form 24 integrin 
heterodimers. Integrin a and p-subunits have a large extracellular domain, a single
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transmembrane spanning domain and a short cytoplasmic domain of between 13 and 70 
amino acids. The extracellular domain of integrins binds to components of the 
extracellular matrix and the cytoplasmic domain is linked to the cytoskeleton. The 
cytoplasmic domain of integrins has no intrinsic enzymatic activity, but interacts with 
adapter proteins linked to the cytoskeleton (Brakebusch & Fassler 2005). This 
connection between the cytoskeleton and extracellular matrix allows cells to transmit 
signals from the extracellular matrix into the cell and results in the activation of cell 
signalling pathways such as the ERK1/2, JNK and PI3K pathways (Schwartz 2001, 
Woodside et al 2001). In addition, the binding of intracellular proteins to the 
cytoplasmic domain results in changes in the binding affinity of the extracellular 
domain. This 'inside-out' activation of integrins allows cells to respond to their 
surrounding environment and to regulate cell processes including cell adhesion, cell 
migration, proliferation and differentiation (Woodside et al 2001). Integrin heterodimers 
bind specific components of the extracellular matrix including fibronectin, laminin, 
vitronectin and collagen. In addition, integrins are activated by the binding of divalent 
cations such as Mg2+ and Mn2+ (Humphries 1996). Furthermore, the extracellular 
domain of integrins has also been shown to be capable of associating with cell 
membrane receptors including the urokinase receptor (uPAR) and epidermal growth 
factor receptor (Brown 2002).
The earliest evidence for an association between TF and integrins came from a study 
where membrane vesicles released from smooth muscle cells were shown to contain TF 
and this was co-localised with the pi integrin subunit (Schecter et al 2000). TF was then 
shown to mediate cell migration through interactions with the a3|31 integrin heterodimer 
(Dorfleutner et al 2004). The induction of cell migration was shown to be dependent on 
both the extracellular domain of TF and the phosphorylation of the cytoplasmic domain
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of TF and it was suggested that the extracellular domain of TF contains a putative 
integrin-binding site (Dorfieutner et al 2004). Recently, cell surface TF has been shown 
to directly bind to the (31 integrin subunit (Versteeg et al 2008). Furthermore, disrupting 
this interaction using specific monoclonal antibodies against the extracellular domain of 
TF was shown to inhibit the growth of breast tumours (Versteeg et al 2008). However, 
neither the structure of the TF-01 integrin complex nor the signalling mechanisms 
initiated by the complex have been elucidated. Moreover, the mechanisms that induce 
the formation of the TF-integrin complex or terminate its function remain unknown.
1.6. Microparticles in cancer
Microparticles are small (0.1-1 um) membrane vesicles that are released from cells 
following cell activation and during apoptosis. These vesicles are composed of a 
phospholipid bilayer rich in the negatively charged phospholipid phosphatidylserine. In 
addition to the phospholipid component, microparticles contain proteins such as 
adhesion proteins derived from the activated cells. Furthermore, it has been shown that 
these microparticle proteins can be transferred to other cell types by incorporation of the 
microparticles into the cell membrane (Scholz et al 2002, Rauch et al 2000). 
Microparticles often possess procoagulant activity which is primarily due to the 
presence of TF (Morel et al 2004). Furthermore, TF-bearing microparticles are the 
major source of blood-borne TF (Yu & Rak 2004).* Microparticles may be released from 
cancer cells (Yu & Rak 2004), endothelial cells, platelets (Schloz et al 2002) and 
leucocytes (Rauch et al 2000). Moreover, elevated levels of microparticles are 
associated with pathological conditions including cancer, cardiovascular disease, sepsis 
and inflammation (Morel et al 2004). Due to the procoagulant activity of TF-containing 
microparticles, elevated levels of circulating microparticles have been associated with
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the increased risk of thrombosis associated with these pathological conditions (Zwicker 
et al 2007).
Increased levels of circulating TF-containing microparticles have been detected in 
breast cancer patients compared to normal healthy patients (Tesselaar et al 2007). As 
well as increasing the risk of thrombosis, elevated levels of microparticles during cancer 
have been shown to influence cellular functions. For example, Janowska-Wieczorek et 
al (2005) demonstrated that incubation of lung cancer cells with microparticles resulted 
in increased metastasis and angiogenesis in lung tumours. Furthermore, incubation of 
breast cancer cells with platelet-derived microparticles has been shown to result in the 
transfer of platelet-derived proteins to the cancer cells, activation of MAPK signalling 
pathways and increased invasiveness of the breast cancer cells (Janowska-Wieczorek et 
al 2006). These studies indicate that far from being inactive cell debris, cell-derived 
microparticles contribute to the progression of cancer by transferring proteins between 
cell types, activating intracellular signalling pathways and influencing cell functions.
1.7. Tissue factor and breast cancer
The association between cancer and thrombosis was first recognised by Trousseau in 
1865 and TF has been identified as a main cause of the hypercoagulation frequently 
observed in cancer patients (Rickles & Falanga 2001). Increased expression of TF has 
been detected in many types of solid tumours including breast cancer (Callander et al 
1992). A number of studies have reported increased expression of TF in 
aggressive/invasive breast tumours. Contrino et al (1996) correlated TF expression and 
tumour histological grade, and higher levels of TF have been observed in malignant 
breast tumours compared to benign forms of the disease. It has also been shown that
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breast cancer cells derived from aggressive breast cancers express high levels of TF, 
whereas cells from benign breast cancers have little to no TF expression (Hu et al 1994).
In addition to increases in tumour cell-derived TF, analysis of TF distribution within 
breast tumours demonstrated higher levels of TF in the tumour stroma. Tumour stroma 
is a connective tissue framework that surrounds the tumour cells and is composed of 
extracellular matrix components such as collagen and fibronectin, macrophages, 
fibroblasts and new blood vessels (Dvorak 1986). Vrana et al (1996) showed that the 
higher levels of TF in breast tumour stroma arose from increased TF expression by the 
infiltrating macrophages and fibroblasts. Furthermore, the appearance of these TF- 
positive stromal cells within breast tumours correlated with the progression of the breast 
tumours to an invasive phenotype (Vrana et al 1996). Moreover, Contrino et al (1996) 
detected functional TF in vascular endothelial cells within invasive but not benign 
breast tumours. In addition, Lwaleed et al (1999) showed that increased TF expression 
in monocytes was associated with greater tumour grade and poorer prognosis, while 
others have reported increased plasma concentrations of TF in breast cancer patients 
compared to controls (Ueno et al 2000). Together these studies highlight the importance 
of TF-positive stromal cells in breast cancer progression. The presence of inflammation 
in the locality of the tumour is also a feature of invasive forms of breast cancer and is 
often associated with a poor prognosis (Blot et al 2003). Furthermore, infiltration of the 
tumour stroma by macrophages in an inflammatory-type response is often observed in 
aggressive tumours. Monocytes-macrophages and endothelial cells are known to 
express high levels of TF in response to inflammatory cytokines (Grignani & Maiolo 
2000). Therefore, leukocytes recruited to the site of the tumour are a potential source of 
TF in the vicinity of breast tumours. In support of this, Blot et al (2003) reported that 
incubation of monocytes with breast tumour cells resulted in increased TF expression in
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both cell types, suggesting a possible paracrine signalling mechanism between tumour 
cells and the infiltrating monocytes leading to up-regulation of TF expression. 
Therefore, far from being an innate component of tumours, the tumour stroma has been 
shown to actively promote tumour growth and progression, as infiltrating inflammatory 
cells and fibroblasts release inflammatory molecules that directly affect the tumour cells 
(Ben-Baruch 2003, Blot et al 2003). Collectively, the evidence from these studies 
suggests that increased TF levels both in the tumour stroma and tumour cells at the site 
of a breast tumour in response to inflammation in the vicinity of the tumour may be a 
determining factor in the progression from benign to invasive forms of breast cancer.
1.8. Aims of the investigation
The aims of this investigation were to examine the influence of TF on breast cancer 
cells and to elucidate the mechanism for the interaction of exogenous TF with the cell 
surface. Factors that alter ERa expression and function in breast cancer cells are 
important to the understanding of the mechanisms involved in the loss of 
responsiveness to oestrogen and progression of tumours to more invasive forms. The 
main objectives were as follows.
  To examine the influence of exogenous TF on ERa expression in breast cancer cell 
lines and the influence of TF on oestradiol-mediated cell proliferation and invasion.
  To investigate the influence of TF on ERa activity through the classical ERE 
pathway and ERa phosphorylation.
  To examine the influence of TF on ERa activity through the AP-1 dependent 
pathway.
  To investigate the interactions of exogenous TF with the cell surface and the 
resultant signalling mechanisms that lead to the regulation of ERa expression and 
cellular proliferation.
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CHAPTER 2
Materials and Methods
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2.1. Materials
Abeam, Cambridge, UK
Anti-human FVIIa antibody
Active Motif, Rixensart, Belgium
ERa ELISA kit, nuclear extract kit, phosphatase inhibitors, recombinant human ERa, 
TransAM AP-1 kit, TransAM ER kit
Amersham Biosciences, Little Chalfont, UK
GFX PCR DNA and gel band purification kit, high-range rainbow molecular weight 
protein marker, Ready-To-Go PCR beads, Ready-To-Go RT-PCR beads
Autogen Bioclear, Calne, UK
Mouse monoclonal anti-human pi integrin PE-conjugated antibody, mouse monoclonal 
anti-human 03 integrin PE-conjugated antibody
Axis-Shield Diagnostics Ltd, Dundee, UK
Mouse monoclonal anti-human TF FITC-conjugated antibody, recombinant human 
factor Vila, recombinant human factor Xa
BD Biosciences, Oxford, UK
Becton Dickinson FACSCalibur flow cytometer, CellQuest software program, 8 well 
cultureslides, Falcon FACS tubes, pEGFP-C3 vector, rat tail collagen type 1
BDH Laboratories Supplies, Poole, UK
Bromophenol blue, glycerol, MgC^, sodium acetate, NaOH
Beckman Coulter, High Wycombe, UK
Mouse monoclonal anti-human PAR1 antibody (WEDE15)
Berthold Technologies Ltd, St Albans, UK
Junior LB 9509 luminometer, luminometer tubes
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Bioline Ltd, London, UK
BioTaq DNA polymerase, molecular grade agarose, HyperLadder II (50-2000 bp), PCR 
Ranger DNA ladder (50-1000 bp)
BioRad Laboratories Inc, Hemel Herapstead, UK
Nitrocellulose membrane
Calbiochem/Merck Chemicals, Nottingham, UK
HBTU, mouse monoclonal anti-human TF antibody, Triton X-100
Dade Behring, Liederbach, Germany
Recombinant truncated human tissue factor Innovin reagent
Developmental Studies Hybridoma Bank University of Iowa, Iowa City, USA
Mouse anti-human pi integrin antibody (AIIB2)
Fermentas Inc, Glen Burnie, USA
GeneRuler 1 kb DNA ladder
Fisher Scientific, Loughborough, UK
Glycine, NaCl, Tris base
Flowgen, Ashby de la Zouch, UK
ProtoFLOW acrylamide solution, ProtoFLOW resolving buffer, ProtoFLOW stacking 
buffer, TEMED, electrophoresis tank
Gibco Invitrogen Corporation, Paisley, UK
Enzyme-free cell dissociation buffer, kanamycin sulphate, lipofectin reagent, low 
melting point agarose, OptiMEM I reduced serum medium, phosphate buffered saline 
(PBS), phenol red-free MEM, phenol red-free RPMI, SOC medium, Superscript II 
reverse transcriptase
Glaxo Wellcome Research and Development, Stevenage, UK
Raswin version 6 program
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Greiner Bio-One Ltd, Stonehouse, UK
12 well culture plates, 24 well culture plates, T25, T75 and T150 cell culture flasks
Helena Laboratories, Sunderland, UK
Cascade M coagulometer, normal human plasma
Lab Vision Corporation, Runcorn, UK
Rabbit polyclonal anti-human pi integrin antibody
Leica Microsystems, Milton Keynes, UK
Leitz Laborlux S fluorescence microscope
LGC-ATCC, Teddington, UK
MCF-7, MDA-MB-231, T47D and ZR-75-1 human breast cancer cell lines
Media Cybernetics, Wokingham, UK
Cool Snap-Pro camera, Image-Pro Plus Version 5.1.2.
MP Biomedicals, Cambridge, UK
Serum replacement media
MWG-Biotech AG, Ebersberg, Germany
P-actin primers, ERa primers, ERp primers, ERE DNA sequences
Nikon, Kingston-upon-Thames, UK
Nikon TMS inverted microscope
Promega Corporation, Southampton, UK
Anti-mouse alkaline phosphatase-conjugated antibody, lOO* BSA, calf intestinal 
alkaline phosphatase (CIAP), cell lysis buffer (5x), CellTiter 96 AQueous One Solution 
reagent, luciferase substrate (Luciferin), pGL3-promoter vector, protease inhibitor 
cocktail, restriction enzymes (BamH. I, EcoR I, Mlu I), Tris-borate EDTA (TBE) buffer, 
TMB stabilised substrate for horse radish peroxidase, Western blue stabilized substrate 
for alkaline phosphatase, Wizard Plus Minipreps DNA purification system
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PromoCell, Heidelberg, Germany
Foetal calf serum (PCS)
R&D Systems, Abingdon, UK
Escherichia coli TB-1 strain
Santa Cruz Biotechnology Inc, Heidelberg, Germany
Donkey anti-goat alkaline phosphatase-conjugated antibody, donkey anti-goat HRP- 
conjugated antibody, goat anti-human GAPDH HRP-conjugated antibody, goat anti- 
human phospho-serine 118 ERa antibody, goat anti-mouse HRP-conjugated antibody, 
goat anti-rabbit IgG FITC-conjugated antibody, goat anti-rabbit HRP-conjugated 
antibody, mouse monoclonal anti-human ERa antibody, mouse monoclonal anti-human 
PAR1 antibody (ATAP2), mouse monoclonal anti-human PAR2 antibody (SAM 11), 
rabbit polyclonal anti-human TF antibody
Scientific Laboratory Supplies Ltd, Hessle, UK
CC>2 incubator
Sigma Chemical Company Ltd, Poole, UK
Absolute ethanol, ammonium persulphate, antibiotic/antimycotic solution, basic 
fibroblast growth factor, Bradford reagent, CaC^, carbenicillin disodium salt, 
chloroform, collagen type IV, dioctadecyl-3, 3, 3', 3'-tetramethylindocarbocyanine 
perchlorate (Dil), dimethyl sulphoxide (DMSO), N, N-Diisopropylethylamine (DIPEA), 
DMEM medium, DNase/RNase free water, ethanolamine, fluorescein, glutaraldehyde, 
isopropanol, L-alanyl-L-glutamine (Glutamax), 2x Laemmli's buffer, LB agar, LB 
broth, lipid free BSA, minimum essential medium Eagle (MEM), 10* MEM, MnCli, 
molecular weight marker (27,000-180,000 Da), 17 p-oestradiol, PBS tablets, p- 
nitrophenyl chloroformate-activated agarose, ROD peptide, RPMI medium, sodium 
bicarbonate, sodium dodecyl sulphate (SDS), SYBR Green I, 12-0- 
tetradecanoylphorbol-13-acetate (TPA), Tween 20, TRI reagent, trypsin/EDTA solution
Stratagene, Amsterdam, The Netherlands
pAP-1-Luc PathDetect reporter vector, Herculase enhanced DNA polymerase, Pfu DNA 
polymerase, T4 DNA ligase
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Syngene, Cambridge, UK
GeneSnap imaging system and GeneTool analysis program
TCS CellWorks Ltd, Buckingham, UK
DMSO freeze medium
Techne Incorporated, Cambridge, UK
Techgene PCR thermal cycler
Tocris Bioscience, Bristol, UK
MAPK inhibitor PD98059
Tripos Associates Inc, St Louis, USA
Alchemy III program
UVP Ltd, Cambridge, UK
UV transilluminator
VWR International Ltd, Lutterworth, UK
Boyden chambers (8 |im pore size), RNase Away
Weber Scientific International Ltd, Teddington, UK
Haemocytometer
Wissenchafliche Software, Freberg, Germany
Basepair primer design program
WPA, Cambridge, UK
WPA lightwave UV/Vis diode-array spectrophotometer
Yorkshire Bioscience, York, UK
dNTP mix
52
2.2. Methods
2.2.1. Culture of breast cancer cell lines
All cells were cultured under sterile conditions and all reagents pre-warmed to 37°C. 
The human breast carcinoma cell line MCF-7 was cultured in T75 (75 cm2) flasks with 
minimum essential medium (MEM) supplemented with 2 mM Glutamax I (L-alanyl-L- 
glutamine), 10 % (v/v) foetal calf serum (PCS) and 1 % (v/v) antibiotic (penicillin (5 
units/ml), streptomycin (5 ug/ml) and amphotericin (25 ng/ml)). The human breast 
cancer cell lines T47D and ZR-75-1 were cultured in RPMI medium supplemented as 
above. The human breast cancer cell line MDA-MB-231 was cultured in DMEM 
medium supplemented as above. Cells were incubated at 37°C under 5 % (v/v) COz 
atmosphere and supplemented every 3 days by replacing 3 ml of culture medium with 
fresh medium.
2.2.2. Subculture and determination of the number of cells
Cells were subcultured when approximately 80 % confluent. Medium was removed 
from the flask and the cells washed with 8 ml of phosphate buffered saline (PBS) (pH 
7.2) to remove all traces of medium. Trypsin/EDTA (5 mg/ml porcine trypsin, 2 mg/ml 
EDTA) (5 ml) was added to the flask and the cells incubated for approximately 3 min at 
37°C to detach the cells. The flask was then tapped firmly to release the cells and the 
trypsin, which can be detrimental to cells, neutralized by adding 5 ml of complete 
medium. The cell suspension was transferred to a 20 ml Sterilin tube and centrifuged at 
400 g for 5 min to pellet the cells. The medium was carefully removed to avoid 
disrupting the pellet and the cells resuspended in 5 ml of fresh medium. To determine 
the number of cells, 20 ul of cell suspension was loaded onto a haemocytometer and the 
number of cells in five 1 mm2 squares counted. The density of cells per ml was then 
calculated as the average number of cells counted per mm2 x dilution factor x 104. To
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start new cultures, 106 cells were added to T75 flasks containing 10 ml of medium and 
incubated at 37°C.
2.2.3. Harvesting of cells for experimental analysis
Cells were trypsinised and cell numbers determined as described in section 2.2.2. An 
appropriate volume of medium containing the required number of cells was placed in a 
centrifuge tube and the cells pelleted by centrifugation at 400 g for 5 min. The cells 
were washed by resuspension hi PBS (1 ml), centrifuged at 12,000 rpm (9,000 g) for 3 
min in a microcentrifuge and the supernatant removed. The cell pellet was stored at - 
70°C until required.
2.2.4. Cryopreservation of cells
Cells were trypinised and cell density determined as described in section 2.2.2. Cells 
were then resuspended in DMSO freeze medium (5 ml) and aliquoted into cryotubes at 
a density of 106 cells/tube. The cryotubes were placed in a freezing chamber and 
gradually cooled down at a rate of -rc/min overnight to -70°C. The cells were then 
transferred to liquid nitrogen for long-term storage. To start new cultures from frozen 
cells, the cells were thawed at 37°C and immediately placed in T75 flasks containing 10 
ml of pre-warmed medium.
2.2.5 Adaptation of cells to phenol red-free and low serum medium
Cell culture medium contains the pH indicator phenol red (phenolsulfonphthalein), 
which has been shown to have oestrogenic properties (Berthois et al 1986). 
Furthermore, PCS is a possible source of oestrogens in culture medium, hi order to 
observe the effects of oestrogen on breast cancer cells, cells were adapted to phenol red- 
free medium and 1 % (v/v) PCS over four days prior to experiments using 17 [}- 
oestradiol, in order to reduce the concentration of oestrogens in the culture medium.
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Cells were gradually adapted to 1 % (v/v) PCS by reducing the percentage of PCS in 
medium from 10 % (v/v) to 5 % (v/v) and finally 1 % (v/v) PCS over four days.
2.3. Measurement of cell proliferation using the MTS-based colorimetric assay
The CellTiter 96 AQueous One Solution reagent contains a tetrazolium compound (3- 
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H- 
tetrazolium (MTS)), which is reduced to a coloured formazan product by NADH and 
NADPH produced by dehydrogenase enzymes in metabolically active cells. The amount 
of formazan produced is therefore proportional to the number of viable cells. Following 
incubation of cells with the reagent the number of viable cells is determined by 
measuring the quantity of formazan product by measuring absorption at 490 nm.
Cells (5* 104) were seeded out into 12 well plates and incubated at 37°C for 2 h to allow 
the cells to adhere. Following treatment of cells for 24-72 h, the medium was then 
carefully removed from each well. In order to determine the rate of proliferation, 
medium (500 ul) and CellTiter 96 AQueous One Solution Reagent (40 ul) were added 
to each well, including one well with no cells used as a blank. The cells were incubated 
at 37°C for 1 h, until a colour change was observed. 240 ul of medium from each 
sample was then transferred to a plastic cuvette, diluted with 560 ul distilled water and 
absorptions measured at 490 nm against the blank sample using a spectrophotometer. A 
standard curve was prepared by preparing serial dilutions of MCF-7 cells ranging from 
0 to 2x10' cells in 500 ul of medium and seeding out into a 12 well plate. The plate was 
incubated at 37°C for 2 h to allow the cells to adhere without any proliferation. 
CellTiter 96 AQueous One Solution Reagent (40 ul) was added to each well and the 
cells incubated for a further 1 h until a colour change was observed. The proliferation 
assay was then carried out as above for each sample in order to construct a standard 
curve of cell number against absorption at 490 nm (Fig 2.1).
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Figure 2.1. Standard curve for the proliferation assay
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MCF-7 cells (0-2x105) were seeded out into 12 well plates in 500 ul of medium. 
Following 2 h incubation at 37°C, 40 ul of the CellTiter proliferation reagent was added 
to each well. Absorptions of the samples were measured at 490 nm and a standard curve 
of cell number against absorption at 490 nm constructed. Data represents the mean 
value of two experiments measured in duplicate ± SD.
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2.4. Flow cytometric determination of cell surface TF antigen and DNA- 
transfection efficiency
Flow cytometry is a procedure for measuring physical and chemical characteristics of 
cells as they pass through a laser light. The instrument measures particle size and 
granularity as well as the presence of fluorescent groups. The fluorescent groups may be 
a fluorescent protein or alternatively, a fluorescent-conjugated antibody used to label 
specific cell antigens. Using this technique, the density of fluorescent groups per cell, as 
well as the proportion of positive cells may be determined. The FL1 detection 
wavelength (530 nm) excites green fluorescent tags. In order to determine cell surface 
TF expression, cells (5xl03) were harvested, washed three times in PBS (1 ml) and 
resuspended in 100 ul of PBS. The cells were then incubated with the mouse 
monoclonal FITC-conjugated anti-human TF antibody (2 (J.g/ml) or a goat anti-rabbit 
IgG FITC-conjugated antibody (4 ug/ml) for 30 min in the dark. The cells were then 
centrifuged at 12,000 rpm for 3 min in a microcentrifuge and the antibody solution 
removed. The cells were washed three times in PBS (1 ml) to remove unbound antibody 
and then resuspended in PBS (300 ul) and transferred to polypropylene FACS tubes. 
Alternatively, cells transfected with pEGFP-C3 were analysed directly. Cells were 
analysed on a Becton Dickinson FACSCalibur flow cytometer by recording 10,000 
events and fluorescence on the FL1 channel. A gate was set to contain approximately 
3% of events from unlabelled or untransfected cells, and mean fluorescence and 
maximum fluorescence determined using the CellQuest software.
2.5. Molecular Biology Techniques 
2.5.1. Isolation of total RNA from cells
The total RNA isolation (TRI) system was used to isolate RNA from cells. In order to 
prevent degradation of RNA, all work surfaces were cleaned with RNase Away to 
eliminate ribonucleases (RNase). Previously harvested cells were thawed at room
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temperature, lysed in 200 ul of TRI reagent by repeated pipetting and incubated at room 
temperature for 5 min. Chloroform (40 ul) was added to each tube, vortexed for 15 s 
and the samples allowed to stand for 10 min at room temperature. The samples were 
centrifuged at 12,000 rpm for 15 min in a microcentrifuge to form two visible layers, 
and the clear aqueous upper phase was carefully transferred to a fresh RNase-free 1.5 
ml eppendorf tube. To precipitate the RNA, isopropanol (100 ul) was added to each 
sample, mixed by vortexing and incubated at -20°C for 1 h. In order to pellet the RNA, 
the samples were centrifuged at 12,000 rpm for 10 min in a microcentrifuge. The 
supernatant was removed and the RNA pellet washed with 200 ul of 75 % (v/v) ethanol. 
The RNA pellet was resuspended in 60 ul RNase-free water and the samples stored at 
-70°C until required.
2.5.2. Determination of RNA purity and concentration
The concentration of RNA hi the samples was determined by measuring the absorption
of each sample at 260 run using a spectrophotometer. The spectrophotometer was
calibrated using 54 ul of distilled water in a quartz micro-cuvette as a blank. 6 ul of
RNA sample was then added to the cuvette and the sample mixed by pipetting. The
absorption at 260 nm was measured and the concentration of RNA calculated as
follows:
RNA concentration (|J.g/ml) = Absorption (260 nm) x 40 x dilution factor
The 260:280 ratio was used to determine the purity of RNA in each sample, with a ratio
above 1.3 indicating RNA of sufficient purity for subsequent RT-PCR analysis.
2.5.3. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Each RNA sample was amplified with ERa and ERP primers as well as with B-actin 
primers as a reference, p-actin, a house-keeping gene is constitutively expressed in cells
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and hence is commonly used as a reference. Primers were reconstituted in RNase-free 
water to give a final concentration of 100 pmol/ul. Using the calculated RNA 
concentrations, an appropriate volume of each RNA solution containing 0.3 ug of RNA 
was diluted in RNase free water to a final volume of 147 ul. 49 ul of this solution, 
.containing 0.1 ug of RNA, was placed into three separate RT-PCR tubes. Mixed 
forward and reverse primers (100 pmol) for ERa, ERp and J3-actin primers were then in 
turn added to separate tubes to make up the volume in each tube to 50 ul. Semi- 
quantitative RT-PCR was carried out with each RNA sample to convert RNA to cDNA 
and then amplify the cDNA using Ready-To-Go RT-PCR beads. When made up to a 
final volume of 50 ul each bead contained 2 units of Taq DNA polymerase, 10 mM 
Tris-HCl (pH 9), 60 mM KC1, 1.5 mM MgCl2, 200 uM of each dNTP, Moloney Murine 
Leukemia Virus reverse transcriptase, RNAguard ribonuclease inhibitor and stabilisers 
including RNase/DNase free BSA. The RT-PCR program was carried out as shown in 
table 2.1.
2.5.4. Analysis of DNA by agarose gel electrophoresis
A 2 % (w/v) agarose gel was prepared by dissolving 1 g of agarose in 50 ml of TBE 
buffer (89 mM Tris-borate pH 8.3, 89 mM boric acid, 2 mM EDTA), and heating in a 
microwave until dissolved. The electrophoresis tray was prepared by sealing the ends 
with masking tape and placing combs with an appropriate number of wells into the 
electrophoresis tray. The gel was mixed and poured into the electrophoresis tray, 
allowed to cool down at room temperature for 20 min and then placed at 4°C for 30 min 
to solidify. When the gel had set, the comb was removed and the gel placed in an 
electrophoresis tank and covered with TBE buffer. Samples were prepared for 
electrophoresis by mixing 10 ul of RT-PCR amplified DNA with 2 ul of loading dye
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Table 2.1. RT-PCR program
Number of cycles
1
18-30
1
N/A
Temperature
42°C
95°C
95°C
58/59°C
72°C
72°C
4°C
Time
30 min
5min
1 min
1 min
1 min
10 min
Hold
Step
Conversion of RNA to cDNA
Degradation of RNA
Denature DNA strands
Primers anneal
Extension by Tag polymerase
Final extension
Final hold
The number of amplification cycles and annealing" temperature used for the PCR step 
were optimised for each primer set.
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(10 % (w/v) glycerol, 0.1 % (w/v) bromophenol blue, 89.9 % (v/v) TBE buffer pH 8.3) 
and 1 ul of SYBR Green I. Additionally, a DNA marker was prepared by mixing 5 ul of 
PCR Ranger DNA marker and 1 ul of SYBR Green I. The DNA markers and samples 
were in turn loaded into separate wells and electrophoresis carried out at 100 V until the 
bromophenol blue band was 1 cm from the end of the gel. Following separation of the 
DNA, the bands were visualised with a UV transilluminator and recorded using the 
GeneSnap imaging system. mRNA expression was analysed by comparing the intensity 
of the bands to |3-actin for each sample using the GeneTool program.
2.5.5. Testing of RNA samples for genomic DNA contamination
In order to ensure that the RT-PCR products were representative of DNA amplified 
from RNA only, the RNA samples were routinely checked for genomic DNA 
contamination by carrying out a PCR reaction with the RNA samples. During this 
procedure, RNA samples free of genomic DNA would produce no PCR product, since 
the RNA template would be destroyed during the first denaturing step at 95°C. Genomic 
contamination of the RNA samples would result in PCR products visible when 
examined by agarose electrophoresis. PCR reactions were set up using Ready-To-Go 
PCR beads. Each bead contains 2.5 units of PuReTaq DNA polymerase, 10 mM Tris- 
HC1 (pH 9), 50 mM KC1, 1.5 mM MgCl2 , 200 uM of each dNTP, stabilizers, and BSA 
when reconstituted with 25 ul of DNase free water. 0.1 ug of RNA sample and 100 
pmol of p-actin forward and reverse primer mix were added to the PCR tube and the 
volume made up to 25 ul using DNase free water. The samples were denatured at 95°C 
for 5 min followed by PCR for 1 min at 95°C, 1 min at 58°C and 1 min at 72°C for 18 
cycles. Samples were analysed by 2 % (w/v) agarose gel electrophoresis and viewed on 
a UV transilluminator. On no occasion when the RNA samples were tested were any
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bands detected, indicating that there was no genomic DNA contamination in the 
samples and the RT-PCR products were representative of DNA amplified from RNA.
2.6. Estimation of protein concentration using the Bradford assay
Cell samples were resuspended in 200 ul of Laemmli's buffer (62.5 mM Tris-HCl pH 
6.8, 10 % (w/v) glycerol, 5 % (w/v) 2-mercaptoethanol, 2 % (w/v) SDS, 0.002 % (w/v) 
bromophenol blue) and lysed by repeated pipetting. The samples were heated at 99°C 
for 5 min and diluted in distilled water for the assay. Additionally, standards of a range 
of known protein concentrations (0, 10, 50, 100 and 150 ug/ml) were prepared by serial 
dilutions of lipid-free BSA in distilled water. The Bradford reagent was prepared by 
diluting the stock reagent with distilled water (1:1 v/v). Standards and samples (100 ul) 
were placed into individual 1 ml plastic cuvettes and Bradford reagent (900 ul) added to 
each cuvette. The samples were allowed to develop for 10 min and the absorption of the 
samples measured at 595 nm using a spectrophotometer. The absorption values of the 
standards were used to construct a standard curve (Fig 2.2) of absorption at 595 nm 
against protein concentration and used to determine protein concentrations of the 
samples.
2.7. SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
A 12 % (v/v) polyacrylamide gel was prepared by mixing 4 ml of acrylamide solution 
(30 % (w/v) acrylamide, 0.8 % (w/v) bis-acrylamide), 2.6 ml of resolving buffer (1.5 M 
Tris-HCl pH 8.8, 0.4 % (w/v) SDS), 3.3 ml of distilled water and 50 ul of 10 % (w/v) 
ammonium persulphate. The solution was gently mixed and de-gased for 2 min under a 
vacuum. Tetramethylethylenediamine (TEMED) (10 ul) was then added to start
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Figure 2.2. Standard curve for Bradford assay
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A range of protein concentration standards (0-150 ug/ml) was prepared by serial 
dilutions of BSA in distilled water. 100 ul of each sample was placed in a separate 
plastic cuvette in duplicate and the diluted Bradford reagent (900 ul) added. Samples 
were allowed to develop for 10 min and the absorptions measured at 595 nm using a 
spectrophotometer. The data represents a typical standard curve ± SD that was prepared 
on each occasion.
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polymerisation and the solution was poured in between the electrophoresis plates in a 
gel caster. A layer of butanol was placed on top of the gel to ensure that the gel was 
level and the gel was allowed to polymerise for at least 1 h. A 4 % (v/v) stacking gel 
was prepared by mixing 0.65 ml of acrylamide solution, 1.3 ml of stacking buffer (0.5 
M Tris-HCl pH 6.8, 0.4 % (w/v) SDS), 3 ml of distilled water and 50 ul of 10 % (w/v) 
ammonium persulphate. The solution was gently mixed and de-gased under a vacuum 
for 2 min. TEMED (10 ul) was added and the gel was poured on top of the polymerised 
lower gel. A comb was placed into the gel and the gel allowed to polymerise for 1.5 h. 
The gel was then placed in the electrophoresis tank and covered with electrophoresis 
buffer (25 mM Tris-HCl pH 8.3, 192 mM glycine, 0.035 % (w/v) SDS). A set of 
molecular weight protein markers (10 ul) was loaded into the first well followed by the 
protein samples loaded into subsequent wells. Electrophoresis was carried out at 100 V 
for 1.5 h until the bromophenol blue band had reached approximately 1 cm from the end 
of the gel. The separated proteins were transferred onto nitrocellulose filter as follows. 
The gel was placed in between blotting paper and nitrocellulose filter soaked in transfer 
buffer (20 mM Tris-HCl pH 8.3, 150 mM glycine, 20 % (v/v) methanol), placed in the 
transfer tank and transferred at 16 mA overnight, at 4°C.
2.8. Western blot analysis
Following the transfer of proteins onto nitrocellulose membrane, the membrane was
blocked with Tris-buffered Saline Tween 20 buffer (TBST) (20 mM Tris-HCl pH 8, 150 
mM NaCl, 0.05 % (v/v) Tween 20) for 2 h and then incubated with the mouse 
monoclonal ERa antibody diluted in TBST (0.2 ug/ml final concentration) for 1.5 h at 
room temperature. The membrane was washed twice in distilled water for 5 min each 
and then incubated with an anti-mouse IgG alkaline phosphatase-conjugated secondary 
antibody diluted in TBST (0.1 ug/ml final concentration) for 1.5 h at room temperature. 
The membrane was washed twice in distilled water for 5 min each and developed with
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Western Blue stabilised substrate for alkaline phosphatase. Subsequently, the membrane 
was washed twice in distilled water for 5 min each and then probed with a goat 
polyclonal HRP-conjugated GAPDH antibody diluted in TBST (0.1 ug/ml final 
concentration) for 1.5 h at room temperature. The membrane was washed twice with 
distilled water for 5 min each and developed using 3,3',5,5 tetramethylbenzidine 
(TMB)-stabilised substrate for HRP. The membrane was then photographed under white 
light using the GeneSnap program and ERa expression analysed by comparing the 
intensity of the bands to GAPDH for each sample using the GeneTool program.
2.9. Measurement of TF activity by the one-stage prothrombin time assay
Cells were harvested and 4xl05 , 8xl05 or 106 cells placed into three separate 1.5 ml 
microfuge tubes. The cells were pelleted by centrifugation at 12,000 rpm for 3 min in a 
microcentrifuge, the medium removed and the cells washed with PBS (1 ml). The cells 
were then resuspended in PBS (100 ul). Prior to testing, all reagents, cuvettes and 
pipette tips were warmed up to 37°C. 25 rnM CaC^ (100 ul) was added to a cuvette in 
the Cascade M coagulometer, followed by cell suspension (100 jj.1). Following 
equilibration for 30 s, normal human plasma (100 ul) was added which also triggered 
the timing mechanism automatically. The clotting time for each sample was recorded by 
the coagulometer. A standard curve was prepared using Innovin recombinant human 
truncated tissue factor (TF) dissolved in distilled water (10 ml), and serial dilutions 
prepared of 0,1, 2, 10 and 20 U/ml, where the recombinant TF stock solution was taken 
to have 1000 arbitary units/ml. The TF activity of the diluted TF solutions was 
measured as above, converted to log values and used to prepare a standard curve of TF 
concentration against clotting time. TF concentrations were determined using the 
following equation derived from the standard curve (Fig 2.3): 
Log [TF] (U/ml) = -3.0666 x log clotting time + 5.5675
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Figure 2.3. One-stage prothrombin time assay standard curve
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Serial dilutions of the recombinant human TF Innovin reagent (0-20 U/ml) were 
prepared in distilled water and the clotting times of the samples measured using the PT 
assay to construct a standard curve of clotting time against TF concentration. Data 
represents the average of two experiments measured in duplicate.
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2.10.Bacterial cell culture and plasmid isolation
2.10.1. Preparation of LB broth and propagation of Escherichia coli TB-1
LB broth was prepared by dissolving LB broth powder (6.25 g) in de-ionised water (250 
ml) and autoclaving. E.coli strain TB-1 was propagated overnight in 50 ml of LB broth 
at 37°C with gentle agitation.
2.10.2. Isolation of plasmid DNA
Plasmid DNA from bacterial cells was extracted and isolated using the Wizard Plus 
Miniprep DNA purification system as follows. 3 ml of bacterial cell suspension was 
centrifuged at 2,500 g for 5 min and the supernatant removed. The bacteria were 
resuspended in 200 ul of resuspension buffer (50 mM Tris pH 7.5, 10 mM EDTA, 100 
ug/ml RNase A). Cell lysis solution (0.2 M NaOH, 1 % SDS) (200 ul) was added and 
mixed by inverting the tube. Neutralisation solution (1.32 M potassium acetate pH 4.8) 
(200 ul) was added, mixed and the lysate centrifuged at 12,000 rpm for 5 min in a 
microcentrifuge to pellet the cell debris. For each miniprep, a 3 ml syringe barrel was 
attached to a minicolumn connected to a vacuum manifold. 1 ml of DNA purification 
resin was added to the column. The cell lysate was mixed with the resin and the solution 
cleared through, retaining the resin in the column. The column was washed with 2 ml of 
wash buffer (80 mM potassium acetate, 8.3 mM Tris-HCl pH 7.5, 40 uM EDTA, 55 % 
ethanol) and cleared through under vacuum as before. The minicolumn was then placed 
into a 1.5 ml tube and residual ethanol removed by centrifugation at 12,000 rpm for 2 
min in a microcentrifuge. 50 ul of DNase free water was added to the minicolumn and 
incubated for 1 min. The plasmid DNA was then eluted from the column by 
centrifugation at 12,000 rpm for 1 min in a microcentrifuge.
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2.10.3. Determining plasmid DNA purity and concentration
To determine the purity of the eluted plasmid DNA, the samples were analysed on a 1 
% (w/v) agarose gel, prepared by dissolving 0.5 g agarose in 50 ml of TBE buffer. The 
plasmid DNA samples were prepared for electrophoresis and electrophoresis carried out 
as described in section 2.5.5. The bands were visualized and inspected using a UV 
transilluminator. The concentration of plasmid DNA in each sample was determined by 
measuring the absorption of a 1 in 10 dilution of the DNA at 260 nm against a water 
blank. The concentration of DNA was then calculated as:
DNA concentration (ug/ml) = Absorbance (260 nm) * 50 x dilution factor
DNA purity was determined by measuring the 260:280 ratio, with a ratio above 1.3 
indicating DNA of sufficient purity.
2.10.4. Ethanol precipitation of DNA
The DNA solution was mixed with sodium acetate (5 M) pH 5.2, and 100 % (v/v) 
ethanol at a ratio of 1:1:4 (v/v/v) and incubated at -20°C for 30 min. The sample was 
then centrifuged at 12,000 rpm for 20 min in a microcentrifuge and the pellet washed 
with 200 ul of 75 % (v/v) ethanol. The sample was centrifuged at 12,000 rpm for 10 
min and the ethanol removed. The pellet was dried and resuspended in DNase free 
water (50 ul).
2.10.5. Preparation and transformation of competent bacterial cells
E.coli strain TB-1 was incubated overnight at 37°C in 50 ml of LB broth. The cells were 
then chilled on ice for 30 min and pelleted by centrifugation at 2,500 g for 20 min. The 
cells were resuspended in 20 ml of ice-cold trituration buffer (100 mM CaC^, 70 mM
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MgCl2, 40 mM sodium acetate) pH 7.4, and diluted to 50 ml with trituration buffer. The 
cells were then incubated on ice for 45 min, centrifuged at 1,800 g for 10 min and 
resuspended in 5 ml of fresh trituration buffer. 80 % (w/v) glycerol (750 ul) was added 
gradually with gentle stirring, and the competent cells divided into 0.2 ml aliquots and 
stored at -70°C until use. In order to transform the competent cells with plasmid DNA, 
DMSO (3 ul) was added to 200 ul of competent cells, mixed and 100 ul of the cell 
suspension transferred into two 0.2 ml microfuge tubes. Plasmid DNA (20 ng) was 
added to one tube and the other used as a negative control. The cells were incubated on 
ice for 30 min and then heat shocked at 42°C for 2 min on a heating block. The samples 
were cooled to 4°C for 1 min, 100 ul of SOC medium added, and the samples incubated 
at 37°C for 1 h to allow the expression of the antibiotic resistance gene encoded within 
the plasmid.
2.10.6. Selection of transformed bacteria
To prepare agar/antibiotic plates, LB agar was prepared by dissolving LB agar powder 
(3.5 g) in de-ionised water (100 ml) and autoclaving. The agar was cooled to 50°C and 
an appropriate antibiotic added. LB agar antibiotic plates were then prepared by pouring 
approximately 20 ml of LB agar into separate Petri dishes and allowing the liquid to set. 
The plates were sealed and stored at 4°C until use. To select the transformed bacterial 
cells, bacterial suspension (20 ul) was spread out onto antibiotic-LB agar plates using a 
sterile glass pipette, and incubated at 37°C overnight. Following the incubation, 
colonies were removed from the plates using a sterile pipette tip and transferred to 10 
ml of LB broth. The bacteria were then incubated at 37°C for 24 h. The bacterial cells 
were pelleted by centrifuging at 2,500 g for 15 min and resuspended in 5 ml of LB broth 
containing 1 % (w/v) glycerol. The cells were then aliquoted and stored at -70°C until
use.
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2.11. Transfection of mammalian cells with plasmid DNA using the Lipofectin 
reagent
Lipofectin reagent is an anionic lipid-based reagent which can encapsulate the plasmid 
DNA into liposomes that readily fuse with the cell membrane and release the plasmid 
into the cell cytoplasm. Prior to transfection, cells (4xl05/well) in 0.5 ml of complete 
medium were seeded out into a 12 well plate and incubated at 37°C for 24 h. The 
medium was then removed from each well and the cells washed with PBS (1 ml). 
OptiMEM 1 reduced serum medium (800 ul) with no antibiotic was then added to each 
well. For each transfection, solution A was prepared by diluting 1 ug of plasmid DNA 
for each of the plasmids in turn in OptiMEM 1 medium (100 ul). Solution B was 
prepared by diluting Lipofectin reagent (10 ul) in OptiMEM 1 reduced serum medium 
(100 ul) for each sample. The two solutions were allowed to stand at room temperature 
for 30 min and then mixed together and allowed to stand at room temperature for a 
further 15 min. Lipid-DNA complexes were then added to the corresponding wells and 
incubated at 37°C for 6 h. Following transfection, the medium was removed and the 
cells washed with 1 ml of PBS. Medium (1 ml) was then added to each well and the 
cells incubated at 37°C for 16 h.
2.12. Luciferase assay
In order to measure transcriptional activation in the cells, resultant luciferase activity 
was developed by adding the luciferase substrate (luciferin) to the cell lysates as 
described below. Luciferase converts luciferin to oxyluciferin and the reaction produces 
light, which is measured and used to determine transcription factor activity in the 
samples.
Firefly Luciferase 
Luciferin + ATP + O2 ————————> Oxyluciferin+AMP + PPj + CO2 + LightMg 2+
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The medium was removed and the cells washed with PBS (1 ml). Lysis buffer (25 mM 
Tris-phosphate pH 7.8, 2 mM DTT, 2 mM l,2-diaminocyclohexane-N,N,N',N'- 
tetraacetic acid, 10 % (w/v) glycerol, 1 % (v/v) Triton X-100) was prepared with 
distilled water and allowed to equilibrate to room temperature. Lysis buffer (200 ul) was 
then added to the cells and left for 1 min. The cells were lysed by pipetting, and each 
sample transferred to a 1.5 ml microfuge tube and kept on ice. The samples were 
vortexed for 15 s and centrifuged at 12,000 rpm for 15 s in a microcentrifuge to pellet 
the cell debris. The supernatant from each sample was transferred to a fresh 1.5 ml 
microfuge tube and kept on ice. The luciferase substrate was equilibrated to room 
temperature and 100 ul added to each luminometer tube. 20 ul of cell lysate was added 
to the luciferase substrate, the sample mixed and the luciferase activity of each sample 
measured over 5 min using a Junior LB 9509 luminometer.
2.13. Statistical analysis
The data are shown as the mean of experiments ± standard deviation (SD). The 
statistical package for the social sciences (SPSS) was used for statistical analysis of the 
results. Significance was determined using one-way ANOVA and p values < 0.05 were 
taken as significant.
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CHAPTER 3
The influence of exogenous tissue factor on the expression 
of ERa in breast cancer cells
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3.1. Introduction
3.1.1. The role of ERa expression in breast cancer cell proliferation and invasion
Oestradiol-ERa signalling results in the increased rate of cell proliferation of ERa-positive 
cells by upregulating the expression and activity of proteins involved in the cell cycle such 
as cyclin D and cyclin dependent kinases (Foster et al 2001, Prall et al 1998). In breast 
tissue, increased rates of cellular proliferation in response to oestrogens can promote the 
initiation of breast cancer and also the growth of existing breast tumours (Clarke et al 
1997). However, the presence of ERa in breast tumours has been associated with more 
differentiated, less invasive tumours, with a better prognosis for the patient (Godolphin et al 
1981). Furthermore, the loss of ERa is associated with the progression of breast tumours to 
a less differentiated, invasive phenotype and oestradiol-independent growth (Thompson et 
al 1992, Desombre 1984). Therefore, it has been suggested that ERa may have a protective 
function against cell invasion and consequently the rate of cancer metastasis. During the 
progression of tumours from benign to malignant forms, cancer cells acquire the ability to 
degrade the surrounding extracellular matrix and migrate through basement membranes, 
allowing cancer cells to metastasise to secondary sites (Knowles & Selby 2005). The ability 
of cancer cells to invade surrounding tissues is the first step in this process and involves the 
loss of cell to cell adherence, rearrangement of the cytoskeleton and the production of 
enzymes to degrade the extracellular matrix (Knowles & Selby 2005). Several studies have 
reported an anti-invasive function for ERa in breast cancer cells. Initially it was observed 
that ERa positive breast cancer cell lines are less invasive than ERa negative cells both in 
vitro and in vivo (Thompson et al 1992). In addition, treatment of ERa-positive cells with 
oestrogen was shown to reduce cell invasiveness whereas anti-oestrogens increased cell
invasiveness (Rochefort et al 1998). Furthermore, transfection of functional ERa into
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highly invasive, ERa-negative breast cancer cell lines results in reduced invasiveness in 
these cells (Platet et al 2000, Garcia et al 1992). The oestradiol-ERa complex 
downregulates the transcription of specific genes that promote cell invasion such as the 
matrix metalloproteinases (MMPs), which degrade the extracellular matrix (Nilsson et al 
2007, Lu et al 2006). Furthermore, the oestradiol-ERa complex upregulates the expression 
of anti-proteases such as al-anti-chymotrypsin, which inhibit matrix degradation 
(Rochefort et al 2001). Therefore, understanding the mechanisms by which ERa expression 
is downregulated will elucidate some of the processes that occur during the progression of 
breast tumours to more invasive, oestrogen-independent phenotypes. Among the signalling 
pathways known to influence ERa expression are the MAPK pathways. One such cell 
signalling pathway is the ERK1/2 pathway (Creighton et al 2006, Kronblad et al 2005), the 
induction of which has been shown to downregulate ERa in breast cancer cells (Holloway 
et al 2004, Oh et al 2001). In addition, the transcriptional enhancer region upstream of the 
ERa gene contains an AP-1 response element (Tang et al 1997), which positively regulates 
ERa expression through the activation of the JNK signalling pathway (Huang et al 2006).
3.1.2. The association between TF expression and breast cancer invasiveness
The association between increased expression of TF and more invasive breast tumours is 
well established (Contrino et al 1996, Vrana et al 1996). Furthermore, overexpression of TF 
in breast cancer cell lines results in increased invasiveness in these cells in vitro (Kato et al 
2005). TF has been shown to promote breast cancer cell migration through the formation of 
the TF:FVIIa:FXa complex which activates PAR2 and downstream signalling pathways 
(Hjortoe et al 2004, Jiang et al 2004). Furthermore, the ability of TF to induce breast cancer 
metastasis in vivo may be inhibited using a specific anti-TF monoclonal antibody (Ngo et al
2007).
74
3.1.3. Aims
Recombinant truncated TF was used in this investigation to represent soluble or 
microparticle-derived TF that is released from infiltrating stromal cells in the vicinity of the 
tumour. Initially, the influence of exogenous TF on breast cancer cell proliferation and 
invasion in the presence and absence of 17 p-oestradiol was examined. The recombinant 
human truncated TF used in this investigation constitutes the active component of the 
Innovin reagent and consists of the extracellular domain and transmembrane domain of TF 
(amino acids 1-242) but lacks the cytoplasmic domain. Furthermore, in the Innovin reagent 
TF is incorporated into phospholipid vesicles (60:20:20 phosphatidylcholine: 
phosphatidylserine: phosphatidylethanolamine) for optimal procoagulant activity. 
Therefore, to confirm that the influence of the Innovin reagent arose from the TF protein 
and not the lipid component, the influence of the lipid component on cell proliferation was 
examined. Subsequently, the influence of exogenous TF on ERa expression was 
investigated. The main objectives of the study were as follows.
• To establish the influence of exogenous TF on the proliferation of ERa-positive breast 
cancer cells
• To confirm that the function was due to the TF component of the Innovin reagent
• To examine the influence of exogenous TF on ERa expression in breast cancer cells
• To examine the influence of exogenous TF on the invasiveness of ERa-positive breast 
cancer cells
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3.2. Methods
3.2.1. Analysis of endogenous TF expression in breast cancer cells
3.2.1.1. Analysis of cell surface TF expression by flow cytometry
MCF-7, T47D, ZR-75-1 and MDA-MB-231 human breast cancer cells (5xl05 each) were 
harvested, washed twice with PBS (1 ml) and resuspended in PBS (100 ul) containing the 
mouse monoclonal anti-human TF FITC-conjugated antibody (2 ug/ml final concentration). 
Parallel sets of cells were incubated with a goat anti-rabbit IgG FITC-conjugated antibody 
(4 ug/ml final concentration) as negative controls. Cells were incubated for 30 min at 4°C 
in the dark, washed and resuspended with PBS (300 ul) and analysed by flow cytometry as 
described in the general methods section 2.4.
3.2.1.2. Determination of TF activity on cells using the PT assay
MCF-7, T47D, ZR-75-1 and MDA-MB-231 cells were harvested and washed with PBS (1 
ml). Cell numbers were determined and serial dilutions of cells (4X103 , 8X 105 and 106) 
were prepared in PBS (100 ul) in duplicate. The clotting time of each sample was 
determined using the PT assay as described in the general methods section. TF activity 
(units/ml) of the samples was determined from the previously prepared standard curve (Fig 
2.3). The calculated concentrations of TF were used to determine TF activity per 106 cells.
3.2.2. The influence of TF and oestradiol on cell proliferation
3.2.2.1. Examination of the influence of TF and oestradiol on cell proliferation
17 p-oestradiol (50 mg) was reconstituted in a minimal volume of absolute ethanol and 
incubated at 50°C until completely dissolved. The solution was then diluted in PBS by
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drop-wise addition to 0.1 uM oestradiol which was used as a stock solution. MCF-7 or 
T47D cells (5><104) were seeded out into 12 well plates in complete medium and incubated 
with the recombinant human truncated TF Innovin reagent (0-500 nM) in the presence and 
absence of oestradiol (0-1000 pM) for 24 h. The rate of cell proliferation was determined 
using the MTS based assay (section 2.3). The study was then repeated over 24, 48 and 72 h 
using phenol red-free medium supplemented with 1 % PCS to reduce the oestrogenic 
influence of phenol red or serum-derived oestrogens.
3.2.2.2. Purification of lipids by delipidation of recombinant TF
The recombinant TF reagent was dissolved in ice-cold chloroform (25 ml) for 2 h on a 
rolling platform. Methanol (25 ml) was added and incubated at -20°C for 2 h to precipitate 
proteins, and the solution was then centrifuged at 500 g for 10 min. The supernatant was 
transferred to a conical flask attached to a rotary evaporator in a water bath at 40°C and 
incubated for 2 h until the chloroform had evaporated. The lipids were then freeze-dried to 
ensure the removal of chloroform and then resuspended in 10 ml of phenol red-free MEM 
to the original concentration in the Innovin reagent and kept under nitrogen. The lipids 
were also supplemented with 1 % (w/v) BSA in order to buffer the lipids, as in the original 
Innovin reagent.
3.2.2.3. The influence of lipids extracted from recombinant TF on cell proliferation
MCF-7 cells (5><104) were seeded out into 12 well plates in phenol red-free medium 
supplemented with 1 % PCS and incubated with lipids (diluted to the same concentrations 
as the Innovin reagent used) extracted from recombinant TF for 24 h. Following 24 h 
incubation, cell proliferation was measured using the MTS-based assay as before.
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3.2.3. Examination of the influence of TF on ERa mRNA expression in breast cancer
cells
3.2.3.1. Design and optimisation of primers for RT-PCR analysis of ERa and ERp
The full length cDNA sequences for ERa and ERp were obtained from published 
sequences on PubMed (Green et al 1986, Mosselman et al 1996). Primers were designed for 
both genes using the Basepair program. Ideally, primers should be 18 to 24 bp in length and 
have a GC content of 40 to 60 %. The expected DNA fragment sizes were 511 bp for ERa, 
456 bp for ERP designed using Basepair program, and 460 bp for the p-actin primer set. In 
addition, a set of published ERP primers (Kurebayashi et al 2000) with an expected 
fragment size of 346 bp were used.
The primer sets for ERa and ERp designed using the Basepair program were optimised for 
RT-PCR by carrying out RT-PCR with RNA isolated from MCF-7 cells over a range of 
annealing temperatures of 50-60°C and number of cycles of amplification. In order to 
optimise the number of amplification cycles, six reactions were set up with RT-PCR beads 
and the primers as described in the general methods section 2.5.3. A tube was removed 
after 21 cycles and subsequently after every second cycle up to 31 cycles, and the RT-PCR 
products analysed by 2 % (w/v) agarose gel electrophoresis. The annealing temperatures 
and number of amplification cycles of the primer sets are shown in table 3.1.
3.2.3.2. Analysis of baseline ERa and ERp mRNA expression using RT-PCR
MCF-7, T47D, ZR-75-1 and MDA-MB-231 cells (5xl05) were harvested and total RNA 
was isolated. The quantity and purity of each RNA sample was determined as described in 
the general methods section. Three RT-PCR reactions were set up with each RNA sample
and the ERa, ERP, and P-actin primers added to separate tubes and the RT-PCR reactions
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Table 3.1. Primer sequences and conditions for RT-PCR
Gene
ERa
ERp
ERp 
(Kurebayashi
et al 2000)
P-actin
Primer sequence
For: 5'-TCA GAT AAT CGA CGC CAG G-3'
Rev: 5'-GGC TCA GCA TCC AAC AAG G-3'
For: 5'-GCA GTC AAT CCA TCT TAG C-3' 
Rev: 5'- TTA CAT CCT TCA CAC ACG ACC-3'
For: 5'-TCA CAT CTG TAT GCG GAA CC-3' 
Rev: 5'-CGT AAC ACT TCC GAA GTC GG-3'
For: 5'-CCA GAG CAA GAG AGG CAT CC-3'
Rev: 5'-CTG TGG TGG TGA AGC TGT AG-3'
Temp.
(°C)
59
N/A
58
58
No. of
cycles
25
N/A
30
18
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carried out as before. The RT-PCR products were examined by agarose gel electrophoresis 
and images recorded using the GeneSnap program.
3.2.3.3. Analysis of the influence of TF on ERa mRNA expression using RT-PCR
MCF-7 and T47D cells (2xl05) were seeded out into 12 well plates and incubated with 
recombinant TF (0-500 nM) for 24 h. The cells were then harvested and total RNA isolated 
from the cell samples. The samples were amplified by RT-PCR using the ERa and p-actin 
primer sets and the products examined by agarose gel electrophoresis. Images were 
recorded using the GeneSnap program and ERa expression compared to P-actin using the 
GeneTool program.
3.2.4. Examination of the influence of TF on ERa protein expression in breast cancer
cells
3.2.4.1. Analysis of the influence of TF on ERa protein expression by western blot
MCF-7 and T47D cells (2X103) were seeded out into 12 well plates and incubated with 
recombinant TF (0-500 nM) for 24 h. The cells were then harvested, lysed in Laemmli's 
buffer (200 ul) and protein concentrations estimated using the Bradford assay as described 
in the general methods section 2.6. Protein samples were separated using 12 % (w/v) SDS- 
PAGE and transferred onto nitrocellulose membranes as described in the general methods 
section 2.7. The membranes were then probed for ERa and GAPDH with appropriate 
antibodies as described in the general methods section 2.8. Images were recorded using the 
GeneSnap program and ERa expression was compared to GAPDH using the GeneTool 
program.
80
3.2.4.2. Analysis of the influence of TF on ERa protein expression by ELISA
A commercial sandwich ELISA kit (NR Sandwich ERa ELISA) was used to measure ERa 
protein levels. MCF-7 or T47D cells (2xl05) were seeded out into 12 well plates and 
treated with recombinant TF (0-500 nM) for 24 h. The cells were then harvested and whole 
cell extracts prepared using the Nuclear Extract Kit as follows. Cells were lysed in 50 ul of 
complete lysis buffer (lysis buffer (composition not revealed), 10 mM DTT, 1 % (v/v) 
protease inhibitors). The samples were vortexed for 10 s, incubated on ice for 10 min on a 
rocking platform at 100 rpm and finally vortexed for a further 30 s to ensure complete cell 
lysis. The cell debris was pelleted by centrifugation at 14,000 rpm for 10 min in a 
microcentrifuge. The supernatant was then transferred to a 1.5 ml tube and protein 
concentrations of the samples determined using the Bradford assay.
10 |4.g of protein from each cell sample was added to separate wells in the ELISA plate in 
duplicate and incubated for 1 h at room temperature on a rocking platform at 100 rpm. The 
wells were washed three times with wash buffer (200 ul) and then incubated with the 
supplied rabbit anti-human ERa antibody, diluted 1:400 in diluent buffer (50 ul), for 1 h at 
room temperature. The wells were then washed three times with wash buffer (200 ul) and 
incubated with the supplied anti-rabbit HRP-conjugated secondary antibody diluted 1:1000 
in diluent buffer (50 ul) for 1 h at room temperature. Finally, the wells were washed four 
times with 200 ul of wash buffer and developed with the supplied HRP substrate solution 
(100 ul) for 9 min in the dark. The reactions were terminated with 0.5 M sulphuric acid 
(100 ul) and the absorptions measured at 450 nm with a reference at 620 nm using an 
Anthos 2010 microplate reader. To prepare a standard curve, serial dilutions of recombinant 
ERa protein were prepared in diluent buffer. 50 ul of each sample was added to wells in
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duplicate to give final concentrations of 0, 31.25, 62.5, 125, 250, 500, 1000 and 2000 ng/ml 
of ERa protein. The ELISA was carried out alongside the samples as described above. The 
standard curve of ERa protein concentration against absorption at 450 nm was prepared and 
used to convert absorption values from the unknown samples into ERa protein 
concentrations.
3.2.5. Analysis of the long-term influence of TF on ERa mRNA and protein expression
MCF-7 cells were cultured in three T75 flasks in complete MEM (12 ml) supplemented 
with recombinant TF (0-500 nM). The cells were supplemented with fresh medium every 3 
days and recombinant TF as above. Samples of cells were harvested from each flask over a 
period of 5 weeks as follows. The cells were subcultured every 7 days and two sets of cells 
(106) from each flask were removed, washed with PBS and pelleted in 1.5 ml eppendorf 
tubes and stored at -70°C until required. The remainder of the cells were cultured under the 
above conditions and harvested periodically. RNA was isolated from the cell samples and 
analysed by RT-PCR using ERa and p-actin primers as described in section 2.5.3. ERa 
protein levels were examined by SDS-PAGE and western blot for ERa and GAPDH as 
described in section 2.8.
3.2.6. Examination of the influence of TF on breast cancer cell invasion 
3.2.6.1. Influence of TF on cell migration using a Boyden chamber based assay
A Boyden chamber method based on the migration of cells across a collagen type IV 
membrane was used to examine the influence of TF on cell invasion. Boyden chambers 
with 8 um pore size were placed in the wells of a 24 well plate and coated with 50 ul 
collagen type IV (1 mg/ml (w/v)) by incubation at 37°C for 12 h. Following the incubation,
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excess collagen solution was removed and MCF-7 or T47D cells (2xl05) were seeded out 
into the upper compartment of each Boyden chamber in phenol red-free medium (250 ul) 
supplemented with 1 % (v/v) PCS. Oestradiol (250 pM) was added to the medium in the 
upper chamber in parallel with control samples without oestradiol. Phenol red-free medium 
(250 ul) supplemented with TF (0-500 nM) was added to the lower compartment (Fig 3.1). 
The cells were incubated at 37°C for 24 h to allow migration through the collagen barrier. 
Following 24 h incubation, cells on the upper side of the filter were removed using a cotton 
swab and discarded. The volume of the medium in the lower chamber was measured and 
adjusted to 500 ul with medium. CellTiter 96 AQueous One Solution reagent (40 ul) was 
added to the lower compartment and the empty Boyden chambers placed back into the 
wells. The cells were then incubated for 5 h at 37°C, until a colour change was observed. 
The absorption of each sample (240 ul) was then measured at 490 nm and the number of 
cells that had migrated across the filter determined using the previously prepared standard 
curve (Fig 2.1).
3.2.6.2. Examination of changes in cell morphology in response to exogenous TF
MCF-7 cells (2 * 104) were seeded out into 8 well cultureslides in MEM medium 
containing 1 % PCS and incubated at 37°C for 24 h. The cells were treated with TF (0-500 
nM) or basic fibroblast growth factor (bFGF) (30 ng/ml) as a positive control (Johnston et 
al 1995) and incubated at 37°C for 48 h. The cells were then washed with PBS and fixed 
with 3 % (v/v) glutaraldehyde for 20 min at room temperature. The cells were washed three 
times with PBS and incubated at 37°C for 15 min with the cell membrane stain 1,1'- 
Dioctadecyl-3, 3, 3', 3'-tetramethylindocarbocyanine perchlorate (Dil) at a final
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Figure 3.1. Schematic representing the set up of the Boyden chamber based migration 
assay.
Upper compartment of 
Boyden chamber
Lower compartment
Collagen type IV 
Cells
Boyden chambers with pores (8 um) were placed into 24 well plates and coated with type 
IV collagen. Cells (2xl05) were placed in the upper chamber containing medium with 
oestradiol (0-250 pM). The lower compartment containing medium was supplemented with 
TF (0-500 nM) and the cells incubated for 24 h to allow cells to migrate across the filter. 
Cells in the upper compartment were removed and the CellTiter reagent placed in the lower 
compartment. The number of migrated cells was determined by measuring absorption of 
the samples at 490 nm.
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concentration of 10 ug/ml. The cells were then washed three times with PBS and visualised 
using a CoolSnap Pro camera attached to a Leitz Laborlux S fluorescence microscope. 
Images were processed using the Image-Pro Plus Version 5.1.2.
3.2.6.3. Influence of TF on cell invasion using collagen type I gels
A collagen solution was prepared by mixing rat tail collagen type I (4.66 mg/ml in 0.02 M 
acetic acid (w/v)) mixed with appropriate amounts of lOx sterile MEM to produce a range 
of collagen concentrations (0.28-0.38 % (w/v)) and neutralised with 1 M sterile NaOH. The 
collagen solutions (0.5 ml) were placed in individual wells in a 24 well plate and incubated 
at 37°C overnight to allow the collagen to solidify. Cells (104) were seeded out onto the 
collagen gels in 0.5 ml complete MEM and incubated at 37°C for 24 h to allow adherence. 
The cells were supplemented with TF (0-500 nM) and examined daily using a light 
microscope. The cells were supplemented with fresh medium and test reagents every 3 days 
up to 7 days.
3.3. Results
3.3.1. Determination of cell surface TF expression in breast cancer cell lines
The expression of cell surface TF in four breast cancer cell lines was examined by flow 
cytometry using a monoclonal anti-human TF FITC-conjugated antibody. 10,000 events 
were measured and a gate set to contain 3 % of unlabelled cells. 7.2 % of MCF-7 cells, 6.5 
% of T47D cells, 3.7 % of ZR-75-1 cells and 35.4 % of MDA-MB-231 cells were in this 
region (Fig 3.2). In addition, TF procoagulant activity on the surface of each cell line was 
measured using the PT assay, since there is often disparity between TF antigen and
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Figure 3.2. Analysis of cell surface TF in breast cancer cell lines by flow cytometry
MCF-7
10°
T47D
M1
10" 10'
FLl-H 10
Cells (5 X 105) were labelled with an anti-TF FITC-conjugated antibody or a goat anti-rabbit 
FITC-IgG control antibody for 30 min in the dark. The cells were then washed three times 
in PBS (1 ml), resuspended in PBS (300 ul) and analysed on a FACSCalibur flow 
cytometer. 10,000 events were measured and a gate was set to contain 3 % of unlabelled 
cells. The mean fluorescence and number of fluorescent events was measured and analysed 
using the CellQuest software program. Area = untreated cells, red line = anti-human TF 
FITC-conjugated antibody, green line = FITC-IgG control.
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procoagulant activity in tumour cells. The TF procoagulant activities of the breast cancer 
cells mirrored TF antigen expression, with MCF-7 cells having no detectable procoagulant 
activity and MDA-MB-231 cells showing high TF activity (Table 3.2). ZR-75-1 cells 
exhibited very low procoagulant activity, while T47D cells had slightly higher procoagulant 
activity. These data indicate that MCF-7, T47D and ZR-75-1 cells express little to no TF, 
while MDA-MB-231 cells express high levels of TF.
3.3.2. Analysis of cell proliferation in response to TF and oestradiol
Incubation of MCF-7 cells with TF (50 and 500 nM), in culture medium containing phenol 
red and 10 % (v/v) PCS, had no detectable influence on the proliferation rate of MCF-7 
cells at 24 h post-treatment (Fig 3.3). Furthermore, the addition of oestradiol (50-1000 pM) 
resulted only in small increases in the rate of cell proliferation. The addition of TF (50 and 
500 nM) together with oestradiol (100-500 pM) appeared to interfere with the oestradiol- 
mediated cell proliferation, but the differences were not significant (Fig 3.3). Since the pH 
indicator phenol red, which is present in culture medium, is known to have oestrogenic 
properties the assay was repeated in phenol red-free culture medium containing 1 % (v/v) 
PCS in order to reduce the amount of oestrogens in the medium. Measurement of the 
response of MCF-7 cells to TF (50 nM) indicated increased rates of proliferation over 24 to 
48 h (Fig 3.4 & 3.5). Examination of the influence of TF (500 nM) showed no detectable 
effect on cell proliferation at 24 h, but appeared to inhibit MCF-7 cell proliferation rates 
between 48 and 72 h compared to the untreated control (Fig 3.5 & 3.6). The addition of 
oestradiol (100-500 pM) to MCF-7 cells seemed to induce proliferation when examined 
over 24 to 72 h, and was largely unaffected by the addition of 50 nM TF. However, the 
appearance of a trend was observed in which the addition of a combination of TF (500 nM) 
with a range of concentrations of oestradiol (100-500 pM) seemed to reduce the rate of
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Table 3.2. Procoagulant activity of breast cancer cell lines
Breast cancer 
cell line
MCF-7
ZR-75-1
T47D
MDA-MB-231
Clotting time (s)
4x 10s cells
No clot
No clot
No clot
38.2 ±1.6
8 x 105 cells
No clot
98.5 ± 8.5
No clot
31.4 ±3.6
106 cells
No clot
90 ±1.4
64.7 ± 2.4
27.7 ± 2.9
TF (U/106 
cells)
0
0.39
1.04
14.2
Breast cancer cells were harvested and serial dilutions of the cells (4*105, 8><105 and 106) 
were prepared in PBS (100 ul) in duplicate. The PT assay was carried out with each sample 
and the clotting time recorded using a Cascade M coagulometer. Clotting times were 
converted to units of TF activity using a standard curve prepared with a range of 
concentrations of recombinant TF. The calculated concentrations of TF were then used to 
determine TF activity per 106 cells. The data represents the average of two independent 
experiments ± SD.
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Figure 3.3. The influence of TF on the rate of MCF-7 proliferation in complete 
medium
50 100 250 500 
Oestradiol concentration (pM)
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D 500 nM 
TF
1000
MCF-7 cells (5*104) were seeded out into 12 well plates and treated with recombinant TF 
(0-500 nM) and oestradiol (0-1000 pM). The rate of proliferation was measured at 24 h 
post-treatment using the MTS-based assay and cell numbers determined using the standard 
curve. The data is representative of eight individual experiments ± SD.
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Figure 3.4. The influence of TF on the rate of MCF-7 proliferation in phenol red-free 
medium at 24 h
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MCF-7 cells were (5*104) were seeded out into 12 well plates and treated with recombinant 
TF (0-500 nM) and oestradiol (0-500 pM). The rate of proliferation was measured at 24 h 
post-treatment using the MTS-based assay. The data is representative of two independent 
experiments ± SD.
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Figure 3.5. The influence of TF on the rate of MCF-7 proliferation in phenol red-free 
medium at 48 h
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MCF-7 cells (5xl04) were seeded out into 12 well plates and treated with recombinant TF 
(0-500 nM) and oestradiol (0-500 pM). The rate of proliferation was measured at 48 h post- 
treatment using the MTS-based assay. The data is representative of two independent 
experiments ± SD.
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Figure 3.6. The influence of TF on the rate of MCF-7 proliferation in phenol red-free 
medium at 72 h
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MCF-7 cells (5*104) were seeded out into 12 well plates and treated with recombinant TF 
(0-500 nM) and oestradiol (0-500 pM). The rate of proliferation was measured at 72 h post 
treatment using 
experiments ± SD
the MTS-based assay. The data is representative of two independent
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MCF-7 cell proliferation, with maximal suppression observed in the presence of 250 pM 
oestradiol. Incubation of T47D cells with TF (0-500 nM) and oestradiol (0-500 pM) 
appeared to have little influence on cell proliferation following 24 h (Fig 3.7). However, 
T47D cells incubated with oestradiol (100-250 pM) exhibited an increased tendency to 
proliferate when measured at 48 h (Fig 3.8). The inclusion of TF (500 nM) together with 
oestradiol (250 pM) appeared to reduce the rate of T47D cell proliferation at 48 and 72 h 
(Fig 3.8 & 3.9).
3.3.3. Analysis of cell proliferation in response to the lipids extracted from 
recombinant TF
Lipids extracted from recombinant TF were tested for residual TF using the PT assay, and 
were shown to be free from any procoagulant activity. The influence of the lipids on cell 
proliferation was examined using the MTS-based assay. Incubation of MCF-7 cells with 
lipids alone (diluted x 100 and * 10) had no measurable effect on cell proliferation over 24 h 
(Fig 3.10). Furthermore, the addition of lipids (diluted xlOO and X 10) together with 
oestradiol (250 pM) slightly reduced the rate of proliferation, but not to the same extent as 
recombinant TF (500 nM) with oestradiol (250 pM) (Fig 3.4), indicating that the 
contribution of the TF-associated lipids to the suppression of oestradiol induced 
proliferation is minimal.
3.3.4. Optimisation of the RT-PCR conditions using the ERa and ERfJ primers
The annealing temperature and number of cycles of amplification for the ERa and ERp 
primer sets, designed using the BasePair program, were optimised for RT-PCR. The 
optimal annealing temperature and number of cycles of amplification for the ERa primers
were determined as 59°C and 25 cycles respectively (Fig 3.11). A range of annealing
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Figure 3.7. The influence of TF on the rate of T47D proliferation in phenol red-free 
medium at 24 h
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T47D cells (5><104)were seeded out into 12 well plates and treated with recombinant TF (0- 
500 nM) and oestradiol (0-500 pM). The rate of proliferation was measured at 24 h post- 
treatment using the MTS-based assay. The data is representative of two independent 
experiments ± SD.
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Figure 3.8. The influence of TF on the rate of T47D proliferation in phenol red-free 
medium at 48 h
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T47D cells (5x 104) were seeded out into 12 well plates and treated with recombinant TF (0- 
500 nM) and oestradiol (0-500 pM). The rate of proliferation was measured at 48 h post- 
treatment using the MTS-based assay. The data is representative of two independent 
experiments ± SD.
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Figure 3.9. The influence of TF on the rate of T47D proliferation in phenol red-free 
medium at 72 h
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T47D cells (5><104)were seeded out into 12 well plates and treated with recombinant TF (0- 
500 nM) and oestradiol (0-500 pM). The rate of proliferation was measured at 72 h post- 
treatment using the MTS-based assay. The data is representative of two independent 
experiments ± SD.
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Figure 3.10. The influence of lipids extracted from TF on MCF-7 proliferation
x100 
lipids
x10
lipids
250 pM E2 x100 
lipids+ 
250 pM 
E2
x10 
lipids+ 
250 pM 
E2
MCF-7 cells were treated with lipids extracted from recombinant TF (diluted xlOO and 
xlO) and oestradiol (0-250 pM). The rate of proliferation was measured at 24 h post- 
treatment using the MTS-based assay. The data is representative of five independent 
experiments in duplicate ± SD.
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Figure 3.11. Optimisation of the ERa primers for RT-PCR
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RNA was isolated from MCF-7 cells and six reactions set up using Ready-to-go RT-PCR 
beads and the ERa primers. RT-PCR was carried out for 31 cycles amplification with an 
annealing temperature of 59°C. A tube was removed every two cycles starting from cycle 
21 and the RT-PCR products analysed by 2 % (w/v) agarose gel electrophoresis and images 
taken using the Gene Snap program.
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temperatures was used to optimise the ERp amplification reaction using the designed ERp 
primers, but no observable bands were obtained with any of the test conditions. Therefore, 
a second set of published ERp primers were tested according to the published conditions 
(Kurebayashi et al 2000). However, no detectable bands were obtained using the procedure 
and therefore it was presumed that MCF-7 cells do not express this protein.
3.3.5. Analysis of baseline expression of ERa and ERp mRNA in breast cancer cells
Baseline expression of ERa and ERP mRNA in four breast cancer cell lines was examined 
by RT-PCR. MCF-7 cells expressed the highest levels of ERa, while T47D cells had lower 
levels of ERa (Fig 3.12). ZR-75-1 cells expressed very low levels of ERa and MDA-MB- 
231 had no detectable ERa. No ERp bands were detected using either set of primers in any 
of the breast cancer cell lines tested and therefore it was assumed that these cells do not 
express this protein.
3.3.6. Investigation of the influence of TF on ERa expression in breast cancer cell lines 
3.3.6.1. Investigation of the influence of TF on the expression of ERa mRNA
MCF-7 and T47D cells were used to examine the influence of TF on ERa expression, as 
these cells were shown to express high levels of ERa but had little to no TF. The influence 
of TF on ERa expression in MCF-7 cells was initially examined over 72 h. The expression 
of ERa mRNA in MCF-7 cells appeared to follow a trend in which the initial decrease at 24 
h incubation was normalised by 48 h post-treatment with TF (500 nM) (Fig 3.13.). 
Furthermore, the decrease in ERa mRNA expression seemed to be TF concentration 
dependent, with 25 % and 36 % reductions in ERa mRNA expression observed on 
incubation with 50 and 500 nM TF respectively (Fig 3.14). Incubation of T47D cells with
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Figure 3.12. Baseline ERa expression levels in breast cancer cell lines
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RNA was isolated from breast cancer cells (5*105) and RT-PCR carried out using Ready- 
to-go RT-PCR beads and the ERa primers. The DNA products were separated by 2 % (w/v) 
agarose gel electrophoresis and visualised under UV light.
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Figure 3.13. Short-term influence of TF on ERa mRNA expression in MCF-7 cells
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MCF-7 cells (2xl05) were incubated with recombinant TF (0 or 500 nM) and harvested at 
intervals over 72 h. RNA was isolated from the samples and ERa amplified by RT-PCR. 
The products were examined using agarose gel electrophoresis, images recorded using the 
GeneSnap program and ERa expression compared to p-actin using the GeneTool program. 
Data represent the average of two independent experiments ± SD.
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Figure 3.14. The influence of TF on ERa mRNA expression in MCF-7 and T47D cells
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MCF-7 or T4JD cells (2xl05) were incubated with TF (0-500 nM) for 24 h, total RNA 
isolated and ERa mRNA expression examined by RT-PCR. DNA products were examined 
by agarose gel electrophoresis and images recorded using the GeneSnap program. ERa 
expression was compared to P-actin using the GeneTool program. Data represent the 
average of five independent experiments for MCF-7 cells (blue) and two independent 
experiments for T47D cells (red) ± SD. * p<0.05 vs. untreated control for MCF-7 cells.
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TF (50 and 500 nM) showed similar trends in reductions in ERa mRNA expression at 24 h.
3.3.6.2. Investigation of the influence of TF on ERa protein expression
The downregulation of ERa mRNA expression was reflected in the level of protein 
expressed. The expression of ERa protein in MCF-7 cells appeared to follow a similar trend 
in which the initial decrease in ERa protein expression at 24 h post-treatment with TF (500 
nM) as measured by western blot, seemed to increase to levels comparable to that of the 
control sample by 48 h (Fig 3.15). Similarly, incubation of T47D cells with TF (500 nM) 
resulted in the reduction of ERa protein expression at 24 h (Fig 3.16). Moreover, since 
western blot analysis results are only semi-quantitative, the protein levels were also 
measured using an ELISA for ERa, and interpreted from a standard curve prepared using 
recombinant human ERa (Fig 3.17). The data obtained by the ELISA showed reductions in 
ERa protein expression of 20 % and 50 % in MCF-7 and T47D cells respectively, 
following 24 h incubation with TF (500 nM) (Fig 3.18).
3.3.6.3. Investigation of the long-term influence of TF on ERa expression
MCF-7 cells were incubated with recombinant TF (0-500 nM), which was supplemented 
every 3-4 days for 5 weeks. Cell samples were collected every 7 days and ERa expression 
measured by RT-PCR and western blot. In general, the presence of TF (50 and 500 nM) 
appeared to result in the downregulation of ERa mRNA expression compared to control 
cells. Moreover, the decrease in ERa mRNA expression seemed to be progressive and 
reached 50 % of the control by day 28 (Fig 3.19). The downregulation of ERa mRNA was 
reflected in the level of protein expression, which decreased to 40 % by 21 days incubation 
with TF (500 nM) (Fig 3.20), although the trend observed was less consistent. Furthermore, 
due to the nature of the experiment the analysis was carried out using only one set of cells.
103
Figure 3.15. Short-term influence of TF on ERa protein expression in MCF-7 cells
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MCF-7 cells (2><105) were incubated with recombinant TF (0 or 500 nM) and harvested at 
intervals over 72 h. The cells were lysed and proteins separated by 12 % (w/v) SDS-PAGE. 
The proteins were transferred onto nitrocellulose membranes and probed for ERa and 
GAPDH. Images were recorded using the GeneSnap program and ERa compared to 
GAPDH using the GeneTool program. The data are from one experiment.
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Figure 3.16. The influence of TF on ERa protein expression as examined by western 
blot
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MCF-7 or T47D cells (2xl05) were incubated with TF (0-500 nM) for 24 h, the cells lysed 
and protein separated by 12 % (w/v) SDS-PAGE. Proteins were transferred onto 
nitrocellulose membranes and probed for ERa and GAPDH. ERa expression was compared 
to GAPDH using the GeneTool program. MCF-7 cells = blue, T47D cells = red. Data 
represent the average of five independent experiments for MCF-7 cells (blue) and three 
independent experiments for T47D cells (red) ± SD.
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Figure 3.17. Standard curve for the ERa ELISA
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Serial dilutions of recombinant ERa protein were prepared to give a range of concentrations 
(0-2000 ng/ml). 50 ul of each diluted sample was added to wells in duplicate and the 
ELISA carried out using the rabbit anti-human ERa antibody. The absorption of the 
samples was measured at 450 nm with a reference of 620 nm and the standard curve 
constructed. Data is representative of one experiment in duplicate ± SD. A new standard 
curve was prepared for each experiment.
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Figure 3.18. The influence of TF on ERa protein expression as examined by ELISA
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MCF-7 or T47D cells (2*105) were incubated with TF (0-500 nM) for 24 h, harvested and 
protein concentrations determined using the Bradford assay. Each sample containing 10 ug 
of protein was placed in the wells of the ELISA plate in duplicate and probed for ERa 
protein. Absorptions were measured at 450 nm with a reference at 620 nm using an Anthos 
2010 microplate reader. Absorption values were converted to protein concentrations using 
the standard curve prepared with recombinant ERa protein. Data represent the average of 
three independent experiments for MCF-7 cells (blue) and two independent experiments for 
T47D cells (red) ± SD. * p<0.05 vs. untreated control for MCF-7 cells.
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Figure 3.19. Long-term influence of TF on ERa mRNA expression in MCF-7 cells
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MCF-7 cells were cultured in T75 flasks and supplemented with recombinant TF (50 and 
500 nM) every three days over five weeks. The samples were subcultured every 7 days and 
samples collected for RT-PCR analysis of ERa mRNA expression. Data represents one 
experiment analysed by RT-PCR in duplicate ± SD.
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Figure 3.20. Long-term influence of TF on ERa protein expression in MCF-7 cells
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MCF-7 cells were cultured in T75 flasks and supplemented with recombinant TF (50 and 
500 nM) every three days over five weeks. The samples were subcultured every 7 days and 
samples collected for western blot analysis of ERa protein expression. Data represents one 
experiment.
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3.3.7. Influence of TF on cell migration using a Boyden chamber based assay
A Boyden chamber based invasion/migration assay was used to examine the influence of 
TF on breast cancer cell invasion in the presence and absence of oestradiol. In order to 
reach the lower chamber, the cells must digest the collagen type IV barrier and actively 
migrate across the filter. The TF was placed in the lower chamber and the number of cells 
that had migrated across the filter determined using the MTS-based assay. The rate of 
MCF-7 cell migration across the filter increased when TF (50 and 500 nM) was placed in 
the lower chamber by 59 % and 70 % respectively (Fig 3.21). Furthermore, the addition of 
oestradiol (250 pM) to the upper chamber containing the cells inhibited MCF-7 cell 
migration by 38 % of that of the untreated control. The addition of TF (50 nM) together 
with oestradiol (250 pM) had no significant effect on migration compared to cells treated 
with oestradiol alone. However, the addition of a higher concentration of TF (500 nM) 
together with oestradiol (250 pM) increased the mean rate of cell migration over that of 
oestradiol treated cells. Similarly, the addition of TF (50 and 500 nM) increased the rate of 
T47D cell migration across the filter (Fig 3.22). The addition of oestradiol (250 pM) to the 
upper chamber containing the cells had no effect on cell migration compared to the 
untreated control. The addition of TF (50 nM) to the lower chamber also had no effect on 
rates of cell migration in the presence of oestradiol (250 pM). However, the addition of TF 
(500 nM) together with oestradiol (250 pM) resulted in increased rates of T47D cell 
migration.
3.3.8. Examination of changes in cell morphology in response to exogenous TF
Incubation of MCF-7 cells with TF (500 nM) appeared to result in the formation of sheet- 
like extensions of the cell membrane (lamellipodia) which were not present in the untreated 
cells (Fig 3.23). This was also observed in cells treated with bFGF (30 ng/ml). bFGF was
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Figure 3.21. MCF-7 cell migration in response to TF in the presence and absence of 
oestradiol
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MCF-7 cells (2xl05) were seeded out in phenol red free medium supplemented with 1 % 
(v/v) PCS into Boyden chambers coated with collagen type IV. The upper compartment 
containing the cells was supplemented with oestradiol (E2) (250 pM), and the lower 
compartment supplemented with TF (0-500 nM). The cells were incubated at 37°C for 24 h 
to allow migration across the collagen barrier. Following incubation, the cells on the upper 
side of the filter were removed and the number of migrated cells determined using the 
CellTiter proliferation reagent. Data is representative of four independent experiments ± 
SD. Average number of cells migrated: untreated control = 3600 cells, 500 nM TF = 6100 
cells. * p<0.05 vs. untreated control.
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Figure 3.22. T47D cell migration in response to TF in the presence and absence of 
oestradiol
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T47D cells (2xl05) were seeded out in phenol red free medium supplemented with 1 % 
(v/v) PCS into Boyden chambers coated with collagen type IV. The upper compartment 
containing the cells was supplemented with oestradiol (E2) (250 pM), and the lower 
compartment supplemented with TF (0-500 nM). The cells were incubated at 37°C for 24 h 
to allow migration across the collagen barrier. Following incubation, the cells on the upper 
side of the filter were removed and the number of migrated cells determined using the 
CellTiter proliferation reagent. Data is representative of four independent experiments ± 
SD. Average number of cells migrated: untreated control = 2900 cells, 500 nM TF = 6800 
cells. * p<0.05 vs. untreated control. + p<0.05 vs. oestradiol treated control.
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Figure 3.23. Changes in cell morphology in response to exogenous TF
MCF-7 cells were adapted to medium containing 1 % (v/v) PCS and seeded out into 8 well 
cultureslides. The cells were treated with TF (500 nM) or bFGF (30 ng/ml) as a positive 
control and incubated at 37°C for 48 h. The cells were fixed with 3 % (v/v) glutaraldehyde 
and then incubated with the membrane stain Dil for 15 min. The cells were washed with 
PBS and visualised using a CoolSnap Pro camera attached to a Leitz Laborlux S 
fluorescence microscope. Images were processed using the Image-Pro Plus Version 5.1.2. 
Data are representative of two independent experiments. (Magnification ><25).
113
used as a positive control as it is known to induce changes in cell morphology associated 
with cell migration (Johnson et al 1995). Furthermore, in the close up of cells treated with 
TF, microspikes (filopodia) are visible at the edge of the cell membrane.
3.3.9. Influence of TF on cell invasion using collagen type I gels
A procedure for an invasion assay was devised in order to observe the influence of TF on 
the rate of cell invasion into a surrounding collagen I matrix. Initially, a range of collagen I 
concentrations (0.28-0.38 % (w/v)) were used with the highly invasive breast cancer cell 
line MDA-MB-231 and invasion was recorded over 7 days. Optimal rate of invasion was 
observed with 0.28 % (w/v) collagen I gels (Fig 3.24). However, no accurate invasion could 
be measured with MCF-7 cells as the cells formed colonies which overgrew into the gel. 
Consequently, it was not possible to measure the change in the rate of invasion in response 
to TF and the assay was not further employed.
3.4. Discussion
Increased TF expression within the stroma surrounding breast tumours has been associated 
with aggressive/invasive forms of breast cancer (Vrana et al 1996). In contrast, the 
expression of ERa is associated with more differentiated, less invasive tumours. In this 
section of the investigation, the influence of exogenous truncated TF on breast cancer cell 
proliferation and invasion and the expression of ERa was examined. The recombinant TF 
used in this investigation represents the soluble or microparticle-derived TF, released by 
infiltrating stromal cells such as macrophages and fibroblasts within the vicinity of tumour 
cells in response to inflammatory mediators. Furthermore, the concentrations of TF used 
throughout this investigation represent TF concentrations observed during mild
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Figure 3.24. Collagen gel invasion assays
D
MCF-7 or MDA-MB-231 cells flO4) were seeded out onto collagen I gels (0.28 % (w/v)) in 
medium (500 ul) and incubated at 37°C. The cells were examined daily under a light 
microscope. Following 24 h and 7 days incubation, images were taken using a CoolSnap 
Pro camera. A = MDA-MB-231 cells at 24 h, B = MDA-MB-231 cells at 7 days, C = 
MCF-7 cells at 24 h, D = MCF-7 cells at 7 days. Data are representative of six independent 
experiments. (Magnification xlO).
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pathological conditions (50 nM TF) and severe pathological conditions (500 nM TF) 
(Watanabe et al 1999).
The breast cancer cell lines MCF-7 and T47D expressed little to no surface TF antigen as 
determined by flow cytometry (Fig 3.2) or TF activity as shown by the PT assay (Table 
3.2). In addition, both of these cell lines expressed ERa but not ER0. The breast cancer cell 
line ZR-75-1 expressed low levels of TF as well as low levels of ERa, while MDA-MB- 
231 cells expressed high levels of cell surface TF and exhibited no ERa expression. Both 
MCF-7 and T47D cell lines have frequently been used in the past as models for breast 
cancer cells with a low invasive potential (Rochefort et al 1998, Thompson et al 1992) and 
are known to be suitable for investigating the progression of ERa positive breast cancer 
cells to invasive, ERa negative phenotypes (Schiemann et al 1998). Consequently, both 
MCF-7 and T47D cells were deemed as appropriate cell lines and used throughout this 
study.
Initially, the influence of exogenous TF on the proliferation of breast cancer cell lines in the 
presence and absence of oestradiol was investigated. Cells cultured in culture medium 
containing phenol red and 10 % PCS showed little alterations in the rate of proliferation in 
response to oestradiol (50-1000 pM) (Fig 3.3). The lack of change in the rate of 
proliferation following the addition of oestradiol was due to the oestrogenic influence of the 
medium pH indicator phenol red (Berthois et al 1986) and oestrogenic compounds in PCS, 
hence masking the effects of the addition of physiological concentrations of oestradiol. 
Therefore, all subsequent assays using oestradiol were performed in phenol red-free 
medium. However, the cells did not respond to oestradiol in the total absence of PCS. The
lack of cell response to oestrogen in the absence of serum has been reported previously and
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is suggested to be as a result of the lack of albumin (Germain & Harbrioux 1993) or other 
unknown serum-derived factors (Ruedl et al 1990) which act as carrier proteins for 
oestrogen. To overcome this, the medium was supplemented with 1 % PCS to permit the 
transport of oestradiol to the cells.
Another issue requiring confirmation prior to performing these studies arose from the fact 
that the recombinant TF component of the Innovin reagent used in this investigation is 
incorporated into phospholipid vesicles for optimal procoagulant activity. To confirm that 
any observed effects of the Innovin reagent on cells arose from the TF apoprotein and not 
the lipid component, any influence of the lipids derived from the Innovin reagent on cell 
proliferation was examined. The lipids extracted from the Innovin reagent were found to 
have no procoagulant activity when examined by the PT assay, confirming the absence of 
residual TF. Moreover, the addition of lipids alone had no measurable influence on MCF-7 
cell proliferation (Fig 3.10). The addition of the Innovin reagent-derived lipids together 
with oestradiol (250 pM) resulted in a small decrease in the rate of proliferation compared 
to cells treated with oestradiol alone. However, this lowering in the rate of proliferation was 
not comparable to the decreases observed in the presence of the complete TF Innovin 
reagent (500 nM) together with oestradiol (250 pM). This indicates that the lipid 
component of the Innovin reagent does not have a significant effect on the cells and also the 
lipids do not sequester sufficient amounts of oestradiol to account for the decreases in 
proliferation observed with the Innovin reagent.
Next, the influence of oestradiol on cell proliferation was examined in order to ensure 
oestradiol stimulated cell proliferation in the cells and determine optimal oestradiol
concentration. Incubation of cells with oestradiol (100-500 pM) appeared to increase the
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rate of cell proliferation in both cell lines with the maximal proliferation rate observed with 
100-250 pM oestradiol (Fig 3.4 & 3.8), which is in agreement with previous reports that 
physiological concentrations of oestradiol stimulate the proliferation of ERa-positive breast 
cancer cells (Prall et al 1998, Anderson et al 1998, Laidlaw et al 1995). However, the rate 
of proliferation of T47D cells in response to oestradiol increased at a later time point than 
MCF-7 cells, possibly due to the slower growth rate of these cells or lower levels of ERa 
expression. Examination of the influence of exogenous TF on oestradiol-induced cell 
proliferation revealed an appearance of a trend in which a high concentration of TF (500 
nM) appeared to suppress oestradiol-induced cell proliferation in MCF-7 cells and to a 
lesser extent in T47D cells, possibly due to a downregulation of ERa expression in the 
cells. Alternatively, the suppression of oestradiol-mediated proliferation by exogenous TF 
may be due to the increased rate of apoptosis. Prolonged arrest of the progression through 
the cell cycle, during cell division often results in apoptosis of the cells (Johnson & Walker 
1999). Furthermore, it has previously been shown that high concentrations of exogenous 
TF inhibit components of the cell cycle, leading to cell cycle arrest and apoptosis (Pradier 
& Ettelaie 2007). Since oestradiol promotes ERa-positive cells to enter the cell cycle (Prall 
et al 1998), it is possible that the suppression of oestradiol-mediated proliferation observed 
in this investigation is due to the inhibition of specific cell cycle proteins by exogenous TF, 
leading to the arrest of the cell cycle and subsequent apoptosis.
In the absence of oestradiol, incubation of MCF-7 cells with a low concentration of 
exogenous TF (50 nM) appeared to increase the rates of proliferation following 24 h 
incubation (Fig 3.4), whereas incubation with a high concentration of TF (500 nM) seemed 
to reduce the rate of MCF-7 cell proliferation measured at 48 and 72 h. These differential
influences of exogenous TF on cell proliferation depending on the concentration of TF have
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been previously reported in endothelial cells (Pradier & Ettelaie 2007). Furthermore, the 
addition of TF (500 nM) alone did not reduce the rate of proliferation to the same extent as 
the combination of 500 nM TF and oestradiol, which may be explained by fewer cells 
entering the cell cycle in the absence of oestradiol, and therefore fewer cells undergoing 
apoptosis.
The ability of cells to respond to oestradiol depends on the presence of ERa. Therefore, in 
order to identify the underlying mechanism involved in the reduction in oestradiol- 
mediated proliferation by exogenous TF, the influence of TF on ERa expression was 
examined next. A trend was observed in which incubation of MCF-7 and T47D cells with 
TF (50 and 500 nM) resulted in decreases in the expression of ERa mRNA and protein at 
24 h (Fig 3.14 & 3.18), which then normalised at 72 h post-treatment (Fig 3.13 & 3.15), 
indicating that single exposure of cells to exogenous TF may have a short-term influence on 
ERa expression. Since ERa is required for cells to respond to oestradiol, this 
downregulation in ERa expression may partly account for the suppression of oestradiol- 
mediated cell proliferation in these cell lines in the presence of a high concentration of TF 
(500 nM). Moreover, since breast cancer cells in vivo would be exposed to a continuous 
level of exogenous TF released from stromal cells over period of time, the cumulative 
influence of continuous exposure to exogenous TF on ERa expression over 5 weeks was 
examined. Exposure of MCF-7 cells to continuous levels of TF (500 nM) for 28 days 
appeared to result in a cumulative decrease in the expression of ERa mRNA by 50 % (Fig 
3.19), which was also reflected as a 40 % decrease in protein expression following 21 days 
incubation compared to the untreated control (Fig 3.20). Despite the limited number of 
times that this experiment was repeated these results may indicate the role of exogenous TF
as a factor involved in the depletion of ERa expression in breast cancer cells. Breast cancer
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cells derived from aggressive tumours often lack ERa expression but express high levels of 
TF (Hu et al 1994) indicating that TF may have a role in ERa downregulation. One possible 
mechanism by which exogenous TF may influence ERa expression is the activation of the 
MAPK ERK1/2 signalling pathway, since previous studies have shown that the activation 
of the ERK1/2 pathway by growth factors results in the downregulation of ERa expression 
in breast cancer cells (Oh et al 2001, Creighton et al 2006). Moreover, the TF:FVIIa 
complex has been shown to be capable of initiating the activation of signalling pathways 
including the ERK1/2 pathway (Ettelaie et al 2007, Sorensen et al 1999), leading to 
changes in gene expression (Camerer et al 2000a, Camerer et al 1999, Pendurthi et al 
1997). It is therefore possible that the incubation of breast cancer cells with exogenous TF 
results in the activation of signalling pathways such as the ERK1/2 pathway leading to the 
downregulation of ERa expression. In conclusion, TF may suppress oestradiol-mediated 
cell proliferation, which may in part involve the downregulation of ERa, reducing the 
responsiveness of cells to oestradiol. Furthermore, it is possible that TF may suppress 
oestradiol-mediated proliferation by inducing apoptosis in cells stimulated to enter the 
cycle by oestradiol, although this requires further investigation.
Next the influence of exogenous TF on breast cancer cell invasiveness was examined. A 
frequently used in vitro procedure involving the migration of cells across a collagen IV 
coated Boyden chamber was employed to assess the rate of cell invasion in response to 
exogenous TF. In this assay, cells must degrade the collagen IV barrier and actively migrate 
across the barrier towards the stimulus (Rochefort et al 1998). Since collagen IV is a major 
component of the basement membrane which surrounds blood vessels, this assay represents 
an in vitro measurement of the ability of cancer cells to cross blood vessel basement
membranes and metastasis. Addition of TF (50 or 500 nM) to the lower chamber increased
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the rate of MCF-7 and T47D invasion across the barrier in a concentration-dependent 
manner (Fig 3.21 & 3.22). Previously, the induction of smooth muscle cell migration 
towards TF has been demonstrated (Sato et al 1996), suggesting that TF acts as a 
chemokine promoting cell migration along the TF concentration gradient. Furthermore, cell 
surface TF has been shown to enhance migration through mechanisms that involve TF 
binding to FVIIa and subsequent PAR activation (Jiang et al 2004), as well as through 
interactions of the cytoplasmic domain of TF with specific intracellular proteins resulting in 
cytoskeletal reorganisation (Ott et al 1998). Since the exogenous TF used in the present 
study is devoid of the cytoplasmic domain, the ability of this TF to induce cell migration 
may be attributed to the interaction with FVIIa present in the small concentration of serum 
included in the medium and the subsequent activation of PARs on the surface of the 
examined cells. Furthermore, in the presence of TF (500 nM), MCF-7 cells appeared to 
form sheet-like extensions of the cell membrane known as lamellipodia as well as 
microspikes termed fllopodia at the edge of the cell membrane (Fig 3.23). These structures 
are formed following reorganisation of the actin cytoskeleton in response to external stimuli 
and are required for cell migration as they contain adhesion molecules that attach to the 
substratum and pull the cell along (Yamaguchi et al 2005). These data are in agreement 
with those previously reported by Versteeg et al (2000), showing the induction of 
lamellipodia and filopodia formation in fibroblasts by TF:FVIIa signalling. The formation 
of migratory structures in breast cancer cells in the presence of TF also supports the data 
from the Boyden chamber invasion assay, demonstrating that TF induces breast cancer cell 
invasion. In contrast, the addition of oestradiol (250 pM) to the upper chamber containing 
the cells inhibited MCF-7 cellular invasion, which is in agreement with several previous 
studies which show that oestradiol inhibits invasion of ERa-positive cells (Platet et al 2000,
Rochefort et al 1998, Garcia et al 1992). However, the ability of oestradiol (250 pM) to
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inhibit cell invasion was reversed by the inclusion of a high concentration of TF (500 nM) 
to the lower chamber, resulting in increased average rates of cell invasion in both MCF-7 
and T47D cells. The increase in the rate of invasion following incubation with TF in the 
presence of oestradiol may in part be explained by the downregulation of ERa in the 
presence of exogenous TF. In addition, an invasion assay employing collagen I gels was 
used to further investigate the influence of TF on cellular invasion. In this assay, the highly 
invasive MDA-MB-231 cell line was shown to invade through the collagen I gels in the 
absence of any external stimuli (Fig 3.24). However, MCF-7 cells were not able to invade 
through even the lowest concentration of collagen I gels. Therefore, since the purpose of 
the assay was to examine the influence of TF on ERa-positive cells, the assay was not 
deemed suitable and no longer employed in the studies.
In summary, a trend was observed in which the exposure of breast cancer cells to high 
concentrations of TF appeared to result in a reduction in oestradiol-mediated cell 
proliferation below that of the untreated cells, possibly through the downregulation of ERa 
expression in the breast cancer cells and/or by increasing the rate of cell apoptosis. 
Moreover, incubation of breast cancer cells with exogenous TF reversed the anti-invasive 
effect of oestradiol and enhanced the rate of cell invasion, as well as inducing the formation 
of lamellipodia and filopodia which are required for cell migration. These observations may 
be partly explained by the downregulation of ERa, particularly as the long-term incubation 
of MCF-7 cells with TF (500 nM) resulted in a progressive suppression of ERa expression. 
In conclusion, high levels of TF, detected in the stroma of invasive breast cancers (Vrana et 
al 1996, Contrino et al 1996) may alter the response of ERa-positive breast cancer cells to 
oestradiol and contribute to the progression of breast cancer cells to an invasive, oestradiol-
independent phenotype.
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CHAPTER 4
The influence of exogenous TF on ERa activity through
the ERE pathway
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4.1. Introduction
4.1.1. The involvement of ERa activation in breast cancer
The presence of functional ERa in breast tumours has been associated with well 
differentiated, less invasive breast tumours and is indicative of a good prognosis. These 
properties are largely due to oestradiol-ERa mediated regulation of the transcription of 
genes involved in cell proliferation, differentiation, migration and invasion, some of the 
more prominent of which are shown in table 4.1. Furthermore, the detection of 
functional ERa in breast tumours is predictive of the response of breast cancers to anti- 
hormone therapies such as Tamoxifen that inhibit ERa activity.
4.1.2. The classical pathway of the transcriptional activation of ERa
Transcriptional activation of ERa through the classical mechanism involves the binding 
of the oestradiol-ERa complex to specific DNA sequences known as oestrogen response 
elements (ERE), which are located within upstream promoter regions of ERa-regulated 
genes (Klein-Hitpass et al 1988). The consensus ERE DNA sequence is a 13 bp 
palindromic sequence with three variable bases (N) in the middle: 5'- 
GGTCANNNTGACC-3'. Many of the genes controlled by ERa have imperfect ERE 
sequences which vary by a few nucleotides. The binding affinity of ERa for these ERE 
sequences decreases with the amount of variation compared to the consensus ERE DNA 
sequence. This permits transcription of ERa-target genes at different rates and 
magnitudes in response to oestradiol (Gruber et al 2004). In the absence of its ligand 17 
P-oestradiol, ERa is normally sequestered in the nucleus as an inhibited complex with 
heat shock protein 90 (hsp90) (Smith & Toft 1993). The binding of 17 p-oestradiol to 
the ligand binding domain of ERa results in a conformational change within the 
receptor, which leads to the release of hsp90 and induces receptor
124
Table 4.1. Genes controlled by oestrogen and containing ERE regulatory 
sequences within the promoter DNA regions
Gene*
c-myc
Progesterone receptor
Transforming growth 
factor-a (TGF-a)
Vascular endothelial 
growth factor (VEGF)
c-Fos
pS2
Function
Proliferation
Response to progesterone
Proliferation
Angiogenesis 
Vascular permeability
Proliferation 
Differentiation
Proliferation 
Differentiation 
Cell survival
Reference
Dubik&Shiul992
Petz & Nardulli 2000
El-Ashryetal 1996
Mueller et al 2000
Weisz & Resales 1990
Berry et all 989
* Genes upregulated by 17 (3-oestradiol.
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dimerisation. Furthermore, ERa may be phosphorylated at several sites following the 
binding of oestradiol (Chen et al 2000, Rogatsky et al 1999). These conformational 
changes upon ligand binding allow the DNA binding domain of ERa to interact with 
ERE DNA sequences. This in turn promotes the recruitment of coactivator proteins and 
RNA polymerase II to the DNA, leading to the formation of the transcription initiation 
complex and subsequent transcriptional activation from ERE promoters. Subsequently, 
ERa is ubiquitinated and then degraded by proteasomes within 45 minutes of binding to 
the DNA (Reid et al 2003). This rapid turnover of ERa allows cells to respond rapidly 
to small alterations in oestradiol levels.
4.1.3. Phosphorylation of ERa
Phosphorylation of proteins is a common mechanism used to alter protein functions, 
such as DNA binding activity, protein dimerisation and transcriptional activity. ERa is 
known to be regulated by phosphorylation at multiple sites, mediated through both 
oestradiol-dependent and oestradiol-independent signalling pathways (Chen et al 2002, 
Ali et al 1993) (Fig 4.1). The main phosphorylation sites in ERa are serine residues 104, 
106, 118 and 167, which are located within the N-terminus AF-1 domain of the receptor 
(Rogatsky et al 1999, Joel et al 1998, Chen et al 2002). Serine 167 is phosphorylated 
following the activation of MAPK pathways, phosphatidylinositol 3-kinase (PI3K) and 
ribosomal S6 kinase (RSK), but not by oestradiol (Joel et al 1998, Campbell et al 2001). 
Conversely, serines 104 and 106 are phosphorylated only in response to oestradiol 
through the activation of cyclin-dependent kinase 2 (cdk2) (Rogatsky et al 1999).
An important regulatory phosphorylation site in ERa is on serine 118, the 
phosphorylation of which is essential for full activity of the AF-1 domain of ERa (Ali et
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Figure 4.1. Phosphorylation sites in ERa
Oestradiol
cdk2
S104 S106
ERa
A/B C D E F
Oestradiol
ERa has several phosphorylation sites that can be phosphorylated by oestradiol- 
dependent and/or oestradiol-independent pathways. The main phosphorylation sites in 
ERa are serine residues 104, 106, 118 and 167, located in the N-terminus trans- 
activation-1 (AF-1) region of the receptor. Serine 104, 106 and 118 are phosphorylated 
in response to oestradiol binding to the receptor. Serine 118 is also phosphorylated by 
the activation of the MAPK pathway. Serine 167 is phosphorylated by the activation of 
the MAPK and PI3K pathways, but is not phosphorylated in response to oestradiol. 
PKB = protein kinase B, RSK = ribosomal s6 kinase.
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al 1993). Serine 118 is rapidly phosphorylated by cyclin-dependent kinase 7 (cdk?) 
following the binding of oestradiol to ERa (Chen et al 2000). Cdk7 is part of the general 
transcription factor TFIIH. On ERa binding to ERE sequences and the formation of the 
pre-initiation complex, which consists of RNA polymerase II and general transcription 
factors including TFIIH, cdk7 phosphorylates ERa on serine 118 (Chen et al 2000). In 
addition, phosphorylation of serine 118 can occur through an oestradiol-independent 
pathway, by the extracellular signal-regulated kinase 1/2 (ERK 1/2) pathway, which 
occurs by the activation of this pathway by growth factors (Chen et al 2002, Kato et al 
1995). The phosphorylation of ERa serine 118 by either pathway results in enhanced 
ERa dimerisation and recruitment of co-activator proteins, and results in increased ERa 
transcriptional activity from ERE DNA sequences (Dutertre & Smith 2003). The 
functional importance of serine 118 phosphorylation has been demonstrated by alanine 
substitution of serine 118, which resulted in decreases in ERa transcriptional activity in 
response to both oestradiol and growth factors (Kato et al 1995). In contrast, mutation 
of serine 118 to glutamic acid to substitute for phosphoserine, resulted in a 150 % 
increase in ERa transcriptional activity compared to wild type ERa (Ali et al 1993). 
Phosphorylated ERa has been detected in breast tumour samples, and studies have 
correlated the phosphorylation of serine 118 with well differentiated tumours and a 
better prognosis (Murphy et al 2004, Sarwar et al 2006). Furthermore, the oestradiol- 
independent pathways of ERa activation have been suggested as a mechanism for the 
resistance of some ERa positive breast tumours to anti-hormone therapies (Campbell et 
al 2001, Sarwar et al 2006).
4.1.4. Aims
Functional ERa is essential for oestradiol-controlled proliferation and invasion and 
response to anti-hormone therapies. The results obtained in the previous chapter
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demonstrate that exogenous TF can suppress oestradiol-mediated proliferation and 
overcome the anti-inhibitory effect of oestradiol on cell invasion, providing a regulatory 
mechanism in oestradiol-mediated pathways. However, the transcriptional activity of 
ERa is regulated at several levels including phosphorylation of the receptor, alterations 
in DNA binding activity, recruitment of coactivator proteins to the promoter and rates 
of ERa degradation. TF is known to initiate the activation of various cell signalling 
pathways which lead to changes in rates of gene transcription. Therefore, the aim of this 
part of the investigation was to examine the influence of exogenous TF on the 
transcriptional activity of ERa through the ERE promoter. The main objectives were as 
follows.
• To examine the influence of exogenous TF on serine 118 phosphorylation within 
ERa.
• To examine the influence of exogenous TF on the DNA binding activity of ERa to 
ERE DNA sequences.
• To construct an ERE luciferase reporter vector and test and optimise its suitability 
for measuring ERa activity.
• To examine the influence of exogenous TF on the transcriptional activity of ERa 
using the constructed ERE reporter vector.
4.2. Methods
4.2.1. Examination of the influence of TF on ERa serine 118 phosphorylation by 
western blot
Cells were cultured in T25 flasks and adapted to phenol red-free medium supplemented 
with 1 % (v/v) FCS. When approximately 60 % confluent, the cells were incubated with 
recombinant TF (0-500 nM) in the presence and absence of oestradiol (250 pM) and
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harvested at intervals over 120 min. The cells were then washed with 2 ml of PBS/ 
phosphatase inhibitors and the cells detached using enzyme-free cell dissociation buffer 
(1.8 ml) to prevent further activation of cell signalling pathways by trypsin. The cell 
suspension for each sample was transferred to a 1.5 ml tube and the cells pelleted by 
centrifugation at 12,000 rpm for 3 min in a microcentrifuge. The cells were then lysed 
in Laemmli's buffer (100 ul) and protein concentrations of the samples determined 
using the Bradford assay. Proteins were separated by 12 % (w/v) SDS-PAGE and 
transferred onto nitrocellulose membranes as described in the general methods section. 
Membranes were probed using a goat anti-human ERa phospho-serine 118 antibody 
diluted in TBST (0.2 ug/ml final concentration) for 1 h at room temperature, followed 
by a donkey anti-goat HRP-conjugated antibody diluted in TBST (0.1 ug/ml final 
concentration) and then developed using TMB stabilised substrate for HRP. Images 
were recorded using the GeneSnap imaging system and the antibodies then removed 
from the membranes by incubation in high salt TBST (20 mM Tris-HCl pH 8, 1 M 
NaCl, 0.05 % (v/v) Tween) at 4°C overnight. Membranes were then washed in distilled 
water and probed for total ERa as described in the general methods section. Images 
were recorded and phospho-serine 118 ERa compared to total ERa using the GeneTool 
program.
4.2.2. Examination of the influence of TF on the DNA binding activity of ERa
ERa DNA binding activity was examined using the TransAM ER kit, an ELISA based 
method which consists of wells coated with the ERE consensus sequence. Active ERa 
in the cell extract binds to the ERE sequence and is subsequently detected using an ERa 
antibody.
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4.2.2.1. Preparation of nuclear extracts
Cells were cultured in T75 cell culture flasks and adapted to phenol red-free medium 
supplemented with 1 % (v/v) PCS. When approximately 60 % confluent, the cells were 
treated with TF (0-500 nM) in the presence and absence of oestradiol (250 pM) and 
harvested at intervals over 120 min. Nuclear extracts were prepared using the Nuclear 
Extract kit. The composition of the reagents in the kit were not disclosed by the 
company, Active Motif. Cells were washed with PBS/phosphatase inhibitors (5 ml) and 
a further 3 ml of PBS/phosphatase inhibitors then added to the flask. The cells were 
gently scraped off the flask, transferred to a 15 ml tube and pelleted by centrifugation at 
400 g for 5 min. The cells were resuspended in the hypotonic buffer (500 ul) and 
incubated on ice for 15 min. The detergent solution (25 ul) was added and the cells 
vortexed for 10 s followed by centrifugation at 12,000 rpm for 30 s in a 
microcentrifuge. The nuclear pellet was resuspended in the lysis buffer (50 ul), vortexed 
for 10 s and incubated on ice on a rocking platform for 30 min. The extract was 
vortexed for 30 s and then centrifuged at 12,000 rpm for 10 min in a microcentrifuge. 
The supernatant (nuclear fraction) was retained and protein concentrations of the 
samples were determined using the Bradford assay.
4.2.2.2. TransAM ER
Complete binding buffer (40 ul) was added to each well. Protein from each nuclear 
extract sample (8 ug) diluted in complete lysis buffer to a final volume of 10 ul was 
added to the wells in duplicate and incubated for 1 h on a rocking platform at 100 rpm 
at room temperature. The wells were washed three times with wash buffer (200 ul) and 
then incubated with the supplied ERa antibody diluted 1:1000 in antibody binding 
buffer (100 ul) for 1 h at room temperature. The wells were then washed three times 
with wash buffer (200 ul) and incubated with the HRP-conjugated secondary antibody
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diluted 1:1000 in antibody binding buffer (100 ul) for 1 h at room temperature. Finally, 
the wells were washed four times with wash buffer (200 ul) and developed using the 
HRP substrate solution (100 ul) for 5 min in the dark. The reactions were terminated 
using 0.5 M sulphuric acid (100 ul) and the absorptions measured using a plate reader at 
450 nm with a reference of 620 nm using an Anthos 2010 microplate reader.
4.2.3. Examination of the influence of TF on the transcriptional activity of ERa
ERa transcriptional activity was examined using a luciferase reporter vector constructed 
by cloning the ERE consensus sequence for ERa into the pGL3-promoter vector (Fig 
4.2) upstream of the luciferase gene. Following transfection of this reporter vector into 
cells, ERa transcriptional activity can be determined by measuring the luciferase 
activity of the cell lysates.
4.2.3.1. Design of the ERE insert
Forward and reverse DNA sequences were designed to contain three tandem ERE 
sequences flanked by the Mlu I restriction site to allow the production of 5' overhangs 
for the ligation of the insert into the digested pGL3 vector. Additionally, the ERE 
sequences were synthesised with 5' phosphate groups to allow the ligation of the insert 
into the dephosphorylated pGL3 vector.
5'-CGCGTGGTCACAGTGACCGGTCACAGTGACCGGTCACAGTGACCCGGGA-3'
3'-ACCAGTGTCACTGGCCAGTGTCACTGGCCAGTGTCACTGGGCCCTGCGC-5'
Mini ERE ERE ERE Mlu I
4.2.3.2. Preparation of the ERE insert
Before ligation into the vector, the ERE construct was prepared by annealing the 
forward and reverse sequences. Forward and reverse ERE sequences (500 pmol each)
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Figure 4.2. pGL3-promoter vector
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The pGL3 promoter vector contains a multiple cloning site where enhancer elements 
can be cloned into the vector upstream of the luciferase gene. The SV40 promoter 
permits transcription of the luciferase gene in mammalian cells upon activation of the 
upstream enhancer element. The vector has a constirutively-expressed ampicillin 
resistance gene (Ampr) for selection and propagation in bacterial cells. Image taken 
from www.promega.com.
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were mixed with annealing buffer (6 mM Tris-HCl pH 7,5, 6 mM MgCl2, 100 mM 
NaCl, 1 mM DTT) and made up to a final volume of 100 ul with distilled water. The 
reaction was incubated at 95°C for 10 min and then gradually cooled to room 
temperature at a rate of-1°C/30 s.
4.2.3.3. Restriction digestion of the pGL3 plasmid
The incubation time required for the Mlu I enzyme to completely digest the pGL3 
plasmid was optimised by examining digested samples at intervals up to 3 h. Following 
optimisation, restriction digestion reactions were set up to contain Mlu I (10 U), 
restriction enzyme buffer (6 mM Tris-HCl pH 7.9, 6 mM MgCl2, 150 mM NaCl, 1 mM 
DTT), BSA (0.1 mg/ml) and pGL3 (100 jig/ml) and made up to 20 ul with distilled 
water. The reactions were incubated at 37°C for 1 h and the plasmid then purified from 
the reaction mix using the GFX DNA purification kit as follows. 
GFX columns contain a glass fibre matrix that binds DNA, allowing plasmid DNA to be 
extracted from reactions. A GFX column was placed in a collection tube and capture 
buffer (500 ul) added to the GFX column. The reaction mixture containing the plasmid 
was added to the GFX column, mixed by repeated pipetting and then centrifuged at 
13,000 rpm for 1 min in a microcentrifuge and the flow-through discarded. Wash buffer 
(500 ul) was added to the GFX column and centrifuged at 13,000 rpm for 1 min in a 
microcentrifuge. The GFX column was transferred to a 1.5 ml tube and distilled water 
(50 pil) added to the top of the glass fibre matrix in the GFX column. The column was 
incubated at room temperature for 1 min and then centrifuged at 13,000 rpm for 1 min 
in a microcentrifuge to elute the DNA from the column.
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4.2.3.4. Removal of 5' phosphates from pGL3 using CIAP
Following restriction digest of pGL3, the 5' phosphate groups were removed from the 
digested plasmid using calf intestinal alkaline phosphatase (CIAP) to prevent the vector 
from self-annealing. A reaction was set up containing plasmid solution (40 ul), CIAP 
reaction buffer (50 mM Tris-HCl pH 9.3, 1 mM MgCl2, 0.1 mM ZnCl2 , 1 mM 
spermidine), CIAP (0.01 U) and made up to a final volume of 50 ul with distilled water 
and incubated at 37°C for 30 min. A further 0.01 units of CIAP was then added and 
incubated for another 30 min at 37°C. This further addition of CIAP was carried out as 
CIAP is known to be inhibited by inorganic phosphate generated during the reaction. 
The vector was then purified from the reaction mix using the GFX kit as described 
above. The quantity of pGL3 was determined by measuring absorption at 260 nm and 
purity assessed by 1 % (w/v) agarose gel electrophoresis.
4.2.3.5. Ligation of the ERE insert into pGL3
Ligation reactions were set up containing T4 DNA ligase (4 U), ligase buffer (50 mM 
Tris-HCl pH 7.5, 7 mM MgCl2, 1 mM DTT), ATP (1 mM) and digested, CIAP treated 
pGL3 and the ERE insert at molar ratios of 1:100, 1:1000, 1:5000 and 1:10,000 
(plasmid:insert) and made up to a final volume of 20 ul with distilled water. The 
reactions were incubated overnight at 4°C, 2 days at 4°C or 2 h at 23 °C. Competent 
E.coli TB-1 were then transformed with each ligation mix in turn (10 ul) as described in 
the general methods section. Transformed bacterial cells (20 ul) were selected by 
plating out on carbenicillin-agar plates (100 ug/ml) and incubated overnight at 37°C. 
Colonies were transferred and grown in LB broth (50 ml) at 37°C overnight and 
plasmids extracted using the miniprep plasmid isolation procedure as described hi the 
general methods section. Plasmids were sequenced externally (Yorkshire Biosciences)
135
using the following forward primer which binds a short distance (50 bp) upstream of the
multiple cloning site of pGL3:
5' -CTAGC AAAATAGGCTGTCCCC-3'
4.2.3.6. Determination of transfection efficiency by flow cytometry
Transfection efficiency was determined by transfecting cells with the pEGFP-C3 
mammalian expression vector, which encodes enhanced green fluorescent protein 
(EGFP), and measuring the expression of green fluorescence by flow cytometry. MCF-7 
cells (4xl05) were seeded out into 12 well plates and transfected with 1 ug of the 
pEGFP-C3 vector using the Lipofectin reagent as described in the general methods 
section. Following 24 h incubation to allow the expression of EGFP, the cells were 
harvested, washed twice in PBS (1 ml) and then resuspended in PBS (300 ul). The cells 
were examined by flow cytometry as described in the general methods section 2.4.
4.2.4. Examination of the influence of TF on transcnptional activity of ERa using 
the pGL3-ERE reporter vector
Cells (4X103) were seeded out into 12 well plates and incubated at 37°C overnight. The 
cells were then transfected with pGL3-ERE (1 ug) using the Lipofectin reagent. 
Following incubation for 6 h, the cells were washed with PBS (1 ml) and phenol red- 
free medium (1 ml) containing 1 % (v/v) PCS added to each well, and incubated at 37°C 
overnight. The cells were then treated with recombinant TF (0-500 nM) in the presence 
and absence of oestradiol (250 pM) for 8 h. The cells were lysed and luciferase activity 
measured by adding luciferase substrate (100 ul) to cell lysate (20 ul) and measuring 
light emitted using a luminometer as described in the general methods section.
136
4.3. Results
4.3.1. Examination of the influence of TF on ERa serine 118 phosphorylation
Incubation of MCF-7 cells with oestradiol (250 pM) resulted in a 4.5 fold increase in 
ERa serine 118 phosphorylation at 90 min post-treatment (Fig 4.3 & 4.4). The addition 
of TF (500 nM) alone resulted in increased ERa phosphorylation, also peaking at 90 
min post-treatment, although the increase in phosphorylation was at a lower magnitude 
compared to that observed with oestradiol. The addition of TF (500 nM) together with 
oestradiol (250 pM) also resulted in increased ERa serine 118 phosphorylation.
Incubation of T47D cells with oestradiol (250 pM) resulted in a small increase in ERa 
serine 118 phosphorylation, peaking at 90 min post-treatment (Fig 4.5). However, the 
level of ERa phosphorylation in T47D cells in response to oestradiol (250 pM) was 
neither as rapid nor as pronounced compared to that in MCF-7 cells (Fig 4.6). 
Moreover, the addition of TF (500 nM) alone resulted in a small increase in ERa 
phosphorylation, reaching a maximum at 60 min post-treatment. Furthermore, the 
combination of TF (500 nM) and oestradiol (250 pM) produced no detectable difference 
in ERa phosphorylation compared to those observed with the individual components 
alone. However, due to the low levels of ERa serine 118 phosphorylation in these cells, 
the phospho-ERa bands for some samples were difficult to detect and subject to errors. 
Therefore, the measured changes in ERa phosphorylation were not deemed to be 
reliable.
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Figure 4.3. The influence of TF on ERa phosphorylation in MCF-7 cells
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MCF-7 cells were cultured in T25 flasks and adapted to phenol red-free medium 
containing 1 % (v/v) PCS. The cells were treated with TF (0-500 nM) and oestradiol 
(E2) (0-250 pM) and harvested at intervals over 120 min. The cells were lysed in 
Laemmli's buffer, and proteins separated by SDS-PAGE. Proteins were transferred onto 
nitrocellulose membranes and then probed for phosphorylated serine 118 ERa using a 
goat anti-human ERa phospho-serine 118 antibody. The membranes were then probed 
for total ERa using a mouse anti-human ERa antibody, and images recorded using the 
GeneSnap program. The ratio of phosphorylated ERa to total ERa was calculated using 
the GeneTool program. Data represent the average of two independent experiments ± 
SD.
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Figure 4.4. ERo serine 118 phosphorylation in MCF-7 cells
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MCF-7 cells were treated with exogenous TF (500 nM) in the presence or absence of 
oestradiol (250 pM). The cells were then lysed in Laemmli's buffer, and proteins 
separated by SDS-PAGE. Proteins were transferred onto nitrocellulose membranes and 
probed for phosphorylated serine 118 ERa using a goat anti-human ERa phospho-serine 
118 antibody. The membranes were then probed for total ERa using a mouse anti- 
human ERa antibody, and images recorded using the GeneSnap program.
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Figure 4.5 The influence of TF on ERa phosphorylation in T47D cells
500 nM TF 
250 pM E2 
500 nM TF + 250 DM
60 80 
Time(min)
T47D cells were cultured in T25 flasks and adapted to phenol red-free medium 
containing 1 % (v/v) PCS. The cells were treated with TF (0-500 nM) and oestradiol 
(E2) (0-250 pM) and harvested at intervals over 120 min. The cells were lysed in 
Laemmli's buffer, and proteins separated by SDS-PAGE. Proteins were transferred onto 
nitrocellulose membranes and then probed for phosphorylated serine 118 ERa using a 
goat anti-human ERa phospho-serine 118 antibody. The membranes were then probed 
for total ERa using a mouse anti-human ERa antibody, and images recorded using the 
GeneSnap program. The ratio of phosphorylated ERa to total ERa was calculated using 
the GeneTool program. Data represent the average of two independent experiments ± 
SD,
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Figure 4.6. ERa serine 118 phosphorylation in T47D cells
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T47D cells were treated with exogenous TF (500 nM) in the presence or absence of 
oestradiol (250 pM). The cells were then lysed in Laemmli's buffer, and proteins 
separated by SDS-PAGE. Proteins were transferred onto nitrocellulose membranes and 
probed for phosphorylated serine 118 ERa using a goat anti-human ERa phospho-serine 
118 antibody. The membranes were then probed for total ERa using a mouse anti- 
human ERa antibody, and images recorded using the GeneSnap program.
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4.3.2. Examination of the influence of TF on ERa DNA binding activity
The DNA binding activity of ERa was examined using the TransAM ER kit. This is an 
ELISA-based method in which active ERa in cell samples binds to synthetic ERE DNA 
sequences immobilised on the plate, and is detected using an ERa specific antibody. 
Incubation of MCF-7 cells with TF (50 and 500 nM) resulted in reductions in 
absorption values below that of the untreated control over 90 min (Fig 4.7A), indicating 
reduced ERa DNA binding activity hi these samples, hi contrast, incubation of MCF-7 
cells with oestradiol (250 pM) resulted in a rapid increase in ERa DNA binding activity, 
peaking at 30 min post-treatment, and subsequently decreasing to untreated control 
levels by 120 min (Fig 4.7B). The addition of a combination of TF (50 nM) and 
oestradiol (250 pM) had no additional influence on oestradiol-mediated DNA binding 
activity of ERa compared to that of oestradiol alone. In contrast, the inclusion of 500 
nM TF with oestradiol (250 pM) resulted in reduced ERa DNA binding activity in 
MCF-7 cells below that of the untreated control at 90 min post-treatment (Fig 4.7B).
Incubation of T47D cells with TF (50 and 500 nM) also resulted in the reduction in ERa 
DNA binding activity over 90 min (Fig 4.8A). However, incubation of T47D cells with 
oestradiol (250 pM) had no measurable effect on ERa DNA binding activity over the 
tested period (Fig 4.8B), and remained unaffected by the inclusion of TF.
4.3.3. Preparation of an ERE reporter vector
4.3.3.1. Optimisation ofMlu I restriction digest of pGL3
The pGL3-promoter vector was digested using the Mlu I restriction enzyme in order to 
produce 5' overhangs to allow the cloning of the ERE insert into the vector. The 
incubation time required for the Mlu I enzyme to completely digest the pGL3 plasmid 
was optimised by examining pGL3 samples digested by Mlu I at 37°C over 1-3 h.
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Figure 4.7. The influence of TF on ERa DNA binding activity in MCF-7 cells 
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MCF-7 cells were cultured in T75 flasks and adapted to phenol red-free medium 
containing 1 % (v/v) PCS. The cells were treated with TF (0-500 nM) in the absence 
(A) and presence (B) of oestradiol (250 pM) and then harvested at intervals (0-120 
min). Nuclear extracts were purified and the ability of ERa to bind to the ERE DNA 
sequence was examined using the TransAM ERa kit. Data represent the average of two 
experiments measured in duplicate ± SD.
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Figure 4.8. The influence of TF on ERa DNA binding activity in T47D cells 
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T47D cells were cultured in T75 flasks and adapted to phenol red-free medium 
containing 1 % (v/v) FCS. The cells were treated with TF (0-500 nM) in the absence 
(A) and presence (B) of oestradiol (250 pM) and then harvested at intervals (0-120 
min). Nuclear extracts were purified and the ability of ERa to bind to the ERE DNA 
sequence was examined using the TransAM ERa kit. Data represent the average of two 
experiments measured in duplicate ± SD.
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Complete restriction digest of the plasmid results in linearisation of the plasmid, which 
is visible as one band. pGL3 digestion by Mlu I was achieved after 1 h incubation at 
37°C (Fig 4.9).
4.3.3.2. Cloning ERE insert into pGL3
A range of molar ratios of the pGL3 plasmid and ERE insert were ligated by incubation 
over a range of durations and at different temperatures. Positive clones were selected 
using carbenicillin-agar plates and plasmids were purified from the bacteria and sent for 
sequencing by Yorkshire Biosciences. The sequencing results showed that two of the 
positive clones had the ERE insert but in reverse. One positive clone, ligated overnight 
at 4°C with a 1:1000 plasmid:insert molar ratio, contained the ERE insert in the correct 
orientation.
4.3.3.3. Optimisation of transfections
To ensure efficient transfection of the cells the optimal cell number was estimated by 
transfecting a range of MCF-7 cell populations (105-6xl05) with the pCMV-Luc 
plasmid. The pCMV-Luc plasmid contains the luciferase gene under the control of the 
cytomegalovirus (CMV) promoter and is capable of constitutively expressing luciferase 
when transfected into mammalian cells. Following transfection, the cells were incubated 
at 37°C for 20 h to allow expression of the luciferase gene, and luciferase activity was 
then measured. Luciferase activity increased in proportion with the number of cells up 
to a maximum of 650,000 relative light units (RLU) with 4xl05 cells (Fig 4.10). In 
comparison, the background count for untransfected cells was 1086 RLU.
The transfection efficiency was assessed by transfection of MCF-7 cells with the 
pEGFP-C3 expression vector, which constitutively expresses enhanced green
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Figure 4.9. Optimisation of Mlu I restriction digest of pGL3
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Reactions were set up containing the pGL3-promoter vector and the Mlu I restriction 
enzyme and incubated at 37°C for 1-3 h. The restriction products were then examined 
alongside the undigested plasmid using 1 % (w/v) agarose gel electrophoresis and 
images recorded using the GeneSnap program.
146
Figure 4.10. Optimisation of cell numbers for transfection
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MCF-7 cells (105-6><105) were seeded out into 12 well plates and transfected with the 
pCMV-Luc plasmid, which constitutively expresses luciferase. The cells were incubated 
at 37°C for 20 h to allow expression of the luciferase gene. The cells were then lysed 
and the luciferase activity of the cell lysates measured using a Junior LB 9509 
luminometer. The data are from one experiment.
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fluorescent protein (EGFP). Transfection efficiency was determined by measuring 
10,000 events and calculating the percentage of cells expressing green fluorescence 
using a flow cytometer. A gate was set to contain 7 % of untransfected cells. The 
average percentage of transfected cells in this area, indicating the transfection 
efficiency, was 27.4 % above that of the untransfected control cells (Fig 4.11).
In order to determine the optimal duration of incubation required for maximal response 
to oestradiol, MCF-7 cells (4xlO5) transfected with the pGL3-ERE reporter vector were 
treated with oestradiol (0 or 250 pM) and luciferase activities were measured at 4, 8, 16 
and 24 h post-treatment. The greatest difference in luciferase activity between oestradiol 
treated and untreated cells was observed at 8 h post-treatment (Fig 4.12). Moreover, by 
24 h incubation the expression of luciferase became independent of oestradiol.
In addition to the duration of incubation, the sensitivity of the pGL3-ERE reporter 
vector to oestradiol (0-1000 pM) was assessed in transfected MCF-7 cells. The 
luciferase activity in response to oestradiol increased in a concentration dependent 
manner up to a maximal value with 500 pM oestradiol (Fig 4.13).
4.3.4. Examination of the influence of TF on ERa transcriptional activity using the 
ERE reporter vector
The addition of oestradiol (250 pM) alone resulted in increased luciferase activity above 
that of the untreated control (Fig 4.14). The addition of recombinant TF (50 and 500 
nM) alone had no significant effect on ERa transcriptional activity in MCF-7 cells. 
However, inclusion of TF (50 and 500 nM) with oestradiol (250 pM) reduced the 
luciferase activity below that of cells incubated with oestradiol (250 pM) alone.
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Figure 4.11. Transfection efficiency
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MCF-7 cells (4xl05) were seeded out into 12 well plates and transfected with the 
pEGFP-C3 vector. The cells were incubated at 37°C for 24 h to allow the expression of 
the enhanced green fluorescent protein (EGFP) gene. The cells were then harvested, 
washed twice in PBS (1 ml) and resuspended in PBS (300 ul). Cells were examined by 
flow cytometry using a FACSCalibur flow cytometer. A gate was set to contain 7 % of 
untransfected cells and 10,000 events were recorded for each sample. The transfection 
efficiency was determined by measuring the number of fluorescent green events. The 
data is representative of two independent experiments. Area = untransfected cells. 
Green, red, blue and orange lines represent four separate sets of cells each transfected 
withpEGFP-C3.
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Figure 4.12. Optimisation of time point for ERE transfections
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MCF-7 cells (4* 105) were seeded out into 12 well plates and transfected with the pGL3- 
ERE reporter vector using the Lipofectin reagent. The cells were then placed in phenol 
red-free medium containing 1 % (v/v) PCS, treated with oestradiol (0 or 250 pM) and 
incubated at 37°C. The cells were harvested at intervals over 24 h and the luciferase 
activities of the cell lysates measured using a Junior LB 9509 luminometer. The data are 
from one experiment.
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Figure 4.13. pGL3-ERE reporter vector function in response to oestradiol
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MCF-7 cells (4xl05) were seeded out into 12 well plates and transfected with the pGL3- 
ERE reporter vector. The cells were treated with oestradiol (0-1000 pM) and incubated 
at 37°C for 8 h. The cells were then lysed and luciferase activity measured using a 
Junior LB 9509 luminometer. Background luciferase activity was subtracted from the 
samples. The data are from one experiment.
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Figure 4.14. The influence of TF on ERa transcriptional activity in MCF-7 cells
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MCF-7 cells (4*105) were seeded out into 12 well plates and transfected with the pGL3- 
ERE reporter vector. The cells were then placed in phenol red-free medium containing 1 
% PCS and treated with recombinant TF (0-500 nM) in the presence or absence of 
oestradiol (250 pM). Furthermore, a set was incubated with lipids diluted xlO 
(containing 1 % (w/v) BSA) extracted from recombinant TF together with oestradiol 
(250 pM). The cells were incubated at 37°C for 8 h, lysed and luciferase activities of the 
cell lysates measured using a Junior LB 9509 luminometer. Data represents the average 
of six independent experiments measured in duplicate ± SD. 
* p<0.05 vs. the untreated control. + p<0.05 vs. oestradiol treated cells.
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Furthermore, addition of the lipids (containing 1 % (w/v) BSA) extracted from 
recombinant TF (500 nM) had no detectable effect on oestradiol-mediated ERa 
transcriptional activation in MCF-7 cells.
Incubation of T47D cells with TF (500 nM) appeared to result in a small decrease in 
ERa transcriptional activity compared to the untreated control (Fig 4.15). The addition 
of oestradiol (250 pM) led to an increase in luciferase activity, although this was not as 
pronounced as observed in MCF-7 cells (Fig 4.14). Inclusion of TF (50 and 500 nM) 
together with oestradiol (250 pM) resulted in a downward trend in the transcriptional 
activity of ERa in T47D cells compared to cells treated with oestradiol alone (Fig 4.15).
4.4. Discussion
The data obtained in chapter 3 demonstrate the suppression of ERa expression on 
exposure of breast cancer cells to exogenous TF. In this part of the study, the hypothesis 
that exogenous TF may also suppress normal oestradiol-ERa signalling was examined. 
The addition of oestradiol (250 pM) to MCF-7 and T47D cells resulted in increases in 
the DNA binding activity of ERa to ERE sequences, peaking at 30 min post-treatment 
(Fig 4.7B & 4.8B). Since steroid receptors such as ERa bind to DNA when in an active 
form (Gross & Yee 2002), this increase in the DNA binding of ERa may indicate 
increases in the activity of ERa in response to oestradiol. Furthermore, oestradiol (250 
pM) increased the rate of phosphorylation of ERa on serine 118 in both MCF-7 and 
T47D cells, peaking at 90 min post-treatment (Fig 4.3 & 4.5). These results are also in 
agreement with previous studies which have shown that the binding of ERa to ERE 
promoters in response to oestradiol results in phosphorylation on serine 118 by cdk7, a 
component of the transcription initiation complex (Ito et al 2004, Chen et al 2000). hi 
addition, oestradiol (250 pM) increased the transcriptional activity of ERa from the
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Figure 4.15. The influence of TF on ERa transcriptional activity in T47D cells
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T47D cells (4xl05) were seeded out into 12 well plates and transfected with the pGL3- 
ERE reporter vector. The cells were then placed in phenol red-free medium containing 1 
% PCS and treated with recombinant TF (0-500 nM) in the presence or absence of 
oestradiol (250 pM). The cells were incubated at 37°C for 8 h, lysed and luciferase 
activities of the cell lysates measured using a Junior LB 9509 luminometer. Data 
represents the average of three independent experiments measured in duplicate ± SD.
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ERE promoter above that observed in the untreated control (Fig 4.14 & 4.15). Together, 
these data are in agreement with previous studies which have shown that oestradiol 
enhances ERa DNA binding and serine 118 phosphorylation, resulting in the increased 
transcriptional activity of ERa and increased expression of genes under the control of 
ERE promoters (Ito et al 2004, Ali et al 1993). Following transcription, ERa is 
degraded by the ubiquitin-proteasome pathway, allowing cells to respond rapidly to 
small changes in levels of oestradiol (Valley et al 2005, Reid et al 2003). Interestingly, 
levels of ERa phosphorylation at serine 118, DNA binding activity and transcriptional 
activation in response to oestradiol (250 pM) were lower in T47D cells compared to 
MCF-7 cells, which may be due to the lower levels of ERa expression in T47D cells.
The influence of oestradiol on cellular processes ultimately arises from the ability of 
oestradiol-ERa complexes to regulate the transcription of oestradiol-target genes (Gross 
& Yee 2002). Therefore, the activation or inhibition of oestradiol-mediated 
transcriptional activity must include the regulation of ERa. In this section, the influence 
of exogenous TF on ERa activity, in the presence of oestradiol was examined. 
Comparison of the DNA binding activity of ERa in response to oestradiol (250 pM) 
showed no variation on inclusion of TF (500 nM) for the first 60 min (Fig 4.7B). This is 
likely to be due to the rapid activation of ERa by oestradiol, leading to binding of ERa 
to ERE sequences. Furthermore, there was no difference in the level of phosphorylation 
of ERa on serine 118 (Fig 4.3), indicating that exogenous TF has no influence on 
oestradiol-mediated serine 118 phosphorylation. However, at 90 min post-treatment, the 
DNA binding activity of ERa, in MCF-7 cells treated with TF (500 nM), appeared to be 
reduced compared to that of the cells treated with oestradiol (250 pM) alone. In contrast, 
the phosphorylation state of serine 118 was not altered. These alterations in the DNA 
binding ability of ERa seemed to be paralleled in the suppression of oestradiol-mediated
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increases in the transcriptional activity of ERa from the ERE promoter in the presence 
of exogenous TF (500 nM) (Fig 4.14 & 4.15). Therefore, it is possible that TF-induced 
signalling inhibits another step essential for ERa-mediated transcriptional activity. For 
example, the recruitment of coactivator proteins to the ERE promoter is prerequisite for 
the transcriptional activity of the oestradiol-ERa complex, and it has been shown that 
inhibition of these coactivators also inhibits ERa transcriptional activity (Higashimoto 
et al 2007). Furthermore, ERa contains multiple phosphorylation sites (Fig 4.1), the 
phosphorylation of which are known to modulate ERa activity (Lannigan 2003) but 
were not explored here. In contrast, incubation of cells with lipids extracted from the 
Innovin reagent together with oestradiol had no measurable effect on oestradiol- 
mediated increases in ERa transcriptional activity (Fig 4.14), confirming that the 
changes in the transcriptional activity of ERa in the presence of the Innovin reagent 
were due to the TF apoprotein. Furthermore, any influence of the TF-associated lipids 
through the sequestration of oestradiol was discounted, hi conclusion, exogenous TF 
reduced oestradiol-mediated ERa transcriptional activity, possibly through a mechanism 
independent of the regulation of serine 118 phosphorylation.
To further investigate the mechanism by which TF influences ERa activity, the outcome 
of the incubation of cells with TF, in the absence of oestradiol, on ERa activation was 
examined. Therefore, the influence of exogenous TF on the phosphorylation, DNA 
binding activity and ERa-mediated expression from the ERE promoter was measured. 
Addition of TF (50 and 500 nM) alone appeared to reduce ERa DNA binding below 
baseline activity of the untreated control in both MCF-7 and T47D cells (Fig 4.7A & 
4.8A). However, incubation of MCF-7 cells with TF (500 nM) alone also seemed to 
induce serine 118 phosphorylation. TF is known to activate the MAPK signalling 
pathway through the activation of PAR2 (Morris et al 2006, Poulsen et al 1998).
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Therefore, it is possible that the addition of exogenous TF may result in the activation 
of the MAPK ERK1/2 pathway, which directly phosphorylates serine 118 within ERa 
(Chen et al 2002, Kato et al 1995). These results are contradictory since MAPK-induced 
phosphorylation of ERa serine 118 has previously been shown to increase ERa 
transcriptional activity (Kato et al 1995), whereas in this study, TF alone appeared to 
increase the phosphorylation of serine 118 but reduce the DNA binding activity of ERa. 
Furthermore TF alone had no effect on ERa transcriptional activity. One possible 
explanation for this discrepancy could be the activation of other signalling pathways 
known to be initiated by TF, which in turn regulate the phosphorylation of other 
residues within ERa necessary for activation of the receptor. For example, 
phosphorylation of serine 236 in the DNA binding domain of ERa has been shown to 
inhibit dimerisation and DNA binding of ERa in the absence of oestradiol (Chen et al 
1999). Furthermore, it has been reported that serine 118 phosphorylation is involved in 
controlling the rate of ERa degradation as well as the initiation of transcription (Valley 
et al 2005).
In summary, although TF (500 nM) alone was shown to increase the rate of 
phosphorylation of ERa at serine 118 while reducing the DNA binding activity, this 
appeared to have no influence on the transcriptional activity of ERa. In contrast, the 
addition of TF (50 and 500 nM) together with oestradiol (250 pM) resulted in a decrease 
in DNA binding of ERa and a reduction in transcriptional activity from the ERE 
promoter, through a mechanism that appears to be independent of the phosphorylation 
state of serine 118. Therefore, in this investigation exogenous TF signalling was capable 
of interfering with oestradiol-mediated transcriptional activity of ERa from ERE 
promoters. Many ERa target genes are involved in the regulation of breast cancer cell 
proliferation and invasion in response to oestradiol. Therefore, in conclusion, the
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downregulation of ERa transcriptional activity in the presence of exogenous TF may 
suppress oestradiol-mediated cell proliferation, which may also lead to the development 
of an oestradiol-independent cell phenotype and increased invasiveness. However, in 
addition to the classical ERE-dependent pathway, the oestradiol-ERa complex can also 
regulate the transcription of genes containing other response elements, such as AP-1 
promoters (Philips et al 1993) and this is considered next.
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CHAPTER 5
The influence of exogenous TF on ERa activity through 
the AP-1-dependent pathway
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5.1. Introduction
5.1.1. AP-1-dependent pathway of ERa transcription
In the classical pathway of ERa transcriptional activity, the oestradiol-ERa complex 
binds to ERE promoters, resulting in increased transcriptional activity of oestradiol- 
responsive genes. However, it has been shown that oestradiol can also modulate the 
expression of genes that do not have ERE promoters, but contain binding sites for other 
transcription factors such as AP-1 (Philips et al 1993, Umayahara et al 1994). 
Incubation of ERa-positive breast cancer cells with oestradiol has been shown to result 
in the enhanced transcriptional activity of AP-1 and lead to the expression of genes 
regulated by AP-1 (Philips et al 1993). Furthermore, it has been demonstrated that ERa 
does not need to bind to DNA in order to alter the transcriptional activation of these 
genes (Jakacka et al 2001). Instead, ERa directly binds to transcription factors such as 
AP-1, which are already associated with their own DNA binding elements (Teyssier et 
al 2001) (Fig 1.3). These protein-protein interactions between AP-1 and ERa at AP-1 
promoters stabilise the transcription initiation complex, hi this way ERa acts as a 
coactivator protein, enhancing the activity of the AP-1 complex and increasing the rate 
of transcription of AP-1 controlled genes (Teyssier et al 2001). Genes that contain AP-1 
promoters and are upregulated by oestradiol-ERa include growth factors (Umayahara et 
al 1994), and genes that are inhibited include those involved in cell invasion such as 
matrix metalloproteinases (Lu et al 2006, Crowe & Brown 1999).
5.1.2. Structure and function of activator protein-1
AP-1 is a dimeric transcription factor that principally consists of the protein subunits 
Jun and Fos (Fig 5.1). The Jun family of proteins includes c-Jun, JunB and JunD, and 
the Fos family of proteins includes c-Fos, FosB, FosD and fos-related antigen-1 (Fra-1)
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Figure 5.1. Schematic representation of the interactions and functions of AP-1 
protein subunits
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AP-1 is a dimeric transcription factor which is composed of Jun and Fos protein 
subunits. Jun subunits include c-Jun, JunB and JunD. Jun proteins can form 
homodimers, and can also form heterodimers with the Fos proteins c-Fos, FosB, Fra-1 
or Fra-2. The combination of Jun or Fos subunits determines the DNA binding affinity 
and transcriptional activation of AP-1. The activation of AP-1 leads to gene 
transcription and regulates cellular processes that are important both in normal and 
cancerous cells. Adapted from Latchman (1998). * Negative regulator of transcription.
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and fos-related antigen-2 (Fra-2). Jun proteins can form homodimers, and can also form 
heterodimers with Fos proteins, whereas Fos can only form heterodimers (Fig 5.1) 
(Latchman 1998). Jun and Fos are immediate early genes that are present in cells in an 
inactive form. The activation of intracellular pathways in response to extracellular 
stimuli including inflammatory cytokines, growth factors and phorbol esters such as 12- 
Otetradecanoylphorbol-13-acetate (TPA), leads to Jun and Fos phosphorylation and 
activation (Karin et al 1997, Adler et al 1992). An example of this is the predominant 
AP-1 subunit, c-Jun, which is activated by phosphorylation at serine residues 63 and 73 
by the JNK pathway (Dunn et al 2002). Jun-Jun or Jun-Fos dimers regulate gene 
transcription by binding to specific DNA sequences termed TPA-response elements 
(TRE) with a consensus sequence of 5'-TGA(C/G)TCA-3' (Karin et al 1997). 
Furthermore, different combinations of Jun and Fos subunits confer different functions 
on the AP-1 complex, for example, Jun-Fos heterodimers have a greater DNA binding 
affinity than Jun-Jun homodimers, and the presence of Fra-1 in AP-1 dimers often 
suppresses the transcriptional activity of AP-1 (Fig 5.1) (Yoshioka et al 1995). Through 
altering the expression of genes, AP-1 regulates many cellular processes including cell 
proliferation, cell differentiation and apoptosis (Ludes-Meyers et al 2001, Bamberger et 
al 1999). Furthermore, AP-1 has been implicated in the oncogenic transformation and 
increased growth of breast cancer cells (Liu et al 2002). In particular, the increased 
expression and activity of the c-Jun and Fra-1 AP-1 subunits is associated with more 
invasive, aggressive breast tumours (Belguise et al 2005, Smith et al 1999).
5.1.3. Aims
In chapter 3 and 4, exogenous TF was shown to reduce oestradiol-mediated 
proliferation and suppress the anti-invasive effect of oestradiol. Furthermore, incubation 
of breast cancer cells with exogenous TF resulted in the downregulation of ERa and
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reduced oestradiol-mediated transcriptional activity through the ERE pathway. In this 
section, the main objectives were as follows.
• To examine the influence of exogenous TF on the transcriptional activity of ERa 
through the AP-1 dependent pathway
• To clone the ERa gene into a mammalian expression vector and mutate serine 118 
to aspartic acid to produce a constitutively active form of ERa and subsequently, 
overexpress the wild type and mutated ERa in breast cancer cells and determine 
whether the influence of exogenous TF on oestradiol-mediated proliferation and 
invasion arises from the downregulation of ERa expression and/or inhibition of its 
activity.
5.2. Methods
5.2.1. Examination of the influence of exogenous TF on AP-1 activity
5.2.1.1. Analysis of AP-1 transcriptional activity by pAP-1-Luc reporter vector
transfections
The pAP-1-Luc reporter vector contains the luciferase gene under the control of 7 
consecutive TRE promoters. Transfection of the plasmid into mammalian cells allows 
AP-1 transcriptional activity to be determined by measuring luciferase activity of the 
cell lysates. Cells (4xl05) were seeded out into 12 well plates and transfected with 1 ug 
of the pAP-1-Luc reporter vector using the Lipofectin reagent as described in the 
general methods section 2.11. Following transfection, the cells were treated with TF (0- 
500 nM) and oestradiol (250 pM) as described in the results section. The cells were then 
lysed and the luciferase activities measured by adding luciferase substrate (100 nl) to 
cell extract (20 ul) and measuring light emitted on a luminometer as described in section 
2.12.
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5.2.1.2. Analysis of AP-1 DNA binding activity using the TransAM AP-1 kit
An ELISA-based TransAM AP-1 kit was used to investigate the influence of TF on the 
DNA binding activity of AP-1 subunits. The TransAM AP-1 kit is an ELISA based 
method, which consists of wells coated with oligonucleotides containing the TRE AP-1 
DNA binding consensus sequence. Active AP-1 in the cell extract binds to this 
sequence and individual AP-1 subunits are detected using antibodies against c-Jun, 
JunB, JunD, FosB, FosB, Fra-1 and Fra-2.
Cells were cultured in T75 flasks to approximately 60 % confluence and then treated 
with TF (0-500 nM) for 20 and 40 min. The cells were then harvested and nuclear 
extracts were prepared using the nuclear extract kit as described previously (section 
4.2.2.1). Protein concentrations were determined using the Bradford assay as described 
in the general methods. TransAM AP-1 was carried out as described in section 4.2.2.2 
using 8 ng of protein from each sample. Control nuclear extract (5 ug) from cells 
stimulated with TPA (supplied) was used as a positive control for AP-1 activation. 
Furthermore, wells containing no nuclear extract were used as a negative control. The 
plates were probed using the supplied phospho-serine 73 c-Jun antibody diluted 1:500 
in antibody binding buffer or the JunB, JunD (phospho-serine 100), c-Fos, FosB, Fra-1 
and Fra-2 antibodies diluted 1:1000 in antibody binding buffer. The absorptions of the 
samples were measured at 450 nm with a reference of 620 nm using an Anthos 2010 
microplate reader.
5.2.3. Cloning of full length ERa
The pEGFP-C3 vector (Fig 5.2) is a mammalian expression vector into which a gene of 
interest may be cloned into the multiple cloning site downstream of the gene for 
enhanced green fluorescent protein (EGFP). Transfection of the vector into mammalian
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Figure 5.2. pEGFP-C3 cloning vector
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The pEGFP-C3 mammalian expression vector encodes the enhanced green fluorescent 
protein (EGFP) gene upstream of a multiple cloning site (MCS). Cloning a gene of 
interest into this vector results in the expression of the gene in tandem with the EGFP 
protein at the N-terminus. The kanamycin resistance gene (Kanr) allows selection of 
transformed bacteria, whereas the geneticin resistance gene (Neor) permits the selection 
of mammalian cells transfected with the vector. Image taken from www.stratagene.com.
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cells results in the expression of a hybrid protein consisting of the gene of interest with 
EGFP attached to the N-terminus. The expression of the hybrid protein permits 
detection by fluorescence microscopy or flow cytometry.
5.2.3.1. Design of primers for PCR amplification of full length ERa
Primers for the PCR of full length ERa were designed from the published ERa cDNA 
sequence (Green et al 1986) using the BasePair program. The restriction sites for EcoR I 
and BamK I were included in the primers to permit the production of 5' overhangs for 
the ligation of the gene into the digested vector. Furthermore, the use of two different 
restriction sites ensures that the gene is inserted unidirectionally into the plasmid in the 
correct orientation. The forward primer was designed to start 16 bp upstream of the start 
codon of the ERa gene and include 18 bp of coding sequence (see below). Additionally, 
an EcoR I restriction site was incorporated into the 16 bp non-coding sequence. The 10 
bp sequence preceding the restriction enzyme site was included to ensure efficient 
restriction digestion. The reverse primer was designed to include the stop codon and 17 
bp of coding sequence which included a BamR I restriction site incorporated after the 
stop codon, followed by another 10 bp.
Forward primer: 5'-CCCGCGGCGAATTCCCATGACCATGACCCTCCAC-3'
EcoR I Start ERa cDNA 
codon
Reverse primer: 5'-GGAAGCCAGGGATCCCTCAGACTGTGGCAGGGA-3'
BamH I Stop ERa cDNA 
codon
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5.2.3.2. First strand cDNA synthesis using Superscript II reverse transcriptase
The reverse transcription step was carried out using mRNA isolated from MCF-7 cells 
and Superscript II reverse transcriptase. A reaction was set up with RNA (0.5 ug), 
dNTP mix (10 mM each) and reverse cloning primer (100 pmol) and made up to a final 
volume of 12 ul with RNase/DNase-free water. The reaction was incubated at 65 °C for 
5 min and then quickly chilled on ice. First strand buffer (50 mM Tris-HCl pH 8, 75 
mM KC1, 3 mM MgCl2) and 2 ul of 0.1 M DTT were added to the reaction and 
incubated at 42°C for 2 min. Superscript II reverse transcriptase (200 U) was added to 
the reaction and made up to a final volume of 20 ul using RNase/DNase-free water. The 
reaction was incubated at 42°C for 50 min and the enzyme then deactivated by heating 
at70°Cfor 15 min.
5.2.3.3. PCR amplification of ERa cDNA
PCR of full length ERa was optimised using different MgCl2 concentrations (1-4 mM) 
and three DNA polymerase enzymes (Pfu DNA polymerase, BioTaq DNA polymerase 
and Herculase enhanced DNA polymerase).
The PCR mix for the amplification of ERa cDNA using BioTaq DNA polymerase, 
contained the template cDNA (100 ng), dNTP mix (4 mM), forward and reverse cloning 
primers (50 pmol each), PCR buffer (16 mM (NH4)2SO4, 67 mM Tris-HCl pH 8.8, 0.01 
% Tween-20), MgCl2 (3 mM) and BioTaq DNA polymerase (2.5 U) and was made up 
to 50 ul with RNase/DNase-free water. The DNA was denatured at 95°C for 5 min, 
followed by 30 cycles of amplification carried out as 1 min at 95°C, 1 min 45 s at 58°C 
and 3 min at 72°C. Final extension was carried out at 72°C for 10 min. The PCR 
products with an expected size of 1785 bp were analysed by 1 % (w/v) agarose gel 
electrophoresis and viewed under UV light using a transilluminator.
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The PCR mix for the amplification of ERa cDNA using Pfu DNA polymerase, 
contained the template cDNA (100 ng), dNTP mix (0.8 mM), forward and reverse 
cloning primers (50 pmol each), PCR buffer (20 mM Tris-HCl pH 8.8, 2 mM MgSO4, 
10 mM KC1, 10 mM, (NH4)2SO4, 0.1 % Triton X-100, 0.1 mg/ml nuclease-free BSA) 
and Pfu DNA polymerase (5 U) and was made up to 100 ul with RNase/DNase-free 
water. The DNA was denatured at 95°C for 45 s, followed by 30 cycles of amplification 
carried out as 45 s at 95°C, 45 s at 58°C and 4 min at 72°C. Final extension was carried 
out at 72°C for 10 min. The PCR products were analysed by 1 % (w/v) agarose gel 
electrophoresis.
The PCR mix for the amplification of ERa cDNA using Herculase DNA polymerase, 
contained the template cDNA (100 ng), dNTP mix (0.8 mM), forward and reverse 
cloning primers (12.5 pmol each), PCR buffer (5 ul) and Herculase DNA polymerase 
(2.5 U) and was made up to 50 ul with RNase/DNase-free water. The DNA was 
denatured at 95°C for 2 min, followed by 30 cycles of amplification carried out as 30 s 
at 95°C, 30 at 58°C and 2 min at 72°C. Final extension was carried out at 72°C for 10 
min.
5.2.3.4. Purification of ERa DNA from agarose gels
ERa DNA was isolated from the PCR reactions mix using the GFX DNA purification 
kit as follows. The products of PCR amplification were separated on a 0.75 % (w/v) low 
melting point agarose gel to separate and identify the transcript for full length ERa. The 
bands were visualised under UV light and the 1785 bp band for ERa quickly excised 
from the gel using a scalpel. The gel slice was transferred to a pre-weighed 1.5 ml tube, 
weighed again and 10 ul of capture buffer added for every 10 mg of the gel. The gel 
was then vortexed and incubated at 60°C for 10 min until dissolved. The solution was
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transferred into a GFX column in a collection tube and incubated at room temperature 
for 1 min, followed by centrifugation at 13,000 rpm for 30 s in a microcentrifuge. The 
flow through was discarded and wash buffer (500 ul) added to the column. The column 
was centrifuged at 13,000 rpm for 30 s in a microcentrifuge and then transferred to a 1.5 
ml tube. Distilled water (50 ul) was added to the glass fibre matrix of the GFX column 
and incubated at room temperature for 1 min. The DNA was then eluted from the 
column by centrifugation at 13,000 rpm for 1 min in a microcentrifuge.
5.2.3.5. Restriction digestion of pEGFP-C3 and the ERa insert
Both the pEGFP-C3 plasmid and the ERa sequence contain the EcoR I and BamH I 
restriction enzyme sites which allow the production of 5' overhangs and permit the 
ligation of the insert into the plasmid. Initially, the duration of incubation for both EcoR 
I and BamH I to achieve full digestion of pEGFP-C3 was optimised by examining 
digested samples at intervals up to 3 h. Following optimisation, restriction digestion 
reactions were set up containing EcoR I (10 U), restriction enzyme buffer (90 mM Tris- 
HC1 pH 7.5, 10 mM MgCl2, 50 mM NaCl), BSA (0.1 mg/ml) and pEGFP-C3 or the 
ERa insert (30 ul) and incubated at 37°C for 1 h. The plasmid and insert were purified 
from the reaction mix using the GFX PCR purification kit as previously described. 
Restriction digest reactions were then set up with BamH I (10 U), restriction enzyme 
buffer (6 mM Tris-HCl pH 7.5, 6 mM MgCl2 , 100 mM NaCl, 1 mM DTT), BSA (0.1 
mg/ml) and pEGFP-C3 or ERa insert (30 ul) and incubated at 37°C for 3 h. The plasmid 
and insert were purified from the reaction mix using the GFX PCR product kit and 
resuspended in distilled water (50 ul). The quantity of both the pEGFP-C3 plasmid and 
ERa insert DNA were determined by measuring absorption at 260 run as described 
before, and the purity of the DNA was confirmed by 1 % (w/v) agarose gel 
electrophoresis.
169
5.2.3.6. Ligation of the ERo insert into the pEGFP-C3 plasmid
Ligation reactions containing T4 DNA ligase (4 U), ligase buffer (50 mM Tris-HCl pH 
7.5, 7 mM MgCl2, 1 mM DTT), ATP (1 mM) and the digested pEGFP-C3 plasmid and 
ERa insert were set up at molar ratios of 1:1, 1:3 and 1:5 (plasmid:insert), as well as a 
negative control with no insert. A volumetric description of the components is shown 
below. The reactions were made up to 20 ul with distilled water and incubated at 4°C 
overnight, 4°C for 2 days or 23°C for 2 h. Competent E.coli TB-1 were transformed 
with each ligation mix (10 ul) in turn as described before (section 2.10.5). Transformed 
bacterial cells (20 ul) were selected by plating out on kanamycin agar plates (45 jig/ml) 
and incubated overnight at 37°C. Colonies were removed, grown in LB broth (50 ml) at 
37°C overnight and plasmids extracted using the miniprep plasmid isolation procedure.
Reaction
components
pEGFP-C3
(176 ug/ml)
ERa insert
10x ligase 
buffer
ATP
(10 mM)
T4DNA
ligase
dH2O
Plasmid : insert ratio
1:1
5 |il
2.5 ul
2 |il
2 Ml
lul
7.5 ul
1:3
5 Ml
7.5 ul
2 pi
2 Ml
iMl
2.5 Ml
1:5
4 Ml
10 Ml
2 Ml
2 Ml
iMl
iMl
Neg control
5 Ml
-
2 Ml
2 Ml
iMl
10 M!
170
5.3. Results
5.3.1. Analysis of the influence of TF and oestradiol on the transcriptional activity 
of AP-1 using the pAP-1-Luc reporter vector
In order to determine the optimal duration of incubation required for maximal AP-1 
activation, MCF-7 cells (4xl05) were transfected with the pAP-1-Luc reporter vector. 
The cells were then treated with TPA (0 or 10 nM) to induce the phosphorylation and 
activation of AP-1 (Adler et al 1992). Luciferase activities in the transfected samples 
were measured at 4, 8, 16 and 24 h post-treatment. The maximal difference in luciferase 
activity between TPA treated and untreated cells was observed at 8 h post-treatment 
(Fig 5.3).
Following the optimisation step, alterations in the transcriptional activity of AP-1 in 
response to TF (0-500 nM), in MCF-7 and T47D cells was examined. Cells previously 
transfected with the pAP-1-Luc reporter vector, were incubated with TF (0-500 nM) in 
the presence of 10 % PCS. Incubation of MCF-7 cells with TF (50 and 500 nM) resulted 
in a TF concentration dependent decrease in AP-1 transcriptional activity compared to 
the untreated sample at 8 h post-treatment (Fig 5.4). The incubation of T47D cells with 
TF (50 and 500 nM) also appeared to result in a downward trend in luciferase activity 
below that of the untreated control (Fig 5.5), although the difference between the 
luciferase activity of untreated cells and untransfected cells was smaller than that 
observed in MCF-7 cells, indicating that T47D cells contain lower levels of active AP- 
1.
In the subsequent experiments, alterations in the transcriptional activity of AP-1 in 
response to TF in the presence of oestradiol were examined. These studies were carried 
out in MCF-7 cells, since these cells exhibited higher levels of AP-1 activity compared
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Figure 5.3. Optimisation of pAP-1-Luc transfections
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MCF-7 cells (4*105) were seeded out into 12 well plates and transfected with the pAP- 
1-Luc reporter vector using the Lipofectin transfection reagent. The cells were treated 
with TPA (0 or 10 nM) and lysed at 4, 8, 16 and 24 h post-treatment. The luciferase 
activities of the cell samples were measured using a Junior LB 9509 luminometer. The 
data are from one experiment.
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Figure 5.4. The influence of TF on the transcriptional activity of AP-1 in MCF-7 
cells
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MCF-7 cells (4*105) were seeded out into 12 well plates and transfected with the pAP- 
1-Luc reporter vector. The cells were placed in medium supplemented with 10 % FCS 
and treated with TF (0-500 nM), alongside an untransfected set of cells to determine the 
background count. The cells were lysed following 8 h incubation at 37°C, and luciferase 
activities of the cell samples measured using a Junior LB 9509 luminometer. The data 
represent the average of three independent experiments measured in duplicate ± SD. 
* p< 0.05 vs. the untreated control.
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Figure 5.5. The influence of TF on the transcriptional activity of AP-1 in T47D 
cells
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T47D cells (4><105) were seeded out into 12 well plates and transfected with the pAP-1- 
Luc reporter vector. The cells were placed in medium supplemented with 10 % PCS and 
treated with TF (0-500 nM), alongside an untransfected set of cells to determine the 
background count. The cells were lysed following 8 h incubation at 37°C, and luciferase 
activities of the cell samples were measured using a Junior LB 9509 luminometer. Data 
represent the average of two independent experiments measured in duplicate ± SD.
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to T47D cells. Following transfection with the pAP-1-Luc reporter vector, MCF-7 cells 
were adapted to phenol red-free medium containing 1 % PCS over 24 h, and then 
treated with TF (500 nM), oestradiol (250 pM) or TPA (10 nM) for 8 h. The incubation 
of MCF-7 cells with either TF (500 nM) or oestradiol (250 pM) alone, in phenol red- 
free/low-serum medium had no measurable influence on AP-1 activity in MCF-7 cells 
(Fig 5.6). Furthermore, the combination of oestradiol (250 pM) and TF (500 nM) had no 
additional effect on luciferase activity compared to the untreated cells. Incubation of 
MCF-7 cells with TPA (10 nM) resulted in increased luciferase activity above that of 
the untreated control, indicating that AP-1 was functional in these cells.
5.3.2. Examination of the influence of TF on the DNA binding activity of AP-1
The influence of TF (0-500 nM) on the DNA binding activity of a set of AP-1 subunits 
was separately examined using the TransAM AP-1 kit. This kit employs an ELISA- 
based procedure in which active AP-1 binds to oligonucleotides containing a TRE 
binding sequence. Individual AP-1 protein subunits are then detected using specific 
antibodies to c-Jun, JunB, JunD, c-Fos, FosB, Fra-1 and Fra-2. Using this procedure, the 
influence of TF (0-500 nM) on the DNA binding activities of the AP-1 subunits c-Jun, 
JunB, JunD, c-Fos, FosB, Fra-1 and Fra-2 over 40 min was examined in MCF-7 cells in 
the presence of 10 % PCS. The nuclear extract from cells stimulated with TPA 
(supplied with the kit) was used as a positive control. The high levels of c-Jun DNA 
binding activity detected in this control confirmed the suitability of this procedure (Fig 
5.7). Measurement of the DNA binding activity of c-Jun on stimulation with TF (50 
nM) indicated a possible increase at 20 min post-treatment. In contrast, 500 nM TF 
seemed to reduce the DNA binding activity of c-Jun by 40 min (Fig 5.7). Incubation of 
MCF-7 cells with TF (50 and 500 nM) appeared to have no measurable influence on the 
DNA binding activities of either c-Fos (Fig 5.8) or Fra-1 (Fig 5.9).
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Figure 5.6. The influence of TF and oestradiol on AP-1 transcriptional activity
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MCF-7 cells (4*105) were transfected with the pAP-1-Luc reporter vector and adapted 
to phenol red-free medium containing 1 % PCS. The cells were treated with TF (500 
nM), oestradiol (250 pM) or TPA (10 nM) and incubated at 37°C for 8 h. The cells were 
then lysed and the luciferase activities of the samples measured using a Junior LB 9509 
luminometer. The data represents the average of two independent experiments carried 
out in duplicate and measured in duplicate ± SD.
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Figure 5.7. The influence of TF on the DNA binding activity of c-Jun
2.5
§1.5
oin
E- 1
o
CO
0.5
^
D20min 
• 40 mm
Untreated control 50 nM TF 500 nM TF Positive control Negative control
MCF-7 cells were cultured in T75 flasks and treated with TF (0-500 nM) when 
approximately 60 % confluent. The cells were harvested at 20 and 40 min and nuclear 
extracts prepared. The protein concentration in each sample was determined using the 
Bradford assay following which the DNA binding activity of c-Jun hi the samples was 
determined using the TransAM AP-1 kit and using a specific phospho-serine 73 c-Jun 
antibody. The positive control sample contained 5 ug of nuclear extract from cells 
stimulated with TPA, while the negative control contained no nuclear extract. The data 
are from one experiment.
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Figure 5.8. The influence of TF on the DNA binding activity of c-Fos
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MCF-7 cells were cultured in T75 flasks and treated with TF (0-500 nM) when 
approximately 60 % confluent. The cells were harvested at 20 and 40 min and nuclear 
extracts prepared. The protein concentration in each sample was determined using the 
Bradford assay following which the DNA binding activity of c-Fos hi the samples was 
determined using the TransAM AP-1 kit and using a specific c-Fos antibody. The 
positive control sample contained 5 ug of nuclear extract from cells stimulated with 
TPA, while the negative control contained no nuclear extract. The data are from one 
experiment.
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Figure 5.9. The influence of TF on the DNA binding activity of Fra-1
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MCF-7 cells were cultured in T75 flasks and treated with TF (0-500 nM) when 
approximately 60 % confluent. The cells were harvested at 20 and 40 nun and nuclear 
extracts prepared. The protein concentration in each sample was determined using the 
Bradford assay following which the DNA binding activity of Fra-1 in the samples was 
determined using the TransAM AP-1 kit and using a specific Fra-1 antibody. The 
positive control sample contained 5 ug of nuclear extract from cells stimulated with 
TPA, while the negative control contained no nuclear extract. The data are from one 
experiment.
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Furthermore, TF (50 and 500 nM) appeared to have no measurable effect on the DNA 
binding activities of the AP-1 subunits, Jun D, FosB and Fra-2, over 40 min (results not 
shown).
In order to examine the influence of oestradiol on the DNA binding activity of AP-1, 
MCF-7 cells were adapted to phenol red-free medium containing 1 % (v/v) FCS and 
incubated with oestradiol (0 or 250 pM) for 10 min. Incubation of MCF-7 cells with 
oestradiol (250 pM) seemed to have no measurable effect on the DNA binding activities 
of the following AP-1 subunits; c-Jun, JunB, JunD and FosB, at 10 min post-treatment 
(Fig 5.10).
5.3.3. ERa cloning
5.3.3.1. PCR amplification of ERa
Three different DNA polymerase enzymes were tested for suitability for the PCR 
amplification of ERa cDNA. Furthermore, a range of MgCb concentrations (1-4 mM) 
were used at various annealing temperatures to optimise the PCR amplification reaction 
of ERa. A band at approximately 1800 bp corresponding to full length ERa was 
amplified using BioTaq DNA polymerase in the presence of 3 mM MgCb carried out at 
an annealing temperature of 58°C (Fig 5.11). The ERa PCR product was then purified 
from the spurious amplification bands using the GFX DNA purification kit to obtain 
one clear band at 1800 bp (Fig 5.12). PCR amplification of ERa using Pfu DNA 
polymerase and Herculase DNA polymerase did not amplify full length ERa at any 
annealing temperature or MgCla concentration tested.
5.3.3.2. Optimisation of BamH I and EcoR I restriction digest of pEGFP-C3
The EGFP-C3 plasmid was digested using the BamH I and EcoR I restriction enzymes 
in order to produce 5' overhangs to allow unidirectional cloning of ERa into the
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Figure 5.10. The influence of oestradiol on the DNA binding activity of AP-1 
subunits
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MCF-7 cells cultured in T75 flasks were adapted to phenol red-free medium containing 
1 % (v/v) PCS and treated with oestradiol (0 or 250 pM) for 10 min. The cells were then 
harvested and nuclear extracts prepared. The protein concentration in each sample was 
determined using the Bradford assay and the DNA binding activity of AP-1 subunits 
determined using the TransAM AP-1 with specific antibodies for c-Jun, JunB, JunD and 
FosB. The data are from one experiment.
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Figure 5.11. PCR amplification of ERa using BioTaq DNA polymerase
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PCR reactions were set up containing cDNA (100 ng) previously amplified from MCF- 
7 RNA, BioTaq DNA polymerase (2.5 U) and a range of MgCl2 concentrations (1-4 
mM). PCR amplification of ERa was carried out with an annealing temperature of 58°C 
for 30 amplification cycles. The PCR products were analysed by 1 % (w/v) agarose gel 
electrophoresis and viewed under UV light using a transilluminator.
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Figure 5.12. ERa purified from PCR reaction
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The PCR products amplified using BioTaq DNA polymerase were separated on a 0.75 
% (w/v) low melting point agarose gel. A band at approximately 1800 bp corresponding 
to ERa was excised from the gel and purified using the GFX PCR purification kit. The 
purified ERa PCR product was then examined by 1 % agarose gel electrophoresis.
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plasmid. The incubation times required for the restriction enzymes to completely digest 
pEGFP-C3 were optimised by examining pEGFP-C3 samples digested by BamH I and 
EcoR. I individually at 37°C over 1-3 h and examining the restriction products by 
agarose gel electrophoresis. pEGFP-C3 was digested by BamH I after incubation at 
37°C for 3 h, while EcoR I required incubation at 37°C for 1 h (Fig 5.13).
5.3.3.3. Ligation of ERa into pEGFP-C3
A range of ligation conditions were tested in order to clone ERa into the pEGFP-C3 
vector, including a range of plasmid:insert molar ratios, different temperatures and 
different durations of incubation. However, no positive clones were obtained under any 
of these conditions.
5.4. Discussion
The aim of this investigation was to examine the influence of exogenous TF on the 
transcriptional activity of ERa, mediated through the AP-1-dependent pathway. 
Incubation of MCF-7 cells with exogenous TF (50 and 500 nM) resulted in reductions 
in the transcriptional activity of AP-1 in the presence of 10 % FCS (Fig 5.4) and a 
similar trend was observed in T47D cells (Fig 5.5). These results are in contrast to 
previous studies that have shown that TF signalling results in the activation of the JNK 
pathway (Camerer et al 1999) which is known to directly phosphorylate and activate c- 
Jun (Dunn et al 2002). However, differential responses of cells to TF concentrations are 
likely and were reported in chapter 3. In fact, measurement of the DNA binding activity 
of c-Jun in the presence of TF (50 nM) indicated a possible increase, while 500 nM TF 
seemed to reduce the DNA binding activity of c-Jun (Fig 5.7), which was reflected in 
the decreased transcriptional activity of AP-1 hi the luciferase assay (Fig 5.4). Since c- 
Jun is strongly associated with cell proliferation (Liu et al 2002), the contrasting
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Figure 5.13. Optimisation of pEGFP-C3 restriction digest by BamH I and EcoR I
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Reactions containing the pEGFP-C3 plasmid were prepared with the BamH I or EcoR I 
restriction enzymes. The reactions were incubated at 37°C for 1-3 h and the restriction 
products then examined by 1 % (w/v) agarose gel electrophoresis alongside uncut 
pEGFP-C3.
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influences of exogenous TF on cell proliferation observed in chapter 3 may be due to 
differential influences of exogenous TF on c-Jun DNA binding activity, although this 
requires further investigation.
Following establishment of the ability of TF to modulate AP-1 transcriptional activity, 
any ability of exogenous TF to interfere with oestradiol-mediated AP-1 activity was 
explored. The levels of active AP-1 in MCF-7 cells were found to be suppressed in low- 
serum medium (Fig 5.6) compared to that observed in the presence of 10 % FCS (Fig 
5.4). Furthermore, exogenous TF (500 nM) seemed to have no measurable influence on 
AP-1 transcriptional activity under these conditions (Fig 5.6). Moreover, the addition of 
oestradiol (250 pM) appeared to have no effect on AP-1 transcriptional activity, 
although in agreement with previous studies, oestradiol (250 pM) did not seem to affect 
the binding activity of Jun or Fos proteins to TRE DNA sequences (Fig 5.10) (Chen et 
al 1996). However, increased transcriptional activity from AP-1 response elements on 
treatment of ERa-positive cells with oestradiol has been previously reported (Philips et 
al 1993, Umayahara et al 1994). The addition of TPA (10 nM) stimulated AP-1 
transcriptional activity in MCF-7 cells in low serum, confirming that these cells 
contained functional AP-1 (Fig 5.6). However, since AP-1 has to be recruited to DNA 
before ERa binds (Fig 1.3), and oestradiol (250 pM) did not appear to affect AP-1 DNA 
binding (Fig 5.10), the lack of response to oestradiol may be attributed to the repression 
of AP-1 binding to TRE sequences in the presence of low serum (Fig 5.14). This 
obstacle may be overcome by using charcoal-stripped FCS, which does not contain 
oestrogens but still has serum to permit AP-1 activation, to examine the effect of 
addition of oestradiol on the transcriptional activity of AP-1. However, since incubation 
of cells with exogenous TF (500 nM) appeared to result in reduced DNA binding 
activity of c-Jun, this may by default indirectly suppress any oestradiol-mediated AP-1
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Figure 5.14. Schematic representation of proposed mechanism for TF regulation of 
ERa-AP-1 transcriptional activation
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The presence of serum increases AP-1 DNA binding activity, allowing ERa to bind to 
the AP-1 complex and increase transcriptional activation from TRE promoters. A high 
concentration of TF (500 nM) suppresses AP-1 binding to TRE promoters and may 
therefore indirectly prevent oestradiol-ERa transcriptional activity through the AP-1- 
dependent pathway.
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transcription by reducing AP-1/c-Jun binding to TRE DNA sequences (Fig 5.14). In 
effect, in the absence of functional AP-1 at TRE promoters, ERa would not be able to 
mediate transcription through the AP-1-dependent pathway (Fig 5.14). However, due to 
the limited number of experiments in this part of the study further investigations would 
be needed to confirm this.
The aim of the final part of the investigation was to clone ERa into a mammalian 
expression vector and mutate serine 118 to aspartic acid to mimic phospho-serine 118 
and therefore produce a constitutively active form of ERa (Ali et al 1993). By 
overexpression of the wild type or mutated ERa in MCF-7 cells, it would have been 
possible to explore and determine whether the influence of exogenous TF on oestradiol- 
mediated cell proliferation and invasion arises from the downregulation of ERa 
expression and/or activity. Although the ERa gene was amplified by PCR using Tag 
DNA polymerase (Fig 5.12), ligation of the gene into the pEGFP-C3 mammalian 
expression vector was not possible under any of the tested conditions and due to time 
limits was not continued further.
In conclusion, incubation of breast cancer cells with exogenous TF resulted in decreases 
in the transcriptional activity of AP-1 and possibly the DNA binding activity of the c- 
Jun protein. However, the possible ability of oestradiol to alter the transcriptional 
activity of AP-1 is dependent on other activating factors present in serum (Fig 5.14).
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CHAPTER 6
Investigation of the mechanism of exogenous TF 
signalling in breast cancer cells
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6.1. Introduction
In the previous chapters, exogenous TF was shown to induce changes in ERa 
expression and activity, as well as oestradiol-mediated cell proliferation and invasion. 
However, the mechanism by which exogenous TF interacts with the cell surface and 
initiates these cellular changes has not been explored. Since the exogenous TF used in 
this investigation lacks the cytoplasmic domain, signalling by this domain can be ruled 
out. Therefore, the main mechanisms by which the extracellular domain of TF can 
initiate cell signalling are through protease activated receptors (PARs) and integrins.
6.1.1. TF-mediated cell signalling through protease activated receptors
One known mechanism by which TF can initiate cell signalling pathways is through the 
activation of protease activated receptors 1 and 2. PAR1 is activated by the cleavage of 
the N-terminus of the receptor by FXa and thrombin downstream of TF in the 
coagulation cascade (Riewald & Ruf 2001), whereas PAR2 may be activated by both 
FXa and FVIIa following the formation of the TF:FVIIa complex (Camerer et al 
2000b). Proteolytic cleavage of PARs leads to the activation of G-proteins which 
subsequently induce intracellular signalling pathways such as the ERK1/2 and PI3K 
pathways (Riewald & Ruf 2001), resulting hi changes in the expression of genes 
encoding for growth factors and proinflammatory cytokines (Liu & Mueller 2006, 
Hjortoe et al 2004). A number of outcomes arising from TF:FVIIa signalling, including 
Ca2+ oscillations, induction of the MAPK pathway and alterations in patterns of gene 
expression are mediated through the activation of PARs, and do not involve the 
cytoplasmic domain of TF (Sorensen et al 1999, Poulsen et al 1998). Furthermore, 
activation of PARs has been shown to lead to reorganisation of the cytoskeleton and cell 
migration through the induction of the PI3K pathway and the small GTPase Rac 
(Versteeg et al 2000). Both PAR1 and PAR2 are known to participate in promoting
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tumour cell migration and metastasis (Bromberg et al 2001), and both the TF:FVIIa 
complex and FXa have been shown to induce breast cancer cell migration through the 
activation of PAR2 (Morris et al 2006). Furthermore, activation of both PAR1 and 
PAR2 promotes tumour cell growth and proliferation (Versteeg et al 2008, Yin et al 
2003). PARs are essential mediators by which the TF:FVIIa:FXa complex can initiate 
cell signalling pathways leading to changes in gene expression and cell morphology.
6.1.2. The interaction of TF with FVIIa and FXa
The extracellular domain of TF consists of two fibronectin type III domains (Harlos et 
al 1994), which interact with the coagulation factors FVIIa and FXa to form a tertiary 
complex (Fig 6.1). FVIIa and FXa are composed of a single Gla domain followed by 
two tandem epidermal growth factor (EOF) domains and an N-terminus serine protease 
domain. All four domains of FVIIa are involved in the interaction with the two 
fibronectin domains of the extracellular domain of TF (Banner et al 1996). In addition, 
the first EOF domain (EGF-1) in the C-terminus of FXa is known to bind to the first 
fibronectin domain of TF (Fig 6.1) (Zhong et al 2002). Mutagenesis studies have 
identified the amino acids Asp48, GluSl, Ser52, Asn57, Phe76, Asn80 and Glu82 
within the EGF-1 domain of FXa as residues essential for binding to TF (Zhong et al 
2002). In addition, residues Arg200 and Lys201 within the first fibronectin domain of 
TF have been shown to interact with the EGF-1 domain of FXa (Manithody et al 2007).
6.1.3. TF signalling through integrins
Recently it has been shown that TF can mediate changes in cell migration and 
proliferation by interacting with the integrin family of adhesion molecules (Dorfleutner 
et al 2004, Versteeg et al 2008). The integrin family of cell surface receptors link the 
extracellular matrix to the cytoskeleton, allowing cells to respond to their surroundings
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Figure 6.1. Structure of the TF:FVIIa:FXa complex
The extracellular domain of TF (purple) forms a complex with FVIIa and FXa. Both 
FVIIa and FXa contain a C-terminal Gla domain (yellow), followed by an EGF-1 
domain (green), an EGF-2 domain (blue) and a serine protease domain (red). FVIIa uses 
all four domains to bind to TF, whereas the EGF-1 domain of FXa binds to the 
extracellular domain of TF. Adapted from Ruf et al (2003).
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and controlling cellular processes including cell adhesion, migration and proliferation 
(Woodside et al 2001). Integrins bind to components of the extracellular matrix 
including fibronectin, laminin and collagens through short sequences within the ligands, 
such as the arginine-glycine-aspartate (ROD) sequence (Brakebusch & Fassler 2005). 
The binding of integrins to ligands, as well as the binding of divalent cations such as 
Mn + and Mg2*, results in the activation of integrins (Humphries 1996). Integrins exists 
as heterodimers of a and p subunits. The pi integrin subunit is an elongated molecule of 
130 kDa that has a small cytoplasmic domain, a single transmembrane domain and a 
large extracellular domain (Fig 6.2). The extracellular domain of pi integrin consists of 
a proximal membrane domain termed the pTD domain followed by four epidermal 
growth factor domains termed EGF-4 to EGF-1 hi ascending order away from the cell 
membrane, and a ligand-binding domain (Fig 6.2) (Xiong et al 2001). TF has been 
shown to mediate changes in cell migration and gene expression by interacting with 
integrins (Dorfleutner et al 2004, Versteeg et al 2008). Furthermore, TF has been shown 
to directly bind to the pi integrin subunit in both keratinocytes and breast cancer cells 
(Versteeg et al 2008). However, the mechanism by which TF binds to the integrin 
subunit is unknown and has not been previously explored.
6.1.4. Aims
In the previous chapters, the influence of exogenous TF on ERa expression and activity 
and breast cancer proliferation and invasion was examined. However, the mechanisms 
by which exogenous TF interacts with the cell surface and promotes these cellular 
changes have not been examined. The main objectives of this chapter were:
• To examine the interaction of exogenous TF with the surface of breast cancer cells
• To explore the possible role of integrins in exogenous TF binding to the cell surface
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Figure 6.2. Schematic representation of the structure of 01 integrin
Ligand binding 
domain
uh —— EGF-4« — PTD
Transmembrane domain
Cytoplasmic domain
The (31 integrin subunit is an elongated molecule composed of a large extracellular 
domain, a single transmembrane domain and a small cytoplasmic domain. The 
extracellular domain consists of a membrane-proximal domain termed the PTD domain, 
followed by four EOF domains and a ligand binding domain. Adapted from Luo et al 
(2007).
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• To investigate the involvement of PARs in TF mediated cell signalling in breast 
cancer cells and elucidate the associated mechanisms in the control of ERa expression 
and cell proliferation.
6.2. Methods
6.2.1. Examination of the mechanisms of TF-mediated signalling
6.2.1.1. Examination of the expression of PARs in breast cancer cells by RT-PCR
Total RNA was isolated from MCF-7, T47D and MDA-MB-231 cells (106 each) and 
amplified by RT-PCR using published primers specific for PAR1 and PAR2 (Jiang et al 
2004) shown below. PCR was carried out with an annealing temperature of 56°C and 
for 29 amplification cycles. The DNA products were examined by agarose gel 
electrophoresis and images recorded using the GeneSnap program. The expected band 
sizes were 850 bp for PAR1 and 503 bp for PAR2.
PAR 1 forward: 5'-TGT ACG CCT CTA TCT TGC TCA TGA C-3' 
PAR 1 reverse: 5'-GCA GGT ATG CAA GTC GTA CAT CTG-3'
PAR 2 forward: 5'-TGA GCA GCT CTT GGT GGG AGA CAT-3' 
PAR 2 reverse: 5'-ACT CAA TAG GAG GTC TTA ACA GTG G-3'
6.2.1.2. Examination of the involvement of PARs in TF mediated breast cancer cell 
proliferation
MCF-7 cells (2.5*104) were seeded out into 24 well plates in phenol red-free medium 
supplemented with 1 % (v/v) FCS and treated with combinations of recombinant TF 
(500 nM), 17 p-oestradiol (250 pM), PAR agonist peptides (SFLLRN for PAR1 and 
SLIGRL for PAR2) (20 uM each), or pre-incubated with the PAR1 inhibitory
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antibodies ATAP2 and WEDE15 (25 ug/ml each), the PAR2 inhibitory antibody 
SAM 11 (25 ng/ml) or a rabbit polyclonal anti-human TF antibody (100 ug/ml), as 
described in the results. The cells were incubated for 24 h at 37°C and cell proliferation 
examined using the MTS-based assay described in the general methods section 2.3.
6.2.1.3. Examination of the involvement of PARs, FVIIa, FXa, pi integrin and 
MAPK in the downregulation of ERa expression by exogenous TF
MCF-7 cells (2xl05) were seeded out into 12 well plates in medium supplemented with 
1 % (v/v) PCS and incubated at 37°C overnight. The cells were then washed four times 
with PBS (1 ml), medium containing 2 % (v/v) serum replacement medium added to 
each well and the cells incubated for 3 h at 37°C. The cells were then treated with 
combinations of TF (50 and 500 nM), FVIIa (5 nM) and FXa (10 nM) as described in 
the results section. Similar samples were incubated with PAR1 and PAR2 inhibitory 
antibodies (25 ug/ml) prior to the addition of TF (500 nM), or treated with PAR1 and 
PAR2 agonist peptides (20 uM). hi addition, cells were pre-incubated with a rabbit 
polyclonal anti-human pi integrin antibody (5.3 ug/ml) or a pi integrin inhibitory 
antibody (AIIB2) (50 ug/ml). Finally, samples were incubated with an ERK1/2 MAPK 
inhibitor PD98059 (50 uM) in the presence or absence of TF (500 nM). Following 24 h 
incubation at 37°C the cells were harvested and total RNA isolated and analysed by RT- 
PCR as described in section 2.5.3. Alternatively, whole cell extracts were prepared 
using the nuclear extract kit, and levels of ERa protein expression analysed using the 
ERa ELISA as described in section 3.2.4.2.
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6.2.2. Investigation of the interaction of exogenous TF with breast cancer cells
6.2.2.1. Preparation of fluorescein-labelled TF
Fluorescein molecules were coupled to recombinant TF by the catalysis of 
carboxyamide bond formation between COO" groups on fluorescein molecules and free 
NH3+ groups on TF using the reagents O-(benzotriazol-l-yl)-N,N,N',N- 
tetramethyluronium hexafluorophosphate (HBTU) and N, N-diisopropylethylamine 
(DIPEA). Recombinant TF (0.5 g) was dissolved in distilled water (10 ml) containing 
HBTU (0.1 M). To initiate the reaction, a fluorescein solution (25 umol) containing 
DIPEA (0.1 M) was added to the TF/HBTU solution and incubated for 2 h at room 
temperature with stirring. Excess fluorescein was removed by stepwise dialysis, first in 
PBS (5 L) at 4°C for 2 h. The PBS was then replaced with fresh PBS (5 L) and 
incubated at 4°C, overnight. The dialysis step was repeated until all excess fluorescein 
had been removed. The presence of TF was determined by 12 % (w/v) SDS-PAGE, 
followed by western blot analysis for TF using a mouse monoclonal anti-human TF 
antibody (0.5 ug/ml final concentration). The activity of the fluorescein-labelled TF was 
confirmed by measuring the procoagulant activity using the PT assay as described in 
section 2.9.
6.2.2.2. Examination of the interaction of fluorescein-labelled TF with the cell 
surface by fluorescence microscopy
MCF-7 cells (5><104) were seeded out into 8 well cultureslides in medium (300 ul) and 
incubated at 37°C overnight. Fluorescein-labelled TF solution (5 ul) was added to the 
wells at intervals up to 60 min. The cells were then washed three times with PBS (500 
ul) and fixed with glutaraldehyde (3 % (v/v)) for 20 min at room temperature in the 
dark. The cells were washed three times with PBS (500 ul) and viewed using a Leitz
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Laborlux S fluorescence microscope. Images were recorded and analysed using Image- 
Pro Plus Version 5.1.2.
6.2.3. Identification of receptors involved in the interaction of exogenous TF with 
the cell surface
6.2.3.1. Analysis of pi and p3 integrin expression on the surface of breast cancer 
cells by fluorescence microscopy
MCF-7 or T47D cells (5*104) were seeded out into 8 well cultureslides in medium (300 
ul) and incubated at 37°C overnight. The cells were washed three tunes with PBS (500 
ul) and fixed with glutaraldehyde (3 % (v/v)) as before. The cells were then washed 
three times with PBS (500 ul) and incubated with anti-human pi integrin or P3 integrin 
phycoerythrin (PE)-conjugated antibodies (0.1 ug/ml final concentration) for 1 h in the 
dark. Finally, the cells were washed three times with PBS (500 ul) and viewed using a 
Leitz Laborlux S fluorescence microscope. Images were recorded and processed using 
Image-Pro Plus Version 5.1.2.
6.2.3.2 Co-localisation of TF with pi integrin by fluorescence microscopy
MCF-7 cells (5><104) were seeded out into 8 well cultureslides in medium (300 ul) and 
incubated at 37°C overnight. Fluorescein-labelled TF solution (5 ul) was added to the 
wells and incubated at 37°C for 15 min. The cells were then washed twice with PBS 
(500 ul) and fixed with glutaraldehyde (3 % (v/v)) as before. The cells were washed 
three tunes with PBS and incubated with the pi integrin PE-conjugated antibody (0.1 
ug/ml final concentration) for 1 h in the dark. The cells were washed three times with 
PBS (500 ul) and visualised using a Leitz Laborlux S fluorescence microscope. Images 
were recorded and analysed using Image-Pro Plus Version 5.1.2.
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In a separate experiment, MCF-7 cells (5xl04) were incubated at 37°C for 2 h with a 
range of concentrations of a rabbit polyclonal antibody (0-5.3 |o,g/ml) directed against 
the C-terminus, including the cytoplasmic domain to the EGF-4 domain (amino acids 
579-799) of pi integrin (Fig 6.2). The cells were washed twice with PBS (500 \d) and 
fluorescein-labelled TF solution (5 ul) was added to the wells and incubated at 37°C for 
15 min. The cells were then washed twice with PBS (500 ul) and visualised using a 
fluorescence microscope.
6.2.3.3. Examination of TF binding to 01 integrin by co-precipitation
TF-agarose and BSA agarose-conjugated microbeads (resins) were prepared by 
attaching recombinant TF or BSA to activated agarose. Recombinant TF (0.5 g) or BSA 
(0.5 g) were dissolved in 0.1 M sodium bicarbonate buffer, pH 7.2 (4 ml), p-nitrophenyl 
chloroformate-activated agarose (0.5 ml) was pipetted into separate pre-boiled dialysis 
tubing and the TF or BSA solutions were added to the agarose, sealed and placed in 0.1 
M sodium bicarbonate buffer (1 L). The samples were incubated at 4°C overnight to 
allow the binding of TF or BSA to the activated agarose. The dialysis tubing was then 
transferred to 0.1 M ethanolamine (1 L) and incubated at 4°C for 2 days to block the 
remaining free chloroformate groups. The TF or BSA-conjugated agarose resins were 
transferred to 15 ml tubes, centrifuged at 400 g for 10 min and the resins washed twice 
in PBS (10 ml).
MCF-7 cells were cultured in T150 flasks and when at approximately 80 % confluency, 
were washed three times with PBS (10 ml) and then lysed with cell lysis buffer (20 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1 % (v/v) Triton X-100 and protease inhibitor cocktail 
(1 %)) (2 ml). The cell lysate was sonicated twice on ice, each for 20 s, cleared by 
centrifugation at 400 g for 5 min and then transferred to a 15 ml tube. The TF and BSA-
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conjugated agarose resins were washed three times in cell lysis buffer (2 ml) and 
transferred to 1.5 ml tubes (0.3 ml of resin/tube). Cell extract (0.5 ml) was added to 
each resin sample and incubated at 4°C overnight on a rolling platform. The resins were 
then washed four times with cell lysis buffer (1 ml), 2x Laemmli's buffer (30 ul) added 
and the samples heated at 99°C for 5 min. The denatured agarose resins were then 
removed by centrifuging at 6000 rpm for 2 min in a microcentrifuge and the supernatant 
containing interacting proteins retained. The proteins were separated by 10 % (w/v) 
SDS-PAGE and membranes were probed using a rabbit anti-human pi integrin antibody 
(0.4 ug/ml) and a rabbit anti-human FVIIa antibody (1.4 ng/ml).
6.2.3.4. Visualisation and modification of protein domain structures
Protein structure files from the "Brookhaven protein data bank" (PDB) were down­ 
loaded from PubMed and visualised using the Raswin version 6 program. Files were 
edited using a general text editor to select the domains of interest. The edited protein 
structure files were uploaded into the Alchemy III program and ammo acid side chains 
altered according to sequences described in the results section. Finally, the amino acids 
of interest were highlighted and the protein domain structures compared using the 
Alchemy III program.
6.3. Results
6.3.1. Examination of the role of PARs and coagulation factors in TF mediated
signalling in breast cancer cells
6.3.1.1. Examination of the involvement of PARs in TF mediated breast cancer cell
proliferation
Initially, baseline levels of PAR1 and PAR2 mRNA expression in MCF-7 and T47D
cells were examined by RT-PCR. Both MCF-7 and T47D cells expressed low levels of
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PARl, and higher levels of PAR2 (Fig 6.3). MDA-MB-231 cells were used as a positive 
control as these cells are known to express high levels of both PARl and PAR2 
(Kamath et al 2001). The PARl and PAR2 agonist peptides used in this part of the 
investigation mimic the cleaved amino-terminus of the tethered ligands of PARl and 
PAR2 and allow activation of PARl and 2 individually. In addition, the activation of 
PARl and PAR2 was inhibited using the inhibitory antibodies ATAP2, WEDE15, 
SAM11 which bind to the N-terminus and prevent activation of PARs (Shi et al 2004). 
Activation of PAR2 using the agonist peptide was capable of suppressing cell 
proliferation to a similar extent as that observed with the sample incubated with TF (500 
nM) together with oestradiol (250 pM) (Fig 6.4). In addition, the ability of TF (500 nM) 
to suppress oestradiol-mediated cell proliferation was reversed on incubation of cells 
with an inhibitory antibody against PAR2 or a polyclonal antibody against TF. The 
activation of PARl in the presence of oestradiol (250 pM) had no influence on rates of 
proliferation. However, the ability of TF (500 nM) to suppress oestradiol-mediated cell 
proliferation was reversed on incubation of cells with the PARl inhibitory antibodies 
(Fig 6.4).
6.3.1.2. Examination of the influence of FVIIa and FXa on ERa expression
Incubation of MCF-7 cells with recombinant TF (50 nM and 500 nM) in serum-free 
medium reduced ERa mRNA and protein expression in a concentration dependent 
manner, with 500 nM TF reducing mRNA expression by 40 % compared to the 
untreated control (Fig 6.5). Incubation of MCF-7 cells with a combination of FVIIa (5 
nM) together with recombinant TF (500 nM) had little additional influence on ERa 
mRNA expression compared to cells incubated with TF alone. In contrast, the 
combination of TF and FVIIa appeared to induce increased ERa protein expression (Fig 
6.6). The supplementation of TF/FVIIa with FXa (10 nM) restored ERa mRNA and
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Figure 6.3. PAR1 and PAR2 mRNA expression in breast cancer cell lines
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Total RNA was isolated from MCF-7, T47D and MDA-MB-231 cells (106) and used for 
RT-PCR of PAR1, PAR2 and P-actin. DNA products were analysed by 2 % (w/v) 
agarose gel electrophoresis and viewed under UV light. Images were recorded using the 
GeneSnap program.
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Figure 6.4. The involvement of PAR1 and PAR2 in breast cancer cell proliferation
^ O
MCF-7 cells (2.5 X 104) were seeded out into 24 well plates and adapted to phenol red- 
free medium containing 1 % (v/v) PCS. The cells were treated with combinations of 
recombinant TF (500 nM), oestradiol (250 pM), PAR1 and PAR2 agonist peptides (20 
uM each), the PAR1 inhibitory antibodies ATAP2 and WEDE15 (25 ^ig/rnl each), the 
PAR2 inhibitory antibody SAM11 (25 ug/ml) and a polyclonal anti-TF antibody (100 
ug/ml). The cells were incubated at 37°C for 24 h and rates of cell proliferation 
determined using the MTS-based assay. Data are representative of four independent 
experiments, each in duplicate ± SD. * p<0.05 vs. the untreated control.
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Figure 6.5. Examination of the influence of FVIIa and FXa on ERa mRNA
expression
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MCF-7 cells were seeded out into 12 well plates and adapted to medium containing 2 % 
(v/v) serum replacement medium. The cells were treated with TF (50 and 500 nM), and 
combinations of TF (500 nM), FVIIa (5 nM) and FXa (10 nM). Cells were incubated at 
37°C for 24 h, RNA isolated and used for RT-PCR. Images were recorded using the 
GeneSnap program and ERa expression compared to (3-actin using the GeneTool 
program. Data represent the average of five independent experiments ± SD. * p<0.05 
vs. the untreated control.
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Figure 6.6. Examination of the influence of FVIIa and FXa on ERa protein 
expression
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MCF-7 cells were seeded out into 12 well plates and adapted to medium containing 2 % 
(v/v) serum replacement medium. The cells were treated with combinations of 
recombinant TF (0-500 nM), FVIIa (5 nM) and FXa (10 nM). The cells were incubated 
at 37°C for 24 h, harvested and whole cell extracts prepared. 10 |j,g of protein for each 
sample was placed into the wells of an ERa ELISA. Absorption values were converted 
to ERa protein concentrations using a standard curve prepared with recombinant ERa. 
Data are from one experiment.
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protein expression to that of the untreated controls (Fig 6.5 and 6.6). Furthermore, the 
addition of FXa alone increased ERa mRNA expression above that of the untreated 
control by 18%.
6.3.1.3. Examination of the involvement of PAR1 and PAR2 in ERa expression
Incubation of MCF-7 cells with the PAR1 agonist peptide resulted in an 18 % increase 
in ERa mRNA expression, which was reflected in the ERa protein expression (Fig 6.7 
& 6.8). Furthermore, pre-incubation of cells with PAR1 inhibitory antibodies 
suppressed both ERa mRNA and protein expression. Incubation of MCF-7 cells with 
the PAR2 agonist peptide resulted in an increase of 51 % in ERa mRNA, but only a 
modest increase in protein expression (Fig 6.7 & 6.8). Furthermore, inhibition of PAR2 
using an inhibitory antibody resulted in a 43 % reduction in ERa mRNA expression 
below that of the untreated control, and suppressed ERa protein expression.
6.3.2. Examination of the binding of exogenous TF to the surface of breast cancer
cells
6.3.2.1. Analysis of fluorescein-labelled TF
Recombinant TF was labelled with fluorescein using the reagents HBTU and DIPEA, 
which catalyse the formation of carboxyamide bonds between fluorescein and TF 
molecules. Following labelling, the concentration of fluorescein-labelled TF was 
determined using the Bradford assay and calculated as 1.8 mg/ml compared to 2.3 
mg/ml for the unlabelled TF. Furthermore, the stock solution of fluorescein-labelled TF 
had a clotting time of 27 s, compared to 13 s for the unlabelled TF. Analysis of the 
fluorescein-labelled and unlabelled TF by SDS-PAGE produced a single band at 
approximately 30 kDa (Fig 6.9). However, the band for the fluorescein-labelled TF was 
weaker, indicating that some recombinant TF was lost during the labelling process. The 
recombinant TF used in this investigation lacks the cytoplasmic domain and is not
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Figure 6.7. Examination of the involvement of PARs in ERa mRNA expression
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MCF-7 cells were seeded out into 12 well plates and adapted to medium containing 2 % 
(v/v) serum replacement medium. The cells were treated with recombinant TF (500 
nM), PAR1 and PAR2 agonist peptides (20 jiM), PAR1 or PAR2 inhibitory antibodies 
(25 ug/ml) with recombinant FVIIa (5 nM) and recombinant FXa (10 nM). Cells were 
incubated at 37°C for 24 h and RNA isolated and used for RT-PCR. Images were 
recorded using the GeneSnap program and ERa expression compared to P-actin using 
the GeneTool program. Data represent the average of five independent experiments ± 
SD. * p<0.05 vs. the untreated control.
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Figure 6.8. Examination of the involvement of PARs in ERa protein expression
MCF-7 cells were seeded out into 12 well plates and adapted to medium containing 2 % 
(v/v) serum replacement medium. The cells were treated with combinations of 
recombinant TF (500 nM), PAR1 and PAR2 agonist peptides (20 uM), and PAR1 
inhibitory antibodies ATAP2 and WEDE15 (25 ng/ml each), or PAR2 inhibitory 
antibody SAM11 (25 ug/ml) with TF (500 nM), FVIIa (5 nM) and FXa (10 nM). The 
cells were incubated at 37°C for 24 h, harvested and whole cell extracts prepared. 10 ug 
of protein for each sample was placed into the wells of an ERa ELISA. Absorption 
values were converted to ERa protein concentrations using a standard curve prepared 
with recombinant ERa. Data are from one experiment.
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Figure 6.9. Western blot analysis of fluorescent-labelled TF
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Aliquots (5 ul) of fluorescein-labelled TF and unlabelled TF were separated by 12 % 
(w/v) SDS-PAGE and the proteins transferred onto nitrocellulose membrane. The 
membrane was probed with a mouse monoclonal anti-human TF antibody (0.5 |J,g/ml) 
followed by an anti-mouse alkaline phosphatase-conjugated antibody (0.1 ug/ml). The 
membrane was developed using Western Blue stabilised substrate for alkaline 
phosphatase and images recorded using the GeneSnap program.
209
glycosylated, which accounts for the lower molecular weight of 30 kDa compared to 
full length TF, which has a molecular weight of 42 kDa.
6.3.2.2. Analysis of fluorescein-labelled TF binding to cell surface by fluorescence 
microscopy
The interaction of fluorescein-labelled TF with the cell surface was observable within 5 
min, peaked at 15 min and then progressively diminished up to 60 min post-treatment 
(Fig 6.10). Furthermore, the interaction seemed to be focused at particular points on the 
cell surface rather than a general adsorption onto the cell membrane. To confirm the 
specificity of this interaction, a rabbit polyclonal anti-human TF antibody was used to 
inhibit the binding of exogenous TF. Initially, the concentration of the polyclonal anti- 
TF antibody used to block TF binding was optimised by incubating recombinant TF 
(500 nM) with a range of concentrations (0-100 ng/ml) of the polyclonal anti-TF 
antibody for 1.5 h and then measuring the procoagulant activity of the samples using the 
PT assay. The activity of TF in the samples was calculated as described in section 2.9 
and the percentage of inhibition of TF activity calculated as follows.
(Initial TF activity - Residual TF activity) *100 
(Initial TF activity)
Residual TF activity is TF activity following addition of the anti-TF antibody. The anti- 
TF antibody was shown to inhibit the procoagulant activity of TF by 88 % at a 
concentration of 100 ng/ml (Fig 6.11). Pre-incubation of fluorescein-labelled TF with 
the polyclonal anti-TF antibody (100 ug/ml) reduced the binding of fluorescein-labelled 
TF to the cell surface at 15 min (Fig 6.10). Furthermore, inclusion of a 10-fold excess of 
unlabelled TF diminished the binding of fluorescein-labelled TF to the cell surface (Fig 
6.10).
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Figure 6.10. Interaction of fluorescein-labelled TF with MCF-7 cells
Labelled-TF + excess 
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MCF-7 cells (5><104) were seeded out into 8 well cultureslides and incubated with 
fluorescein-labelled TF solution (5 ul) for 0-60 min. In addition, labelled TF was pre- 
incubated with an anti-TF antibody, or cells were pre-incubated with unlabelled TF and 
fluorescein-labelled TF then added for 15 min. The cells were washed with PBS, fixed 
with 3 % (v/v) glutaraldehyde and visualised using a CoolSnap Pro camera attached to a 
Leitz Laborlux S fluorescence microscope. Images were processed using the Image-Pro 
Plus Version 5.1.2. Data are representative of three independent experiments. 
(Magnification x 10).
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Figure 6.11. Optimisation of anti-TF polyclonal antibody concentration to inhibit 
TF procoagulant activity
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Samples of recombinant TF (500 nM) were incubated with a range of concentrations of 
the polyclonal anti-human TF antibody (0-100 ug/ml) for 1.5 h. The procoagulant 
activity of each sample was measured using the PT assay and the clotting times were 
recorded using a Cascade M coagulometer. Clotting times were converted to percentage 
inhibition of TF activity and the percentage inhibition calculated. Data are from one 
experiment.
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6.3.3. Identification of the receptors involved in the interaction of TF with the cell
surface
6.3.3.1. Co-localisation of TF with pi integrin by fluorescence microscopy
Initially, the cell surface expression of the pi and P3 integrins in breast cancer cells was 
examined. MCF-7 and T47D cells both expressed cell surface pi integrin but had no 
detectable surface p3 integrin as determined by fluorescence microscopy (Fig 6.12). 
Next, the level of co-localisation between the bound exogenous TF and cell surface pi 
integrin was examined using fluorescence microscopy. The proteins were detected at 
different wavelengths by the fluorescein-label of TF (green fluorescence) and a PE- 
conjugated antibody against pi integrin (red fluorescence). Overlaying of the images 
produced orange/yellow points where the two proteins co-localised. A partial co- 
localisation between fiuorescein-labelled TF and pi integrin was observed in MCF-7 
cells folio whig 15 min incubation with fiuorescein-labelled TF (Fig 6.13) as determined 
using the colour-pair function in ImagePro-Plus program. Furthermore, the Pearson 
correlation coefficient was calculated to be 0.936, where a value of 1 is a 100 % match.
In a separate experiment, an anti-pi integrin polyclonal antibody, raised against the C- 
terminus arnino acids 579-799 of pi integrin, including the PTD and EGF-4 domains of 
PI integrin (Fig 6.2), was used to examine whether TF binds to pi integrin on the cell 
surface. MCF-7 cells were incubated with a range of concentrations of the polyclonal pi 
integrin antibody (0-5.3 ug/ml). While low concentrations of antibody (0.7, 1.3 and 2.6 
ug/mi) had no significant effect on TF binding, cells incubated with a higher 
concentration (5.3 ug/ml) had lower fluorescence intensity, indicating that binding of 
exogenous TF to the surface of MCF-7 cells was partially blocked by the pi integrin 
antibody (Fig 6.14).
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Figure 6.12. Cell surface expression of pi and P3 integrins in breast cancer cells
MCF-7 and T47D cells (5x10 ) were seeded out into 8 well cultureslides and incubated 
at 37°C overnight. The cells were washed three times with PBS, fixed with 
glutaraldehyde (3 % (v/v)) and incubated with anti-human pi integrin or (53 integrin PE- 
conjugated antibodies (0.1 ng/ml) for 1 h in the dark. The cells were washed with PBS 
and visualised using a CoolSnap Pro camera attached to a Leitz Laborlux S fluorescence 
microscope. Images were processed using the Image-Pro Plus Version 5.1.2. Data are 
from one experiment. (Magnification x 10).
A = (31 integrin expression in MCF-7 cells, B = 33 integrin expression in MCF-7 cells, 
C = 31 integrin expression in T47D cells, D = 33 integrin expression in T47D cells.
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Figure 6.13. Co-localisation of exogenous TF with PI integrin in MCF-7 cells
MCF-7 cells (5><104) were seeded out into 8 well cultureslides and incubated with 
fluorescein-labelled TF solution (5 ul) at 37°C for 15 min. The cells were then washed 
twice with PBS, fixed with glutaradehyde (3 % (v/v)) and incubated with an anti-31 
integrin PE-conjugated antibody (0.1 ng/ml) for 1 h. The cells were washed three times 
with PBS and visualised using a fluorescence microscope. The first two images where 
overlaid to produce the last image using the Image Pro Plus program. Data are 
representative of two independent experiments. (Magnification x 25).
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Figure 6.14. Examination of the binding of exogenous TF in the presence of an 
anti-pi integrin antibody
MCF-7 cells (5><104) were seeded out into 8 well cultureslides and incubated with a 
range of concentrations of a rabbit polyclonal anti-human 31 integrin antibody (0-5.3 
M.g/ml) at 37°C for 2 h. The cells were washed twice with PBS (500 ul) and fluorescein- 
labelled TF (5 ul) was added to the wells and incubated at 37°C for 15 min. The cells 
were then washed twice with PBS (500 ul) and visualised using a fluorescence 
microscope. Data are representative of two experiments. (Magnification x 25).
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6.3.3.2. Analysis of TF binding to 01 integrin by co-precipitation
The direct interaction between exogenous TF and pi integrin was further examined by 
co-precipitation of TF with proteins from MCF-7 cell extract. On probing of the 
samples pulled-down by TF with an anti-pi integrin antibody, a single band with a 
molecular mass of approximately 130 kDa, corresponding to pi integrin, was detected. 
This band was observable in the samples incubated in the presence of MnCl2 (5 mM) as 
well as in the total cell extract sample (Fig 6.15). Furthermore, addition of the ROD 
peptide (400 uM) had no further influence on the binding of TF to pi integrin. Pre- 
incubation of the TF-conjugated agarose beads with a rabbit polyclonal anti-TF 
antibody (100 ug/ml), or a 10-fold excess of recombinant TF (5 uM) prevented the co- 
precipitation of pi integrin with TF. Furthermore, pi integrin was not present hi the 
sample incubated with the BSA-conjugated agarose beads, discounting non-specific 
protein binding. Examination using an anti-human FVIIa antibody excluded the 
presence of FVIIa in all co-precipitated samples, but was present in the total cell extract.
6.3.3.3. Examination of the involvement of pi integrin and the MAPK pathway in 
TF mediated ERa expression
Incubation of MCF-7 cells with either a polyclonal antibody against the C-terminus of 
pi integrin or an inhibitory anti-pi integrin antibody in the presence of TF (500 nM) 
appeared to interfere with the TF-mediated downregulation of ERa protein expression 
observed with TF (500 nM) alone (Fig 6.16). Furthermore, a polyclonal antibody 
against TF prevented the downregulation of ERa protein expression by exogenous TF 
(500 nM). Inclusion of the MAPK inhibitor PD98059 (50 uM) seemed to have little 
influence on ERa expression (Fig 6.16). However, incubation of cells with the MAPK 
inhibitor PD98059 (50 uM) in the presence of TF (500 nM) appeared to interfere with 
the downregulation of ERa protein expression by TF.
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Figure 6.15. Co-precipitation of TF and 01 integrin
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MCF-7 cells were lysed in cell lysis buffer and sonicated. The cell lysate was cleared by 
centrifilgation and incubated with the TF and BSA-conjugated beads in the presence of 
MnCh (5 mM), ROD peptide (400 uM), 10-fold excess recombinant TF, or a rabbit 
polyclonal anti-TF antibody (100 ug/ml) at 4°C overnight. The resins were then washed 
with lysis buffer and proteins denatured by heating at 99°C in 2x Laemmli's buffer. The 
proteins were separated by 10 % (w/v) SDS-PAGE and membranes were probed using a 
rabbit anti-human (31 integrin antibody (0.4 ug/ml) and a rabbit anti-human FVIIa 
antibody (1.4 ug/ml) and images recorded using the GeneSnap program. Data are 
representative of three independent experiments.
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Figure 6.16. The role of pi integrin and the MAPK pathway in TF-mediated 
downregulation of ERa expression
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MCF-7 cells were seeded out into 12 well plates and adapted to medium containing 2 % 
(v/v) serum replacement medium. The cells were pre-incubated with a rabbit polyclonal 
anti-pi integrin antibody (5.3 ug/ml), an inhibitory anti-pi integrin antibody (AIIB2) 
(50 ug/ml) or a polyclonal anti-TF antibody (100 ug/ml) and then treated with 
recombinant TF (500 nM) or the ERKl/2 MAPK inhibitor PD98059 (50 uM). The cells 
were incubated at 37°C for 24 h, harvested and whole cell extracts prepared. 10 u.g of 
protein for each sample was placed into the wells of an ERa ELISA. Absorption values 
were converted to ERa protein concentrations using a standard curve prepared with 
recombinant ERa. Data are representative of two independent experiments ± SD.
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6.3.3.4. Examination of the structure of TF and pi integrin using Raswin and 
Alchemy programs
In the previous section it was shown that exogenous TF co-localised with cell surface 
pi integrin and a direct interaction between TF and pi integrin was observed, indicating 
that exogenous TF can bind to cell surface pi integrin. Furthermore, a polyclonal 
antibody directed against the C-terminus of pi integrin partially blocked the binding of 
exogenous TF to the cell surface, and therefore it is possible that this region of pi 
integrin may be capable of interacting with exogenous TF. Examination of the structure 
of pi integrin revealed similarities with FXa, since both contain EGF domains in the C- 
terminus in close proximity to the cell membrane. FXa is known to bind to the 
extracellular domain of TF via particular residues (Asp48, GluSl, Ser52, Asn57, Phe76, 
Asn80 and Glu82) within the EGF-1 domain of FXa (Fig 6.1) (Zhong et al 2002). 
Therefore, it is feasible that a similar EGF domain within pi integrin may be capable of 
interacting with exogenous TF. The amino acid sequences for the EGF-1 domain of 
FXa and the EGF-4 domain of pi integrin were aligned using the Align program 
(Pearson et al 1997), to reveal a 29 % sequence identity and a 56 % similarity between 
these domains of the two proteins. Next, the structure of the pi integrin molecule was 
visualised using the Raswin version 6 program (Fig 6.17). Since the crystal structure of 
pi integrin has not been determined, the crystal structure of P3 integrin (Xiong et al 
2001) was used as a template. For clarity, the sequence for p3 integrin was edited to 
leave the C-terminus PTD, EGF-4 and EGF-3 domains. The edited structure for P3 
integrin was then uploaded into the Raswin program and placed next to the extracellular 
domain of TF (Harlos et al 1994) (Fig 6.17) to demonstrate that the size of the two 
molecules was compatible.
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Figure 6.17. Arrangement of the extracellular domain of TF with the C-terminus 
of P3 integrin
PDB files for the structures of P3 integrin (blue) (Xiong et al 2001) and the extracellular 
domain of TF (red) (Harlos et al 1994) were downloaded from PubMed. The C- 
terminus of P3 integrin was arranged next to the extracellular domain of TF in a similar 
place to where FXa binds and the size of the molecules measured using the Raswin 
version 6 program.
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Next, the structural similarities between the EGF-1 domain of FXa and the EGF-4 
domain of pi integrin were explored. Since the crystal structures of the FXa EGF-1 
domain and pi integrin have not been determined, the structure of the EGF-1 domain of 
FVIIa (Banner et al 1996) and the EGF-4 domain of p3 integrin (Xiong et al 2001) were 
used as templates. The structural files were uploaded into the Alchemy III program and 
the side chains of the amino acids in the EGF-4 domain of p3 integrin that differed from 
those in the EGF-4 domain of pi integrin were replaced with those in pi integrin. 
Similarly, the amino acids in the EGF-1 domain of FVIIa were replaced with the 
respective residues found in the EGF-1 domain of FXa. The amino acids within the 
EGF-1 domain of FXa that are known to participate in the interaction with TF were 
highlighted. The structure of the EGF-4 domain of pi integrin was then superimposed 
and the equivalent residues highlighted (Fig 6.18). The amino acids are represented as 
red = negatively charged, blue = hydrophilic, purple = aromatic (the disulphide bridges 
were also highlighted in yellow). The space-fill diagrams (Fig 6.18) show that the EGF- 
4 domain of pi integrin and EGF-1 domain of FXa do not have identical structures. 
However, the amino acids within the EGF-1 domain of FXa that are involved in the 
interaction with TF are conserved between the two structures. Asn57, Phe76 and Glu82 
are identical between the two while GluSl, Ser53 and AsnSO are conservative 
substitutions. Finally, the oxygen molecules present in the side chain of Asp48 in FXa 
are provided by Ser and Thr residues within pi integrin. Moreover, although the length 
of the loop sections within these EGF domains vary, the position of the interacting 
amino acids and the disulphide bridges are similar.
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Figure 6.18. Comparison of the structures of pi integnn EGF-4 and FXa EGF-1
The PDB files for the EGF-4 domain of 03 integrin (Xiong et al 2001) and the EGF-1 
domain of FVIIa (Banner et al 1996) were opened in the Alchemy III program and 
amino acids changed to those in pi integrin EGF-4 and FXa EGF-1. Amino acids within 
the EGF-1 domain of FXa that interact with the extracellular domain of TF were 
highlighted as: blue = hydrophilic amino acids, red = negatively charged amino acids, 
purple = aromatic amino acids. The corresponding amino acids in the EGF-4 domain of 
pi integrin were similarly highlighted. (Yellow = the position of disulphide bridges).
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6.4. Discussion
This part of the investigation initially examined the mechanisms by which exogenous 
TF induces changes in breast cancer cell proliferation and ERa expression. The 
activation of PARs by FVIIa and FXa downstream of TF in the coagulation cascade is 
one of the main mechanisms by which TF initiates cell signalling. Activation of PARs 
has been shown to result in the activation of cell signalling pathways and lead to 
changes hi gene expression (Morris et al 2006, Liu & Mueller 2006). Initially, the 
involvement of PAR1 and PAR2 activation in TF-mediated proliferation was examined. 
Activation of PAR2 using an agonist peptide resulted hi reduced rates of MCF-7 cell 
proliferation to a similar extent of exogenous TF (500 nM) with oestradiol (250 pM) 
(Fig 6.4). However, addition of oestradiol (250 pM) reversed this inhibition. This is hi 
contrast to the observation with TF (500 nM) which suppressed breast cancer cell 
proliferation in the presence or absence of oestradiol (250 pM) and indicates that the 
ability of TF to inhibit proliferation may involve a second pathway in conjunction with 
PAR2 activation, hi contrast, PAR1 activation was shown to have little influence on 
oestradiol-mediated cell proliferation.
ERa expression is known to be downregulated by the activation of the ERK1/2 MAPK 
pathway (Kronblad et al 2005, Oh et al 2001). Furthermore, activation of PARs has 
been shown to activate the ERK1/2 pathway (Riewald & Ruf 2001). hi this study, the 
activation of PAR2 appeared to result in increases in the expression of ERa mRNA and 
protein (Fig 6.7 & 6.8) whereas inhibition of PAR2 suppressed ERa expression. This 
indicates that PAR2 activation may positively regulate ERa expression. In serum-free 
medium, exogenous TF (500 nM) alone downregulated ERa expression and the addition 
of FVIIa (5 nM) had no additional influence on mRNA expression (Fig 6.5 & 6.6). 
These results seem contradictory since FVIIa activates PAR2 (Camerer et al 2000b) and
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activation of PAR2 using the agonist peptide resulted in the upregulation of ERa 
expression. A possible explanation for this observation is that the TF:FVIIa complex 
may activate separate pathways that interfere with signalling downstream of PAR2, 
preventing the upregulation of ERa. Furthermore, the incubation of MCF-7 cells with 
TF:FVHa in the presence of FXa (10 nM) appeared to restore ERa mRNA expression 
back to control levels, and FXa alone resulted in increased expression above that of the 
untreated control. This is in agreement with the data showing that the PAR1 and PAR2 
agonist peptides increased ERa expression, since FXa activates both PAR1 and PAR2 
(Riewald et al 2001). Furthermore, the addition of exogenous TF (500 nM) alone, in the 
absence of any coagulation factors, resulted in decreases in ERa mRNA and protein 
expression which indicates that the influence of exogenous TF on ERa expression 
probably does not require coagulation factors and is not mediated through the activation 
of either PAR1 or PAR2.
Integrins are known to transduce signals across the cell membrane and induce cell 
signalling pathways including the MAPK and PI3K pathways (Schwartz 2001). Since 
the influence of exogenous TF on ERa expression did not appear to involve the 
activation of PARs by exogenous TF, and exogenous TF was shown to be capable of 
binding to pi integrin, the possibility that the interaction between exogenous TF and pi 
integrin induces the activation cell signalling pathways was explored. Pre-incubation of 
MCF-7 cells with an inhibitory anti-pi integrin antibody or a polyclonal antibody 
against the C-terminus of pi integrin seemed to prevent the downregulation of ERa 
protein expression by exogenous TF (Fig 6.16). This indicates that the binding of 
exogenous TF to pi integrin is capable of inducing cell signalling leading to the 
downregulation of ERa. Furthermore, incubation of cells with exogenous TF in the 
presence of the ERK1/2 inhibitor PD98059 appeared to prevent the downregulation of
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ERa (Fig 6.16). This in turn suggests that exogenous TF may mediate the 
downregulation of ERa expression at least partly through the activation of the ERK1/2 
pathway (Fig 6.16). Therefore, a possible mechanism could include the activation of the 
ERK1/2 pathway through pi integrin following the binding of TF. The activation of the 
ERK1/2 pathway by exogenous TF was not examined in this investigation, although is 
shown elsewhere (Ettelaie et al 2007), and therefore requires further clarification which 
may be carried out using reporter assays for the ERK1/2 signalling pathway.
In the next part of the investigation, the interaction of exogenous TF with the surface of 
breast cancer cells and the signalling mechanisms by which exogenous TF influences 
breast cancer cell proliferation and ERa expression were examined. The truncated form 
of TF incorporated into phospholipid vesicles and used throughout this investigation 
represented microparticle-derived TF such as that released from stromal cells in the 
vicinity of tumour cells. The interaction of exogenous TF with the cell surface was 
examined using fluorescein-labelled recombinant TF which was shown to bind to the 
surface of MCF-7 cells within 5 min and peaked at 15 min incubation (Fig 6.10). 
Furthermore, the TF was localised to particular points on the cell surface. The binding 
of exogenous TF to the surface of endothelial cells has been shown previously (Ettelaie 
et al 2007). Furthermore, localisation of endogenous TF specific sites on the surface of 
epithelial cells has been previously demonstrated (Muller et al 1999). The level of 
fluorescein-labelled TF binding to the cell surface diminished after 60 min incubation 
which may be as a result of internalisation of the TF by the cells.
The exogenous TF used in this investigation was reconstituted in phospholipid vesicles 
which may fuse with the cell membrane, incorporating TF into the cell membrane. 
However, since TF was localised to points on the cell surface, this indicates that the TF
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was interacting with specific proteins rather than random incorporation into the cell 
membrane. Moreover, although studies have shown that TF can form homodimers (Roy 
et al 1991), the lack of TF expression by MCF-7 cells implies that this interaction can 
be excluded. Another putative target set of proteins that TF may bind to is the integrin 
family of adhesion receptors. Recently, a direct interaction between cell surface TF and 
the (31 integrin was demonstrated (Versteeg et al 2008). Examination of p integrin 
expression on breast cancer cells revealed that both MCF-7 cells and T47D cells 
expressed pi integrin but not P3 integrin (Fig 6.12). A partial co-localisation between 
exogenous TF and cell surface pi integrin was observed in MCF-7 cells (Fig 6.13). 
Since the integrin family consists of eight types of p integrins, it is possible that 
exogenous TF can also bind to other p integrins present on the surface of MCF-7 cells 
as well as pi integrin, although these were not examined here. Furthermore, a 
polyclonal antibody against the membrane proximal region of pi integrin appeared to 
partially block the binding of fluorescein-labelled TF to the cell surface (Fig 6.14), 
possibly by disrupting the binding of exogenous TF to pi integrin. This indicates that 
the binding of exogenous TF to the cell surface may depend on forming a complex with 
pi integrin. Therefore, the direct interaction between exogenous TF and pi integrin was 
examined next using agarose-conjugated TF to "pull-down" proteins from whole cell 
extract. The interaction of exogenous TF and pi integrin was dependent on the presence 
of Mn2+ but not FVIIa, or the integrin-activating peptide ROD (Fig 6.15). This 
requirement for Mn2+ may be due to the role of divalent cations in inducing 
conformational changes within integrin molecules (Humphries 1996) and suggests that 
exogenous TF may bind to integrins that are in the activated conformation. An 
interaction between cell surface TF and pi integrin has been recently reported (Versteeg 
et al 2008). However, the interaction between exogenous truncated TF and pi integrin
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has not previously been shown and suggests a mechanism by which exogenous 
microparticle-derived TF may directly bind to tumour cells.
While TF has been shown to bind to 01 integrin, the mechanism by which these proteins 
interact has not been previously examined. The polyclonal anti-pi integrin antibody that 
partially blocked the binding of exogenous TF to the cell surface was directed against 
the C-terminus of pi integrin, including the pTD and EGF-4 domain (Fig 6.2), 
indicating the participation of this region of pi integrin in binding to TF. Further 
examination of this region of pi integrin revealed similarities with the C-terminus of 
FXa, since both contain an EOF domain close to the cell membrane. Furthermore, in 
FXa, the EGF-1 domain is known to interact with the extracellular domain of TF (Fig 
6.1). Alignment of the protein sequence of the EGF-1 domain of FXa with the EGF-4 
domain of pi integrin revealed a 29 % sequence identity and a considerable similarity 
(56 %) between the sequences. Furthermore, alignment of the extracellular domain of 
TF with the C-terminus of P3 integrin in a similar configuration as TF/FXa using the 
Raswin program showed that the scale of the molecules made this interaction feasible 
(Fig 6.17). The amino acids Asp48, GluSl, Ser52, Asn57, Phe76, Asn80 and Glu82 
within the EGF-1 domain of FXa are known to participate in the interaction of FXa with 
the extracellular domain of TF (Zhong et al 2002). Comparison of the structures of the 
EGF-4 domain of pi integrin and EGF-1 domain of FXa revealed that these amino acids 
were conserved between the two molecules (Fig 6.18). This part of the investigation has 
identified a domain within pi integrin which may be a putative binding site for TF due 
to its structural and sequence similarities to the EGF-1 domain of FXa. However, 
further studies using mutagenesis and protein-protein interaction studies may confirm 
the role of this domain of pi integrin as a TF binding site.
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In conclusion, exogenous TF was shown to be capable of interacting with the cell 
surface of MCF-7 cells by directly binding to cell surface pi integrin. Moreover, a 
putative binding site for this interaction was identified. Furthermore, it was 
demonstrated that TF-mediated cell proliferation involves the activation of PAR2 but 
not PARl, and is likely to include other unknown pathways. Furthermore, TF-mediated 
downregulation of ERa did not require either PARl or PAR2 activation but did appear 
to require (31 integrin and the activation of the ERK1/2 pathway.
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CHAPTER 7
General Discussion
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7. General discussion
A number of studies have reported increased expression of TF in aggressive/invasive breast 
tumours (Kato et al 2005, Hu et al 1994). Furthermore, increased expression of TF by 
stromal cells such as macrophages and fibroblasts within breast tumours has been 
associated with the progression to invasive breast cancers (Lwaleed et al 1999, Vrana et al 
1996). Conversely, the expression of ERa in breast cancer cells is associated with well 
differentiated, less invasive tumours which respond to oestradiol and anti-hormone 
therapies. As well as controlling breast cancer cell proliferation (Prall et al 1998), ERa has 
an anti-invasive role (Rochefort et al 1998, Garcia et al 1992) and the loss of ERa 
expression often results in the progression of breast tumours to invasive forms (Thompson 
et al 1992). Factors involved in regulating ERa expression and activity are therefore crucial 
in understanding the mechanisms involved in breast cancer progression to invasive forms. 
Inflammation at the site of breast tumours is associated with more invasive tumours with a 
poor prognosis (Blot et al 2003). TF is a proinflammatory protein that can be released from 
cells in microparticles and transferred to different cell types. Therefore, can exogenous TF, 
such as that released from stromal cells in an inflammatory response within the tumour, 
influence breast cancer cells through altering ERa function?
Initially, the influence of exogenous TF on the expression of ERa in breast cancer cell lines 
was investigated. Exogenous TF (50 and 500 nM) resulted in the downregulation of ERa 
mRNA and protein expression over 24 h. Furthermore, the long-term treatment of cells 
with exogenous TF resulted in a progressive decrease in ERa expression. Exogenous TF 
also appeared to suppress oestradiol-mediated cell proliferation and reverse the anti- 
inhibitory influence of oestradiol on cell invasion. In the second part of the study, the
231
influence of exogenous TF on ERa activity through the ERE pathway was examined. TF 
alone was shown to have no measurable influence on ERa activity. However, in the 
presence of oestradiol (250 pM), exogenous TF reduced ERa activity below that of 
oestradiol alone. TF also appeared to reduce the DNA binding activity of ERa, but this 
seemed to be independent of changes in the phosphorylation state of serine 118 within ERa. 
Next, the influence of exogenous TF on ERa activity through the AP-1-dependent pathway 
was examined. TF alone reduced the transcriptional activity of AP-1 and a high 
concentration of TF (500 nM) appeared to reduce the DNA binding activity of c-Jun. 
However, the transcriptional activity of AP-1 did not seem to be altered by the addition of 
oestradiol (250 pM). Finally, the mechanisms by which exogenous TF interacts with the 
cell surface and induces changes in breast cancer cell proliferation and ERa expression 
were examined. Exogenous TF was shown to bind to the surface of MCF-7 cells and 
directly interact with cell surface pi integrin. TF inhibition of oestradiol-induced cell 
proliferation partly involved the activation of PAR2. Moreover, the downregulation of ERa 
by exogenous TF seemed to require the interaction with pi integrin and activation of the 
ERK1/2 pathway, but was independent of PAR1 and PAR2 activation. In order to ensure 
that the influence of exogenous TF on breast cancer cells observed in this study were not 
limited to one cell line and hence an anomaly, four breast cancer cell lines were selected, of 
which MCF-7 and T47D cells were found to be suitable since these cells expressed ERa but 
lacked significant amounts of TF. However, it is necessary to be cautious when interpreting 
results from cell lines in vitro into relevance for breast cancers in vivo, and this could be 
clarified by further investigations using breast tumour samples to determine if the 
expression of TF on tumour cells themselves and/or TF released by stromal cells, correlates 
with ERa expression in vivo.
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This study demonstrated that the incubation of breast cancer cell lines with exogenous TF 
(50 and 500 nM) results in the downregulation of ERa expression. Since the recombinant 
TF lacks a cytoplasmic domain, cell signalling though the cytoplasmic domain of TF can be 
excluded. The activation of PARs by the coagulation factors FVIIa and FXa downstream of 
TF in the coagulation cascade has been shown to result in changes in gene expression 
(Morris et al 2006, Hjortoe et al 2004). The source of these coagulation factors in tumours 
is likely to be from poorly formed blood vessels within the tumour, which allow plasma 
proteins to escape into the tumour stroma (Knowles & Selby 2005). However, the 
involvement of PARs in the downregulation of ERa by exogenous TF can be excluded 
since the activation of PAR1 and 2 resulted in increases in ERa mRNA and protein 
expression and inhibition of these receptors suppressed ERa expression. Therefore, the 
activation of PAR1 and PAR2 may positively regulate ERa expression and is probably not 
responsible for the downregulation of ERa expression by exogenous TF (Fig 7.1). Tumours 
have been described as wounds that do not heal, since similar processes found in wound 
healing such as cell migration and proliferation and angiogenesis occur, but in tumours 
these processes continue and promote tumour growth (Dvorak 1986). During normal 
physiological wound healing responses, the coagulation cascade is activated and TF is 
exposed to the bloodstream, resulting in the activation of FVIIa and FXa and subsequent 
activation of PAR1 and PAR2. Since PAR1 and PAR2 activation resulted in increases in 
the expression of ERa, this may be a mechanism to promote healing by increasing cell 
proliferation of breast epithelial cells. Furthermore, although the addition of FVIIa had little 
additional influence on ERa mRNA expression in the presence of exogenous TF, inclusion 
of FXa restored ERa expression, indicating that alternative signalling pathways induced by 
TF may be capable of blocking PAR2 signalling initiated by FVIIa, but not PAR1
signalling by FXa (Fig 7.1). A trend was observed in which the short-term exposure of cells
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Figure 7.1. Schematic representation of a proposed mechanism for the control of ERa 
expression by exogenous TF
FX
ERa expression | ERa expression
It is proposed that the activation of PAR1 and 2 by FXa downstream of TF results in 
increased expression of ERa. However, exogenous alone TF leads to the downregulation of 
ERa mRNA expression. The suggested hypothesis is that TF binding to pi integrin results 
in the activation cell signalling pathways such as the ERKl/2 pathway which counteract the 
PAR2 activated signalling pathways, and downregulate ERa expression.
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to exogenous TF downregulated the expression of ERa over 24 h and then normalised by 
72 h. However, long-term treatment of breast cancer cells with exogenous TF appeared to 
result in a progressive decrease in ERa expression over five weeks. In tumours, long-term 
exposure of breast cancer cells to exogenous TF released from stromal cells in an 
inflammatory response, and in the absence of coagulation factors and PAR activation, may 
result in reduced ERa expression and loss of response to oestradiol. This suggests that 
chronic inflammation during breast cancer may alter the level of ERa expression in tumour 
cells by exposing the cells to high levels of TF over a long period of time.
Exogenous TF was shown to interact with the surface of MCF-7 cells and co-localised with 
cell surface pi integrin. Furthermore, a direct interaction between exogenous TF and pi 
integrin was shown and a putative binding site within pi integrin that may be involved in 
binding to TF was identified, although this needs further investigation using mutagenesis 
and protein-protein interaction studies. The downregulation of ERa by exogenous TF also 
appeared to require the activation of the ERK1/2 pathway. The activation of integrins is 
known to initiate cell signalling pathways such as the ERK1/2 and PI3K pathways 
(Schwartz 2001). Furthermore, activation of the ERK1/2 pathway in breast cancer cells has 
been shown to result in the downregulation of ERa expression (Creighton et al 2006). It is 
possible that the binding of exogenous TF to cell surface pi integrin results in the 
activation of ERK1/2 pathway through the integrin molecule and results in the 
downregulation of ERa expression (Fig 7.1). Further studies are required to identify cell 
signalling pathways activated as a result of the binding of exogenous TF to pi integrin 
using reporter assays.
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A trend was observed in which exogenous TF appeared to suppress oestradiol-mediated 
increases in breast cancer cell proliferation. Importantly, incubation of MCF-7 cells with 
the lipids extracted from the Innovin reagent had no measurable influence on cell 
proliferation, indicating that the influence of the Innovin reagent on cell proliferation was 
due to the TF apoprotein and not the lipid component. Oestradiol-ERa signalling results in 
the expression of genes involved in cell proliferation and promotes cells to enter the cell 
cycle (Prall et al 1998). Since exogenous TF downregulated both ERa expression and ERa 
activity through the ERE pathway, this may at least partly explain the observed suppression 
of oestradiol-controlled proliferation by TF. Furthermore, PAR2 activation resulted in 
similar reductions in rates of cell proliferation. These observed decreases in rates of cell 
proliferation in response to exogenous TF may therefore involve the activation of PAR2 by 
FVIIa or FXa downstream of TF in the coagulation cascade. However, PAR2-mediated 
suppression of cell proliferation appeared to be reversed by the addition of oestradiol (250 
pM), while PAR2 activation increased ERa expression. This indicates the participation of 
other pathways, in addition to PAR2 signalling, in the suppression of oestradiol-mediated 
cell proliferation by exogenous TF. Alternatively, it is possible that TF induces the 
apoptosis of breast cancer cells in the presence of oestradiol by inhibiting the progression of 
cells through the cell cycle, although this requires further investigations employing 
apoptosis assays.
Oestradiol-ERa signalling inhibits breast cancer cell invasiveness by controlling the 
expression of genes involved in cell invasion (Nilsson et al 2007, Rochefort et al 2001). In 
this investigation, exogenous TF (50 and 500 nM) reversed the inhibitory influence of 
oestradiol (250 pM) on cell invasion. Moreover, since exogenous TF was capable of
downregulating ERa expression and activity, this may account for the increased cell
236
invasiveness of breast cancer cells in the presence of TF. The hypothesis that exogenous TF 
may suppress oestradiol-induced proliferation and invasion by downregulating ERa 
expression and/or activity was investigated by attempting to overexpress the wild-type or a 
constitutively active form of ERa in breast cancer cells to overcome the influence of TF. 
However, the cloning of ERa was not completed within the permitted time and therefore 
further work to investigate this mechanism is required.
The ability of cancer cells to invade across the basement membrane is an important step in 
metastasis since it allows cancer cells to escape into the bloodstream where they can be 
transported to other organs and form secondary tumours. In this investigation, TF alone 
increased the invasiveness of breast cancer cells and appeared to induce the formation of 
lamellipodia and microspikes structures required for cell migration. The formation of the 
TF:FVIIa complex is known to be capable of inducing changes in cell morphology through 
the activation of the PI3K pathway and reorganisation of the cytoskeleton (Versteeg et al 
2000). Moreover, the activation of PARs can lead to the activation of these cell signalling 
pathways and promote cell migration (Jiang et al 2004). In addition, cross-talk between TF 
and the a3pl integrin complex has been shown to induce cell migration (Dorfleutner et al 
2004). In this study exogenous TF was shown to directly bind to pi integrin. Therefore, it is 
conceivable that exogenous TF may induce changes in cell morphology and increase cell 
invasion by a mechanism mediated either through the activation of PARs or the interaction 
with pi integrin. Further investigation to confirm the role of these mechanisms would 
include the use of inhibitory antibodies for PARs and pi integrin in Boyden chamber-based 
invasion assays.
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In addition to the classical ERE pathway of ERa transcriptional activity, oestradiol-ERa 
signalling has been shown to increase the transcriptional activity of AP-1 (Philips et al 
1993). However, in this investigation oestradiol (250 pM) had no influence on the 
transcriptional activity of AP-1. In contrast, exogenous TF alone was shown to be capable 
of downregulating the transcriptional activity of AP-1 in breast cancer cells. Furthermore, a 
low concentration of TF (50 nM) seemed to increase the DNA binding activity of c-Jun 
whereas a high concentration of TF (500 nM) appeared to reduce the DNA binding activity 
of c-Jun. AP-1 controls many cellular functions including proliferation, differentiation and 
invasion (Ludes-Meyers et al 2001, Bamberger et al 1999), and TF may influence cellular 
processes through changes in AP-1. Furthermore, since TF seemed to reduce the DNA 
binding activity of c-Jun, it is possible that TF may indirectly suppress ERa activity 
through the AP-1 pathway (Fig 5.14). Further investigations of this process may be carried 
out using an immuno-precipitation procedure to examine the influence of exogenous TF on 
the binding of ERa to c-Jun.
Sporadic forms of breast cancer account for the major proportion of the incidence of this 
disease. In addition to genetic mutations, environmental factors within the breast tissue 
constitute a principle risk factor in the formation of breast cancer, and can also promote 
progression to an invasive phenotype. Such environmental factors include those released 
during inflammatory responses towards the tumour and include the expression and release 
of factors such as TF. In conclusion, continuous long-term exposure of breast cancer cells 
to high levels of exogenous TF such as that released from infiltrating macrophages and 
fibroblasts within tumours in an inflammatory response, may directly interact with breast 
cancer cells through binding to pi integrin, leading to the downregulation of ERa 
expression and activity, and resulting in breast cancer cells that are unable to respond to
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oestradiol. This may in turn result in the suppression of oestradiol-mediated cell 
proliferation and increased cell invasiveness, contributing to the progression of breast 
cancers to an ERa-negative, oestradiol-independent and invasive phenotype.
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